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1.1. Physiological properties of the endothelium 
A normal muscular artery consists of three distinct layers (Figure 1.1). The outermost layer, 
known as adventia, contains fibroblasts, collagen, proteoglycans and vasa-vasorum, all of which 
are separated from the media by the external elastic lamina. The media consists primarily of 
smooth muscle cells and collagen fibers and it is separated from the intima by the inner elastic 
lamina. The intima is composed of endothelial cells and underlying connective tissue. The 
vascular endothelium forms a continuous monolayer lining all the blood vessels and the heart 
chambers. In an adult, the endothelium covers a surface of almost 1000 m2 and is considered as 
one of the largest organs in the body (Bachetti and Morbidelli, 2000; Cines et al., 1998). The 
endothelium displays so-called cobblestone morphology, representing a homogeneous and tight 
monolayer of polygonal endothelial cells.  
 
Figure 1.1: Structure of Blood vessel. The largest blood vessels are arteries and veins, which have a thick, tough 
wall of connective tissue and many layers of smooth muscle cells. Vascular endothelial cells (endothelium) form a 
thin layer on the interior surface of all the vessels, separated from the surrounding outer layers by a basement 
membrane (basal lamina). 
The endothelium regulates cellular and nutrient trafficking, maintains blood fluidity, regulates 
vasomotor tone, contributes to the local balance of pro-inflammatory and anti-inflammatory 
mediators and participates in the generation of new blood vessels (Gonzalez and Selwyn, 2003).  
Endothelial cells in different vascular beds are heterogeneous. They show a highly differentiated 
structure and function as a consequence of different gene expression and the influence of the 
surrounding tissue. This functional and structural heterogeneity of endothelial cells may be 
important for adaptive processes. It also could favor the development of disorders that are 
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restricted to specific vascular beds (Aird, 2001). In the quiescent state, endothelial cells are non-
proliferative and maintain a non-thrombogenic, non-adherent surface and produce vasoactive 
substances. Cellular and nutrient trafficking is achieved through a specialized trans-cellular 
system of transport vesicles and by the coordinated opening and closure of cell–cell junctions 
(Stevens et al., 2000). The specialized trans-cellular vesicle system includes vesiculo-vacuolar 
organelles, which participate in the regulated transendothelial passage of soluble 
macromolecules. The trans-cellular vesicle system and the cell-cell junctions must be tightly 
regulated to maintain endothelial integrity and to protect the vessels from any uncontrolled 
increase in permeability, inflammation or thrombotic reactions. In addition, the endothelium has 
secretory functions (Bachetti and Morbidelli, 2000). Endothelial cells regulate the following main 
biological processes (Datta and Ewenstein, 2001): 
Thrombosis and thromboresistance are regulated via secretion of molecules such as P-selectin, 
von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, nitric oxide 
and prostacyclin (Datta and Ewenstein, 2001; Hayward et al., 1998; Nilius and Droogmans, 
2001). 
Vasodilation and vasoconstriction are regulated via formation of nitric oxide, prostacyclin, 
endothelin-1, angiotensin II and superoxide radicals (Datta and Ewenstein, 2001; Harrison et al., 
1995; Nilius and Droogmans, 2001; Wang et al., 2002).  
Inflammation is regulated via secretion of IL-8, TNF-α and superoxide radicals (Datta and 
Ewenstein, 2001; Kaplanski et al., 1997; Nilius and Droogmans, 2001). 
Cell proliferation is regulated via secretion of aFGF and bFGF (Prudovsky et al., 2002; 
Swinscoe and Carlson, 1992; Tarantini et al., 2001).   
The endothelium regulates vascular hemodynamics under physiological conditions. It is 
constantly exposed to hemodynamic forces, which consist of pressure acting perpendicular to the 
vessel wall and mechanical forces exerted by the flowing blood in parallel to the vessel wall. 
Laminar flow with its high flow rate in the arterial system leads to continuous shear stress of the 
endothelium. Shear stress stimulates NO formation, which is important for the thromboresistance 
of the endothelium under physiological conditions.  
1.2. Pathophysiological activation of endothelium 
Qualitatively or quantitatively abnormal endothelial stimulation, such as bacterial infection and 
inflammatory stimuli, can result in localized alteration of the endothelium. The endothelium at 
the arterial branch points, which is exposed to turbulent flow, is more prone to functional 
disturbances. These will affect the antihaemostatic properties, control of the vascular tone, 
permeability and anti-adhesive properties of the endothelium. These alterations are collectively 
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termed “endothelial dysfunction” (Gimbrone et al., 1993). Endothelial dysfunction is one of the 
important early steps in atherosclerosis (Ross, 1993).  
Abnormal endothelial cell activation plays also an important role during inflammation. Vascular 
inflammation is a key component in several pathological conditions, including atherosclerosis, 
ischemia/ reperfusion, hypertension, restenosis, angiogensis and septic shock. It involves a 
complex series of events: i) dilatation of arterioles, capillaries, and venules, with increased 
permeability and blood flow; ii) exsudation of fluids and macromolecules such as LDL; and iii) 
leukocyte migration into the vascular wall. Leukocytes and endothelial cells are the major cellular 
players of the inflammatory reactions (Nathan, 2002). Endothelial cells coordinate the 
recruitment of inflammatory cells to sites of tissue injury or infection and produce and release 
cytokines and growth factors that serve as communication signals for leukocytes (Muller, 2002). 
In addition, endothelial cells respond to inflammatory stimuli such as lipopolysaccharides (LPS) 
or cytokines. Finally, a series of cell adhesion molecules expressed on leukocytes and on 
endothelial cells mediate leukocyte attachment on and migration across the endothelium in a 
stepwise process. In the normal state, the role of inflammatory endothelial cell activation is to 
minimize the damage induced by injury and/or infection via the recruitment of blood cells to the 
site of injury, by initiating blood coagulation and by healing and promoting repair for recovery of 
function (Jung et al., 1998; Tan et al., 1999). 
In adults, the proliferation rate of endothelial cells is very low, and the growth of new vessels 
only occurs in reproduction, wound healing, or in pathological states such as myocardial 
infarction, hypoxia and cancer. The construction of this new vascular network requires different 
sequential steps, including the release of proteases from ‘‘activated’’ endothelial cells with 
subsequent degradation of the basement membrane, migration of endothelial cells into the 
interstitial space, endothelial cell proliferation, and differentiation into mature blood vessels in 
collaboration with other cells such as smooth muscle cells. These processes are mediated by a 
wide array of angiogenic inducers, including growth factors, chemokines, angiogenic enzymes, 
endothelial specific receptors, and adhesion molecules (Carmeliet, 2000; Carmeliet and Jain, 
2000).  
1.3. Endothelial dysfunction and cytoskeleton 
The normal function of the endothelium is highly dependent on the endothelial cytoskeleton. 
Actin microfilaments, their associated adherens junctions and focal adhesions are important 
regulators of endothelial permeability and cell adhesiveness. After injury of the endothelium, the 
cytoskeleton is essential for endothelial cell migration and proliferation leading to wound repair. 
Disruption and dysfunction of the cytoskeleton may result in impairment of endothelial function, 
subsequently tipping the balance towards vascular disease. Thus, an understanding of the cellular 
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and molecular biology of the endothelial cytoskeleton is important in our understanding of the 
pathogenesis of vascular disease such as atherosclerosis and pathological angiogenesis.  
1.3.1. Actin cytoskeleton 
The term cytoskeleton was originally applied to describe the complex set of protein fibers in the 
cytoplasm (Darnell et al., 1986). The cytoskeleton is composed of three major types of protein 
filaments: microtubules, microfilaments, and intermediate filaments. Microfilaments are 
polymers of actin that together with a large number of actin-binding and associated proteins 
constitute the actin cytoskeleton (Botstein et al., 1997). Modulation of the actin cytoskeletion 
network changes the mechanical properties of the cells that are essential for many cellular 
functions such as shape change, migration, secretion, cell division, phagocytosis and 
pinocytosis. The actin cytoskeleton not only provides mechanical strength to the cells, but it is 
also dynamic and adaptable, constantly changing through cycles of polymerization/ 
depolymerization, and represents an enormous surface area on which proteins and other 
cytoplasmic components can bind.  
Actin filaments are polar helical assemblages of actin protein (43 kDa) that is found in all 
eukaryotic cells and is conserved between species (Pollard and Cooper, 1986). In most of the 
organisms three main actin isotypes (α-, β-, γ-actin) have been found (Herman, 1993).  Actin is 
the most abundant protein in eukaryotic cells, accounting for as much as 20% of total protein (dos 
Remedios et al., 2003). Monomeric (G-) actin has 4 sub-domains (numbered 1-4), each having a 
repeating motif comprising a multi-stranded β-sheet, β-meander, and a right-handed βαβunit. 
The actin cytoskeleton is organized in the cytoplasm in linear bundles as well as 2- and 3-
dimensional networks by a plethora of associated actin-binding proteins, which determine 
structural and dynamic properties and associations with other cell components. 
1.3.2. Actin filament-turnover 
Actin is an adenosine-nucleotide binding molecule with ATPase activity. In physiological salt 
conditions, monomeric G-actin spontaneously self-associates to form polar helical microfilaments 
(F-actin) (Engel et al., 1977). The polymerization of actin can be divided into four steps: 1) 
Activation (salt-binding and conformational changes in monomers); 2) Nucleation (the formation 
of oligomers having a higher probability of growing into filaments than decomposing to 
monomers); 3) Elongation (the bi-directional growth of polymers); and 4) Annealing (the end-to-
end joining of two filaments). All of these steps are reversible. Nucleation is the formation of 
actin trimers which is the rate limiting step and highly unfavorable (Pollard and Cooper, 1986). 
Once a trimer has formed, polymerization by rapid extension is favored during the growth of the 
fiber. The rate of extension gradually lessens as the concentration of remaining free G-actin 
reaches a point where available monomers become exhausted. An equilibrium is then established 
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when the number of actin monomers joining the filaments equals that leaving the filaments, 
which is marked by the so-called critical concentration (Cc) at steady state. Net polymerization 
occurs when the G-actin concentration is higher than Cc, and net depolymerization occurs when 
the G-actin concentration is lower than Cc (Figure 1.2).  
The structural polarity of the actin filaments is created by the regular, parallel orientation of all of 
their subunits. Under appropriate conditions, addition of subunits can occur at both ends. 
However, the rate of addition at the plus end is several times higher than that at the minus end 
(Figure 1.2). G-actin monomers contain tightly bound either ATP or ADP. ATP hydrolysis 
lowers the affinity of ADP-bound G-actin for the filament ends as compared to ATP-bound actin 
(Pollard, 1986). As a consequence, incorporation of ADP-bound actin to existing filaments is 
slower than incorporation of ATP-bound actin. 
 
Figure 1.2 The turnover of an actin filament. The actin filament is a polar structure with two different ends. The 
slow growing pointed end has a higher critical concentration (Cc) than the fast growing barbed end. At steady state, 
the net assembly at the barbed end equals the net disassembly at the pointed end (treadmilling). 
ATP-actin subunits are added at the fast growing or plus end (the barbed end), whereas ADP-
actin disassembles at steady state from the slow growing or minus end (the pointed end). Thus 
ATP hydrolysis is the basis for a turnover of the filament without net change of filament length, a 
process termed treadmilling (Kirschner, 1980; Wegner, 1976; Wegner, 1977). ADP-actin 
disassembly from the pointed end constitutes the rate-limiting step and determines the 
concentration of monomeric actin and thereby the rate of barbed end growth.  
1.3.3. Cellular organization of the actin cytoskeleton 
The best known assemblies of the actin cytoskeleton in cultured cells are stress fibers, 
lamellipodia, microspikes and filopodia, but others like dorsal arcs and peripheral, concave or 
convex bundles of actin filaments as well as geodesic arrays (Heath and Holifield, 1993; Small, 
1988; Small et al., 1999; Small et al., 1998) and less obvious networks between stress fiber 
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bundles, also occur frequently. These assemblies can be divided in two groups, according to 
whether they exhibit unipolar or bipolar arrays of actin filaments.    
Thick bundles of parallel microfilaments are called stress fibers. Stress fibers that delimit the cell 
edge or form the base of non motile lamellipodia, contain bipolar arrays of actin and myosin type 
II and thus possess the ability to contract and to exert tension (Goeckeler and Wysolmerski, 1995; 
Huxley, 1973). They serve mainly to maintain the cellular structure (Schoenwaelder and 
Burridge, 1999). Contraction of stress fibers leads to the rounding of the cells and increased 
permeability of the endothelium (Goeckeler and Wysolmerski, 1995). Stress fibers are common 
in fibroblasts, endothelial cells and epithelial cells and are anchored to the substratum via focal 
adhesions (Bretscher, 1991; Wong et al., 1983).  
Cell movement is initiated by the veil-like protrusion of a thin cytoplasmic sheet of about 200 nm 
thickness, termed the lamellipodium (Small et al., 2002). Lamellipodia are filled with a dense 
network of actin filaments (Small, 1988) that are oriented such that their fast growing barbed 
ends are located next to the membrane (Small et al., 1978). Lamellipodial protrusion is powered 
by actin assembly, involving a rapid turnover of actin filaments operating by a treadmilling 
mechanism, which has been demonstrated in many cell types such as endothelial cells, and 
fibroblasts (Ettenson and Gotlieb, 1994; Small, 1994; Small et al., 1993). 
Electron-microscopic studies of the lamellipodia showed an extensively branched array of actin 
filament network (called dendritic brush) at the leading edge with Y-shaped branches averaging 
70° and a lack of detectable free pointed ends (Svitkina and Borisy, 1999; Svitkina et al., 1997). 
The main actin filament nucleator, the Arp2/3 complex (comprising seven subunits) was found to 
be present at many branch points (Svitkina and Borisy, 1999). This model is consistent with 
binding of the Arp2/3 complex can bind to pointed ends (Mullins et al., 1998) and to the sides of 
actin filaments, where it nucleates new filaments (dendritic nucleation model (Mullins et al., 
1998)), as well as branched filaments (Blanchoin et al., 2000; Gournier et al., 2001). A branched 
network that arises from a tightly coupled nucleation and cross-linking of actin filaments at the 
leading edge is proposed to provide the structural basis for polymerization-driven protrusion. 
Lamellipodia are involved in the formation of adhesions to the substrate, and of ruffles, which 
form when lamellipodia lift upwards and detach from the substratum and fold back (Abercrombie 
et al., 1970). Lamellipodia are important in macropinocytosis as well as in the engulfment of 
particles during phagocytosis (Coppolino et al., 2001). 
Many cells also extend microspikes, which are embedded radially in lamellipodia and are able to 
move laterally within lamellipodia (Wessells et al., 1973), fuse and divide into new microspikes 
(Small et al., 1996). Microspikes have been proposed to serve in the initiation of contacts with the 
substratum (DePasquale and Izzard, 1987). Similar needle-like, highly motile structures termed 
filopodia extend far beyond the border of lamellipodia (Small, 1989). They can protrude 5 to 
50µm beyond the edge of the cell in all three dimensions and can kink and fold back. Filopodia 
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have been most recognized in the neural growth cone as a guidance apparatus located at the tip of 
growing neurons, but they are also present in other cell types, and may fulfill sensory functions 
(Gallo and Letourneau, 1998; Jacinto and Wolpert, 2001; Suter and Forscher, 1998). The 
controlled polymerization of actin filaments at the leading edge creates a force to push the cell 
membrane outwards, with the concomitant protrusion of lamellipodia, filopodia or microspikes. 
In migration, new cell-substratum attachments are established at the front of the cell, the cell 
body is then translocated by intracellularly generated forces, and in a last step all connections to 
the substratum at the back end are broken (Figure 1.3). 
 
 
Figure 1.3 A model for the different steps of cell migration. A migrating cell extends a lamellipodium at the front. 
This extension is stabilized through the formation of new adhesions to the extra-cellular matrix. Rac induces actin 
polymerization and integrin adhesion complex assembly at the cell periphery, leading to membrane protrusion.  The 
cell body is moved forward by actomyosin-mediated contraction (Rho dependent). Finally, the tail of the cell 
detaches from the substratum and retracts. Migrating cells also secrete proteases that cut extra-cellular matrix 
proteins, and this is important for cell movement (Ridley, 2001).  
1.3.4. Regulation of actin dynamics by actin binding proteins 
Under in vitro conditions, the slow addition at the barbed end and even slower dissociation at the 
pointed end of the filaments produces a rate of treadmilling of monomers (~2μm/h) that is ~200-
fold slower than that observed in vivo (dos Remedios et al., 2003). The higher rate of treadmilling 
in vivo is due to proteins, which interact with actin filaments or monomers, called actin-binding 
proteins (ABPs). ABPs present in vivo regulate different aspects of the assembly/ disassembly 
process of actin filaments into two and three-dimensional arrays (Ayscough, 1998). ABPs 
ultimately convey signals to the actin cytoskeleton. A large number of ABPs have been 
identified, about ~162 distinct and separate proteins without including their many synonyms or 
isoforms (dos Remedios et al., 2003). Attempts to classify these ABPs leave many "orphans" that 
do not fit into families, so any attempt to group them is bound to be somewhat arbitrary. 
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Classification according to the function of ABPs can be problematic due to functional overlap. 
Functional classification distinguishes seven groups of ABPs (Figure 1.4).  1) Monomer-binding 
proteins sequester G-actin and prevent its polymerization (e.g., thymosin β4, profiling, DNase I). 
2) Filament-depolymerizing proteins induce the conversion of F- to G-actin (e.g., ADF/Cofilin). 
3) Filament end-binding proteins cap the ends of the actin filament preventing the exchange of 
monomers at the pointed end (e.g., tropomodulin) and at the barbed end (e.g., CapZ). 4) Filament 
severing proteins shorten the average length of filaments by binding to the side of F-actin and 
cutting it into two pieces (e.g., gelsolin). 5) Cross-linking proteins contain at least two binding 
sites for F-actin, thus facilitating the formation of filament bundles, branching filaments, and 
three-dimensional networks (e.g., Arp2/3 α-actinin). 6) Stabilizing proteins bind to the sides of 
actin filaments and prevent depolymerization (e.g., tropomyosin). 7) Motor proteins use F-actin 
as a track upon which to move (e.g., the myosin family of motors). Some ABPs are not limited to 
one class. For example, gelsolin is capable of severing and capping the barbed end of actin 
filaments, and the Arp2/3 complex that consists of seven proteins, can nucleate and elongate 
filaments, and establish branch points in actin networks. 
 
Figure 1.4 Actin polymerization and actin-binding proteins. The actin cycle (lower part) and modulation by 
actin-binding proteins. ATP-actin (black chevrons) will incorporate at the fast-growing ends. Protomers will 
hydrolyze ATP to ADP-Pi (grey chevrons) and subsequently release inorganic phosphate, yielding ADP-protomers 
(white chevrons).  Several actin-binding proteins modulate the cycle by typical activities. Other actin-binding 
proteins mediate linkage to other filaments or to membranes or proteins. 
1.3.5. ADF/Cofilin Family 
The actin depolymerization factor (ADF)/Cofilin (A/C) family of proteins is expressed in 
virtually all eukaryotic cells. These proteins are relatively small (15-19kDa) and exist in multiple 
isoforms. ADF/Cofilin is one of the essential factors for enhancing actin filament turnover. 
ADF/Cofilin weakly severs actin filaments without capping ends, thereby increasing the number 
of free filament ends where polymerization and depolymerization occur. It also enhances the rate 
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of monomer dissociation from the pointed ends (Bamburg et al., 1999; Carlier et al., 1997; 
Maciver et al., 1998). There are over 28 members of the A/C protein family, including 
invertebrate depectin (depolymerises actin), porcine ADF or destrin (destroys F-actin), cofilin 
(cosediments with filamentous actin). They are distributed across the complete spectrum of 
eukaryotic organisms. All of these proteins share considerable (30-40%) amino acid sequence 
identity. Furthermore, two other major protein families are related to ADF through the presence 
of an ADF homology domain. One protein has a duplication of this domain and is consequently 
called twinfilin; the other contains a single ADF homology domain linked to another motif and 
encodes the drebin family of proteins. Vertebrates have genes for only two forms, ADF and 
cofilin. Only one isoform of ADF is known in mammals (and birds), whereas two are known for 
cofilin (cofilin 1 and cofilin 2). Cofilin 1 is expressed in most embryonic tissues and adult cells, 
cofilin 2 is expressed in muscle cells, and ADF expression is limited to epithelial and endothelial 
cells (Vartiainen et al., 2002). Human ADF and cofilin have 72% sequence identity. ADF has a 
much higher depolymerizing activity than cofilin at pH 8. 
The multiple sequence alignment in Figure 1.5 shows the conservation within these A/C family 
members. The vertebrate proteins are somewhat larger than the other three: human cofilin 
contains 166 residues, whereas plant, yeast, and actophorin contain 139, 143, and 137 residues, 
respectively. The vertebrate-specific residues are located principally in loop regions, and include 
a nuclear localization signal (NLS). These residues are found mainly between α-helix 1:β-strand 
1 and β-strand 2: α-helix 3 (Figure 1.5). 
 
Figure 1.5 Sequence alignment of A/C family with known three-dimensional structures. The alignment show 
homologous sequences (boxed), basic/acidic residues (blue/red, respectively), α-helices (green) and β-strands 
(yellow; above for human cofilin with residue numbering and below for yeast cofilin), the salt bridge (red arrows), 




These two inserts are spatially proximal to a vertebrate-specific C-terminal extension that 
together define a contiguous “horseshoe-shaped” surface around the loop between β-strand 3 and 
4, contributing 22% of the total solvent accessible area and giving stability to the loop (Figure 
1.6B). The first vertebrate insert contains a putative NLS that is believed to be responsible for the 
nuclear translocation of the AC upon cellular stress (Figure 1.6B) (Abe et al., 1993).   
 
Figure 1.6 A) The atomic structure of yeast cofilin solved at 1.8 Å showing the NH2 and COOH termini. Putative 
sites for binding F-actin and G-actin (purple helix) are located in the COOH-terminal region of the molecule. The 
solid spheres identify residues that are essential for actin binding. B) It is a ribbon diagram of the lowest energy 
structure of human cofilin. The red arrows indicate the positions of Ser3and Lys96, whose mutation affects G-actin 
and F-actin binding, respectively. The nuclear localization signal and vertebrate specific inserts together make a 
horseshoe-shaped surface (Pope et al., 2004). C) Reconstructed image of F-actin and F-actin with cofilin binding site 
(based on electron cryomicroscopy (McGough et al., 1997). I) The sub-domains of actin and the phalloidin-binding 
site (yellow asterisk) are indicated on reconstructed actin filament. II) Cofilin molecules are shown as copper-colored 
and rugby ball-shaped mass of dimensions 32×37 ×43Å, decorated on actin filament. Cofilin is centered (axially) at 
about the position of subdomain 2 of the lower actin subunit and radially at the cleft between subdomains 1 and 3 of 
the upper actin subunit.   
Porcine destrin (identical in sequence to human ADF) was the first structure in this family of 
proteins to be solved by NMR spectroscopy (Hatanaka et al., 1996) and the structures for yeast 
cofilin (Figure 1.6) (Fedorov et al., 1997) Acanthamoeba actophorin (Leonard et al., 1997) and 
ADF1 from Arabidopsis thaliana (Bowman et al., 2000) were solved by x-ray crystallography. 
Recently the structure of human cofilin was determined by NMR spectroscopy (Pope et al., 
2004). The structural sites to which cofilin binds along the outside of the actin filament, are not 
known in atomic details, but are based on chemical cross-linking and other data. Cofilin binds 
cooperatively between two actin subunits along the filament. F-actin binding by A/Cs requires 
two sites, a G-actin binding site that interacts with subdomains 1 and 3 of the “upper” actin and 
an F-actin binding site that interacts with subdomains 1 and 2 of the “lower” actin (Figure 1.6A, 
C) (McGough and Chiu, 1999). Together these interactions induce a twist change in F-actin and 
weaken both lateral and longitudinal contacts between subunits, preparing the filament for 
severing. One ramification of this structural change is to alter the phalloidin-binding site; thereby 
preventing its binding and making it ineffective as a probe for F-actin (McGough et al., 1997). 
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The weakened actin-actin contacts lead to an increase rate of dissociation at filament pointed 
ends. Both effects contribute to the depolymerizing activities of ADF/cofilin. 
Cofilin binds to ADP-actin with an affinity which is two orders higher than the binding to ATP-
actin or ADP-Pi-actin, and this is true for both the G- and F-actin at pH 7.8 (Carlier et al., 1997). 
Thus cofilin not only promotes the disassembly of ADP-actin monomers from filaments, but it 
also binds to release ADP-actin monomers and inhibits the exchange of their bound nucleotide 
(Nishida, 1985). Besides its binding to actin, cofilin binds to the membrane lipids phosphatidyl 
inositol 4-phosphate (PIP) and phosphatidylinositol 4,5-bisphosphate (PIP2) (Yonezawa et al., 
1990) which inhibit actin binding of cofilin (Kusano et al., 1999), suggesting that transmembrane 
signaling by PIP2 can regulate the function of ADF/cofilin. 
The ability of cofilin to bind G-actin is inhibited by phosphorylation of Ser-3 that is achieved by 
LIM-kinase (LIMK) family of protein kinases. When cofilin is phosphorylated, there is sharp fall 
in its affinity to actin (Yang et al., 1998b).  
1.3.6. Rho GTPases and actin dynamics 
The Rho-family GTPases are key regulators in signaling pathways that link extra-cellular stimuli 
or matrix proteins to the assembly and organization of the actin cytoskeleton (Hall, 1994). 
Signaling through Rho-family GTPases can be initiated by activation of many different types of 
plasma membrane receptors, such as tyrosine kinase receptors, and G-protein-coupled receptors. 
Receptors of cell adhesion molecules such as integrins, cadherins, and Ig superfamily members 
can also affect the Rho-family GTPases (Braga, 2002; DeMali et al., 2003). Cell proliferation is 
normally limited to specific conditions that include stimulation by mitogenic growth factors and 
adhesion to the extra-cellular matrix. Rho-family GTPases can regulate the mitogenic pathways 
that control G1-phase cell cycle progression (Welsh et al., 2001). 
GTPases are molecular switches that use a simple bio-chemical strategy to control complex 
cellular processes. They cycle between two conformational states: one bound to GTP (‘active’ 
state), the other bound to GDP (‘inactive’ state), and they hydrolyze GTP to GDP. In the ‘on’ 
(GTP) state, GTPases recognize target proteins and generate a response until GTP hydrolysis 
returns the switch to the ‘off ’state. The cycling between the active and inactive states is regulated 
by GDP/GTP exchange factors (GEFs), GTPase-activating proteins (GAPs), and guanine 
nucleotide dissociation inhibitors (GDIs) (Figure 1.7). 
The Rho GTPases family belongs to the Ras superfamily of small GTPases and can roughly be 
divided into 5 groups, the Rho-like, Rac-like, Cdc42-like, Rnd, and RhoBTB subfamilies 
(Burridge and Wennerberg, 2004). Rho, Rac and Cdc42, the three best-characterized members of 
the family, stimulate different signaling pathways. The Rho proteins induce the formation of 
stress fibers in response to mitogens such as lysophosphatidic acid (LPA), bombesin, or fetal calf 
serum (FCS) (Ridley and Hall, 1992). Rac proteins stimulate the formation of lamellipodia and 
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membrane ruffles through the activation of Arp2/3 mediated actin polymerization via the indirect 
activation of the WAVE/Scar proteins (Eden et al., 2002; Miki et al., 2000; Ridley et al., 1992). 
Activation of Cdc42-like GTPases by bradykinin, stimulates its binding to WASP inducing a 
conformational change that activates these proteins such that they stimulate Arp2/3  to nucleate 
actin polymerization leading to the formation of peripheral-actin microspikes, filopodia (Kozma 
et al., 1995; Nobes and Hall, 1995).  
 
Figure 1.7 The Rho GTPase cycle. They cycle between an active (GTP-bound) and an inactive (GDP-bound) 
conformation. In the active state, they interact with one of over 60 target proteins (effectors). The cycle is highly 
regulated by three classes of proteins: GEFs (guanine nucleotide exchange factor) catalyze nucleotide exchange and 
mediate activation; GAPs (GTPase activating protein) stimulate GTP hydrolysis, leading to inactivation; and GDIs 
(guanine nucleotide dissociation inhibitors) extract the inactive GTPase from membranes. All Rho GTPases are 
prenylated at their C terminus, and this is required for function (Burridge and Wennerberg, 2004). 
1.3.7. Rho-GTPases activated protein Kinases  
The extra-cellular signals are relayed from the plasma membrane to specific intracellular targets 
mostly through several phosphorylation events catalyzed by different protein kinases. Each of 
these kinases should possess individual target recognition specificity and localization specificity 
in order to ensure the specificity of the signaling flux. Protein kinases are enzymes, which 
catalyze the phosphorylation of the amino acids serine, threonine, or tyrosine in their substrate by 
transfer of the γ -phosphate of ATP to the acceptor amino acid. The regulation of protein 
activities by phosphorylation is a reversible process, with the reverse direction catalyzed by 
protein phosphatases. 
Analysis of the phylogenetic tree of kinase domain alignments, revealed four subfamilies (Hanks 
et al., 1988). Each subfamily consists of protein kinases with related substrate specificities 
(serine/threonine-specific or tyrosine-specific) and modes of regulation (cAMP-dependent, 
calcium/calmodulin-dependent, calcium/diacylglycerol-dependent etc.). The rest of the kinases 
falling outside these major groups are difficult to classify. 
All active Rho GTPases stimulate specific kinases. Rho stimulates several kinases, such as the 
Rho-kinase (p160 ROCK), and cistron kinase. Rho-kinase elevates myosin-light chain (MLC) 
phosphorylation by phosphorylating and inhibiting the MLC phosphatase (Kimura et al., 1996). It 
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can also directly phosphorylate the MLC in vitro (Amano et al., 1996). MLC phosphorylation 
stimulates ATPase activity the interaction of myosin with actin filaments leading to stress fiber 
formation and actin-myosin driven contractility. Cistron kinase, which, like Rho-kinase, 
stimulates MLC phosphorylation and myosin activity, appears to function primarily following 
mitosis in the cleavage furrow of dividing cells (Madaule et al., 1998). Rho-kinase also 
phosphorylates LIM-kinases (LIMKs) and enhances the ability of LIMKs to phosphorylate 
cofilin at Ser3 (Maekawa et al., 1999). Cofilin phosphorylation blocks its actin-depolymerization 
activity. 
 
Figure 1.8 Schematic representation of Rho, Rac, and Cdc42 signaling pathways to the cytoskeleton in 
mammalian cells. 
Both Rac and Cdc42, are known to stimulate p21-activated kinases (PAKs).Overexpression of 
PAKs can promote the formation of lamellipodia (Sells et al., 1997) and lead to the loss of stress 
fibers and focal adhesions (Manser et al., 1997). Several PAK substrates or binding partners have 
been implicated in the effects of PAK, including the actin binding protein filamin, LIM-kinase, 
myosin, the paxillin/Pix/PKL complex, and the adaptor protein Nck. PAK may contribute to the 
loss of stress fibers and focal adhesions by phosphorylating and inhibiting MLCK activity, 
thereby leading to a decrease in MLC phosphorylation. The effect of PAK on MLC 
phosphorylation is particularly controversial (Bokoch, 2003). Additionally, phosphorylation of 
the myosin heavy chain by PAK has also been reported as a mechanism to inhibit myosin 
function and cause the disassembly of actomyosin structures (van Leeuwen et al., 1999). 
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Growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
Phorbol-12-myristate-13-acetate (PMA) and insulin, were observed to stimulate Rac, leading to a 
subsequent Rho activation. PMA stimulates Rac through a PKC-dependent phosphorylation and 
activation of Tiam1 (T-lymphoma invasion and metastasis) (Mertens et al., 2003). 
As shown above, the LIMKs are downstream targets of different pathways, as Rho, Rac, and 
Cdc42 have been linked to the LIMK activation. LIMKs may play an important role in 
endothelial cell biology.  
1.4. LIM-kinase 
LIM-kinase (LIMK) was initially identified in a screen for  novel members of the c-Met/HGF 
receptor tyrosine kinase family (Mizuno et al., 1994). The LIMK family of proteins is a novel 
class of serine/threonine protein kinase family that plays an important role in actin cytoskeleton 
reorganization (Arber et al., 1998), and, as it has been recognized only recently, in cell 
proliferation (Roovers et al., 2003). 
1.4.1. Structure of LIM-Kinases 
LIMK is a unique protein kinase that has two repeats of the LIM domain at the N-terminus, 
followed by a PDZ domain and an unusual protein kinase domain at the carboxy terminus. A 
proline/serine-rich (P/S) region separates the PDZ domain from the kinase domain, which 
comprises approximately half of the 70 kDa masses of the LIMK proteins (Figure 1.9). The 
LIMK protein family is comprised of two members, LIMK1 and LIMK2. Both LIMKs have been 
found in human, rat, mouse, chicken, and Xenopus. Furthermore, the genetic structure of LIMK1 
and LIMK2 genes in human and mouse is well conserved: both genes contain 16 exons and have 
identical intron/exon boundaries (Bernard et al., 1996; Ikebe et al., 1997). Human LIMK1 and 
LIMK2 have 92% homology with mouse LIMK1 and LIMK2, respectively.  
 
Figure 1.9 Schematic structure of LIMK. LIMKs feature two LIM double zinc finger domains at the N-terminus 
followed and one PDZ are separated from the kinase domain by serine/proline spacer region.  
In the mouse, alternative splicing of exon 11 of LIMK1 yields a shorter isoform, LIMK1 (-) 
truncated in the kinase domain (Bernard et al., 1994), which is catalytically inactive (Arber et al., 
1998). LIMK2 is transcribed from two independent sites, which results in the full-length LIMK2a 
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and an N-terminal truncated LIMK2b that lacks the first zinc finger of the first LIM domain. 
LIMK2b may be transcriptionally processed to yield two C-terminal truncated isoforms that 
contain only the LIM and PDZ domains (LIMK2c) or only the LIM domains (LIMK2d) (Nunoue 
et al., 1995). Testis-specific LIMK2 isoform (tLIMK2) lacks the two LIM domains and a portion 
of the PDZ domain (Ikebe et al., 1998; Takahashi et al., 1998). 
Comparisons of selected LIMK homologue protein sequences reveal variations in amino acid 
conservation both within and between domains. The kinase domains are most highly conserved 
between LIMK1 and LIMK2 (~70%), followed by the LIM (~50%) and PDZ domains (~46%). 
Within the LIM domains, the second zinc finger of LIM1 and the first finger of LIM2 are the 
most conserved between the two LIM domains of LIMK1 and LIMK2.  
1.4.1.1. LIM domain 
The LIM domain, as a conserved zinc finger motif, has been found in a variety of different 
proteins from ascidians to man. LIM domains contain 50 to 60 amino acids forming a double 
zinc-finger motif with the consensus sequence (C-X2-C-X16-23-H-X2-C)-X2-(C-X2-C-X16-21-C-X2-
H/D/C). LIM is an acronym of the three transcription factors Lin-11, Isl-1, and Mec-3, in which 
the motif was first identified (Freyd et al., 1990; Karlsson et al., 1990). The conserved cysteine, 
histidine, and aspartic acid residues form two tetrahedral zinc-binding pockets, which stabilize 
the secondary and tertiary structure of the protein. The LIM domain is predominantly made up of 
β –sheets with a short C-terminal α –helix. They are arranged in the order β I–IV, and α -helix, 
where β -sheets I and II are oriented orthogonal to each other and comprise the CCHC zinc 
binding module. Similarly, the orthogonal β -sheets III and IV, together with the α-helix, form the 
C-terminal CCCC subdomain (Figure 1.10B).  
NMR studies of the cytoplasmic LIM proteins CRP1 and CRIP revealed that the LIM domain is 
structurally similar to GATA-type zinc fingers (Perez-Alvarado et al., 1996; Perez-Alvarado et 
al., 1994). However, unlike GATA-type zinc fingers, the LIM domains of animal LIM proteins 
do not seem to bind DNA. Rather, the LIM domain has been implicated in conferring specific 
protein-protein interactions (Arber and Caroni, 1996; Feuerstein et al., 1994; Schmeichel and 
Beckerle, 1994). 
LIM proteins contain one, two or multiple LIM domains and have been divided into three groups 
according to the amino acid homology between their LIM domains. LIM domains were classified 
as types A–E (Figure 1.10) (Dawid et al., 1998). Group 1 LIM proteins contain paired N-terminal 
type A and B LIM domains either alone (Lmo proteins), or in association with a C-terminal 
homeodomain (LIM-homeodomain proteins) or a kinase domain (LIM-kinase). The LIM 
domains of LIMK1 interact with PKC, cytoplasmic domain of the transmembrane ligand 
neuregulin and Bone morphogenetic proteins (BMPs) II (Foletta et al., 2003; Kuroda et al., 1996; 




Figure 1.10 LIM protein structure and classification. A: Schematic representation of a LIM domain. The highly 
conserved cysteine and histidine amino acids form two zinc binding pockets. The two zinc fingers are always 
separated by two amino acids. B: NMR structure of the LIM2 domain of quail CRP2 also showing the zinc ions (red 
sphere, PDB code 1QLI) Both finger domains are constituted by two antiparallel β-sheets in the N-terminal module, 
these are followed by a tight turn that forms the linker to the following module. At the C-terminus of the second 
module, the β-sheets (yellow) is followed by a short α-helix (red). Side chains of the hydrophobic core residues are 
shown in magenta color. (Prepared with the program PyMol (DeLano, 2004). C: Classification of LIM domains 
(dark green, A-E) and groups of LIM domain proteins (Group 1-3) (Please refer text for more details) (Bauer, 2000).  
Group 1 LIM proteins are predominantly nuclear, with the exception of LIMKs. LIM-
homeodomain protein (LHX) perform a critical role embryonic development, tissue 
differentiation, and transcriptional regulation (Bach, 2000). LIM-homeodomain proteins bind 
DNA via their homeodomain (HD), yet their associated LIM domains bind other protein 
transcription factors. The LIM domain appears to have an inhibitory effect on the associated 
homeodomain’s ability to bind DNA (Sanchez-Garcia et al., 1993).  
Group 2 LIM proteins contain one or two type C LIM domains followed by a glycine-rich region 
with no other significant signaling domains. They include muscle LIM protein (MLP/CRP3). 
MLP localizes to the cardiac Z-lines where it binds the important actin-binding protein, α-actinin 
and β-spectrin, interactions that are critical for the structural integrity of the cardiac cytoskeleton 
(Flick and Konieczny, 2000; Pomies et al., 1997). MLP also localizes in the nucleus of myoblasts 
and binds the myogenic transcription factor MyoD, to promote muscle differentiation (Kong et 
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al., 1997), targeted deletion of which has been shown to cause dilated cardiomyopathy in mice, 
due to marked disruption of the cardiac cytoarchitecture (Arber et al., 1997).  
Group 3 LIM proteins contain 1 to 5 predominantly C-terminal type D and E LIM domains either 
alone or in association with other signaling domains such as PDZ or proline-rich motifs. Many 
LIM proteins of group 3 interact with the cytoskeleton and they include the focal adhesion 
proteins paxillin and zyxin. Members of the recently identified FHL protein family also known as 
skeletal muscle LIM proteins (SLIMS) have been shown to localize not only to the cytoskeleton 
but also to the nucleus, where they interact with transcription factors (Brown et al., 1999; Fimia 
et al., 2000). 
1.4.1.2. PDZ domain 
PDZ domains function as protein-protein interaction modules. PDZ domains were first identified 
as regions of sequence homology found in diverse signaling proteins (Kim et al., 1995; Woods 
and Bryant, 1993). The name PDZ derives from the first three proteins in which these domains 
were identified: PSD-95 (a 95 kDa protein involved in signaling at the post-synaptic density), 
DLG (the Drosophila melanogaster Discs Large protein) and ZO-1 (the zonula occludens 1 
protein involved in maintenance of epithelial polarity). These domains have also been referred to 
as DHR (Discs large homology repeat) domains or GLGF repeats (after the highly conserved 
four-residue GLGF sequence within the domain). The primary amino acid sequences of PDZ 
domains may differ considerably (down to some 20% sequence identity), but their three-
dimensional structures appear strikingly similar. Like many other protein-protein interaction 
domains, PDZ domains are relatively small (≤90 residues), show a compact globular structure and 
have N- and C-termini that are close to each other. Thus the domains are highly modular and have 
been integrated into existing proteins without significant structural disruption through the course 
of evolution. The PDZ fold consists of six ß-strands (ßA-ßF) and two α-helice (αA and αB) 
(Figure 1.11A). PDZ domains recognize specific C-terminal sequence motifs that are usually 
about five residues in length, although in some rare cases specificity of recognition extends 
beyond these terminal five residues. The structures of several PDZ-peptide complexes reveal that 
peptide ligands bind in an extended groove between strand ßB and helix αB by a mechanism 
referred to as ß-strand addition. Specifically, the peptide serves as an extra ß-strand that is added 
onto the edge of a pre-existing ß-sheet within the PDZ domain (Figure 1.11B). The peptide ligand 
backbone participates in the extensive hydrogen-bonding pattern normally observed between 
main-chain carbonyl and amide groups in a ß-sheet structure (Figure 1.11C). The structure of the 
PDZ domain does not change upon ligand binding. Structures of PDZ-peptide complexes also 
reveal a loop termed the ‘carboxylate-binding loop’ at the end of the peptide-binding groove. This 
loop contains the well-conserved sequence motif R/K-X-X-X-G-L-G-F. Within the complex, the 
ligand terminal carboxylate is coordinated by a network of hydrogen bonds binding to main-chain 
amide groups in this loop, as well as an ordered water molecule that is coordinated by the side 
chain of a conserved arginine/lysine residue at the beginning of the loop (Figure 1.11). The 
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coordination of the terminal carboxylate, as well as the extensive ß-strand-ß-strand interactions 
between the peptide and strand ßB, firmly positions the peptide in the binding groove. PDZ 
domains can also recognize internal motifs. This second mode of interaction can be recognized, if 
they are presented within the specific tertiary structure context that conformationally mimics a 
chain terminus e.g. interaction of PDZ domain of nNOS with PSD5. 
 
Figure 1.11 Three-dimensional structure of a PDZ domain with or without its peptide ligand. A: solution 
structure of the second PDZ domain of mouse PTP-BL (PDB accession code: 1GM1) showing the 6 β-sheets and 2 
α-helices composing the modular structure characteristic for PDZ domains. The second β-sheet, second α-helice and 
the carboxylate-binding loop (magenta) involved in ligand binding are indicated B: The model of the peptide and 
surrounding domain structure is shown. The electron density map, contoured at 3σ, defines the peptide carboxylate 
group and the last four C-terminal peptide residues. A water molecule, involved in the interaction of the peptide 
carboxylate group with the PDZ domain, is shown as a green sphere. The C-terminal sequence of the peptide is 
KQTSV (Doyle et al., 1996). C: Diagram of the peptide-binding pocket. Residues in the PDZ-domain-binding pocket 
are shown in black; the peptide is shown in blue. Hydrogen bonds are drawn as red dotted lines, and hydrophobic 
packing is indicated by green arcs (Harris and Lim, 2001) 
PDZ domains can be divided into at least three main classes on the basis of their preferences for 
residues in recognition site: class I PDZ domains recognize the motif S/T-X-Φ-COOH (where 
Φis a hydrophobic amino acid and X is any amino acid); class II PDZ domains recognize the 
motif Φ-X-Φ-COOH; and class III PDZ domains recognize the motif X-X-C-COOH. There are a 
few other PDZ domains that do not fall into any of these specific classes. 
The multidomain structure of many PDZ-containing proteins enables them to interact with 
multiple binding partners simultaneously, thereby assembling larger protein complexes. PDZ-
mediated protein complexes are often localized to specific sub-cellular compartments. Such PDZ-
based scaffolds have been shown to organize signal transduction pathways such as 
phototransduction in Drosophila, where ion channels and signaling molecules are co-assembled 
by the multi-PDZ protein InaD (Montell, 1998). PDZ proteins have also been implicated in the 
establishment of cell polarity. In Drosophila, two PDZ-containing proteins, Bazooka and PAR-6, 
form a ternary complex with an atypical protein kinase C that is required for proper establishment 
and maintenance of apical-basal polarity in epithelial tissues (Ohno, 2001).  
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PDZ domains may also serve in coupling cytoplasmic signaling processes to nuclear events 
through nucleocytoplasmic shuttling. Many PDZ containing proteins, like PTP-BL, MAGUK and 
LIMK1, shuttle between nucleus and cytoplasm. The nuclear export of LIMK1 is mediated by 
two leucine rich nuclear export signals within the PDZ domain that might explain the 
predominant cytoplasmic localization of the enzyme (Yang and Mizuno, 1999). The PDZ domain 
of LIMK1 does not contain the carboxylate binding loop and does not bind with the S/TXV 
peptide (Yang et al., 1998a). Thus, the PDZ domain of LIMK1 may have other specific modes of 
protein interaction. 
1.4.1.3. Kinase domain 
The kinase domain of eukaryotic protein kinases, which is well conserved among 
serine/threonine and tyrosine kinases, contains 12 conserved subdomains (Figure 1.12A). These 
subdomains fold into a common catalytic core structure, that is separated into two lobes (Figure 
1.12B) (Hanks et al., 1988). The smaller N-terminal lobe (subdomains I-IV), or N lobe, is 
composed of a five-stranded β sheet and one prominent α helix, called helix αC. The C lobe 
(subdomains VIa-XI) is larger and is predominantly helical. ATP is bound in a deep cleft 
(subdomain V) between the two lobes and sits beneath a highly conserved loop connecting 
strands β1 and β2 (Figure 1.12B). This γ-phosphate binding loop, or P loop, contains a conserved 
glycine-rich sequence motif (GXGXφG) where φ is usually tyrosine or phenylalanine. The 
glycine residues allow the loop to approach the phosphates of ATP very closely and to coordinate 
them via backbone interactions. The conserved aromatic side chain caps the site of phosphate 
transfer. The glycine residues make the P loop very flexible in the absence of ATP (Zheng et al., 
1993).   
Peptide substrate binds in an extended conformation across the front end of the nucleotide-
binding pocket, close to the γ-phosphate of ATP. A centrally located loop known as the 
“activation loop,” typically 20–30 residues in length, spanning conserved sequences DFG and 
APE, provides a platform for the peptide substrate. In most kinases, this loop is phosphorylated 
when the kinase is active. Phosphorylation of the activation loop stabilizes it in an open and 
extended conformation that is permissive for substrate binding. 
Optimal phosphotransfer requires the precise spatial arrangement of several catalytic residues that 
are absolutely conserved among all known kinases. Asp166 and Asn171 (PKA numbering, Asp451 
and Asn456 of LIMK2) emanate from a highly conserved loop structure at the base of the active 
site, called the catalytic loop. Asp166 interacts with the attacking hydroxyl side chain of the 
substrate, while Asn171 engages in hydrogen bonding interactions that orient Asp166 (Figure 
1.12C). Asn171 and another absolutely conserved catalytic residue, Asp184 (Asp469 of LIMK2), are 
also required for the binding of two divalent cations involved in nucleotide recognition (Figure 
1.12C). Asp184 forms part of the highly conserved DFG motif situated at the base of the activation 
loop. The structure of this motif, and in particular the conformation of Asp184, is tightly coupled 
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to phosphorylation of the activation loop. In the N lobe, Lys72 (Lys360 of LIMK2) makes crucial 
contacts with the α- and β-phosphate groups, positioning them properly for catalysis. Lys72 is 
buried deep within the inter lobe cleft, where it is stabilized and oriented properly by an ionic 
interaction with Glu91 (Glu376 of LIMK2), a residue in the αC helix.  
 
Figure 1.12 A: Typical 300 amino acid protein serine/threonine kinase catalytic domain. The 12 conserved 
subdomains are indicated by Roman numerals. Consensus sequences found in the subdomains are shown with 
invariant or nearly invariant residues in bold. B: Schematic diagram of the fold of phosphorylase kinase (PhK), 
illustrating a typical protein kinase fold. The N-terminal lobe is shown in white, the hinge region in magenta and the 
C-terminal lobe in salmon. The catalytic loop is shown in gold and the activation segment in cyan. α-Helices are 
labeled from αC to αI (αI is obscured by αF). β-Strands are labeled β1–β9. The substrate peptide is shown in green 
with all residues displayed and the serine to be phosphorylated marked by S (P0). AMPPNP and two manganese 
atoms (magenta) are shown with all atoms displayed (Johnson et al., 1998). C: A Schematic Representation of ATP 
and Some of the Key Residues at the Catalytic Site and Activation Segment of cAPK. A possible mechanism is 
shown in which base-catalyzed attack by Asp-166 on the substrate serine promotes the formation of an alcoholate 
ion, which can then attack the γ phosphate of ATP. The catalytic mechanism is not definitively established (Johnson 
et al., 1996). 
The characteristic short sequence motif (DLKXXN) of a serine/threonine kinase family, present 
in subdomain VIb, is highly conserved among all the members of this family. This motif is also 
present in subdomain VIB of LIM-kinases. Almost all known serine/threonine-specific protein 
kinases, including the kinases with dual specificity, contain the highly conserved lysine residue at 
the third position of this motif (DLKXXN). In contrast both LIMK1 and LIMK2 contain the 
sequence DLNSHN in this motif, which does not carry either the arginine or the lysine residue at 
the third position, but does have a histidine residue at the fifth position: (Nunoue et al., 1995). 
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1.4.2. Gene expression and subcellular localization of LIM-kinases 
Northern and in situ hybridization (ISH) analyzes from different studies revealed that the highest 
levels of LIMK1 are found in fetal and adult neural tissues, such as the brain, spinal cord, and 
various sensory organs (Bernard et al., 1994; Cheng and Robertson, 1995; Mizuno et al., 1994). 
In contrast, LIMK2 isoforms (see section 1.4.1) display significant variation of expression in 
mouse in tissue distribution. The LIMK2a transcript is ubiquitously expressed in a variety of 
tissues such as kidney, lung heart, including neural tissues, and LIMK2b is predominantly 
expressed in the brain (Koshimizu et al., 1997; Mori et al., 1997). Furthermore, the testis-specific 
LIMK2 isoform (tLIMK2) is specifically expressed in differentiated, meiotic stages of 
spermatogenic cells, therefore suggesting that it contributes to spermatogenesis (Takahashi et al., 
1998). Recently Foletta et. al. (Foletta et al., 2004) demonstrated, using a specific LIMK1 
monoclonal antibody that the expression of LIMK1 is not only limited to neural tissues but is 
present in all tissues, although the levels of expression varied. In this study, LIMK1 in every cell 
and tissue type had an apparent mobility of about 70kDa. In some tissues, notably stomach, 
human fibroblasts and pig kidney cells, smaller bands of 45-50kDa were also evident like LIMK2 
short isoforms. They also observed a high molecular weight form of 80kDa in the mouse brain.  
LIMKs display a unique subcellular localization. LIMK1 and LIMK2a are localized mainly in the 
cytoplasm and to a lesser extent in the nucleus. In contrast, LIMK2b shows exclusive cytosolic 
distribution (Osada et al., 1996). tLIMK2 lacking both LIM domains was found to be 
preferentially localized in the nucleus (Takahashi et al., 2002). In mouse tissues, nuclear 
localization of LIMK1 was more pronounced than reported previously and found in a wide range 
of cell types including epithelial cells, spermatocytes, neuronal cells and muscle fibers. 
Immunofluorescence analysis of cultured cells revealed LIMK1 localization at focal adhesions in 
many adherent cell types suggesting a role in cell attachment and motility. In cultured 
hippocampal neurons, LIMK1 was found highly localized in axonal and dendritic growth cones 
and exhibited strong Golgi staining. 
1.4.3. Regulation of LIMK activation 
The catalytic activity of many protein kinases is usually suppressed in cells and is activated only 
in response to certain upstream stimuli. The extra-catalytic region of the kinase often serves as 
the domain that negatively regulates the kinase activity. Moreover, liberation from its suppressive 
effect by events, such as binding of activators to the extra-catalytic region or phosphorylation of 
residues in catalytic and/or extra-catalytic regions by upstream kinases or by autophosphorylation 
results in activation of the enzyme (Johnson et al., 1996).  
The N-terminal LIM domains play an inhibitory role in the regulation of the kinase activity of 
LIMK1 by direct interaction with the kinase domain (Nagata et al., 1999). The LIM domains may 
fix the kinase domain in an inactive conformation, or inhibit the access of substrates by masking 
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the kinase catalytic site or substrate-binding site. Many serine/threonine kinases are 
phosphorylated on a residue(s) in the activation loop (Figure 1.12B). LIMK1 and LIMK2 have 
threonine at 508 and 505 respectively in the activation loop. Rho-kinase, PAK1 and PAK4 
phosphorylate LIMK1 at Thr508 (Dan et al., 2001; Edwards et al., 1999; Sumi et al., 2001a). 
Rho-kinase phosphorylates LIMK2 at Thr505 thereby activating it. LIMK2 is also 
phosphorylated at Thr505 by MRCKα (Myotonic dystrophy kinase-related Cdc42-binding 
kinase) (Sumi et al., 2001b).  
1.5. Regulation of protein transport between nucleus and cytoplasm 
Eukaryotic cells are characterized by distinct nuclear and cytoplasmic compartments that are 
separated by the nuclear envelope, a double membrane that is continuous with the endoplasmic 
reticulum. Protein transport between nucleus and cytoplasm is an integral part of eukaryotic cells 
processes such as differentiation, proliferation and the control of gene expression. (Jans and 
Hubner, 1996) Because gene transcription and translation take place in separate sub-cellular 
compartments, specific transport events occur: a) mRNA and ribonucleoproteins take away from 
the nucleus into the cytoplasm, b) the proteins that are required in the nucleus need to be 
specifically transported into the nucleus. Therefore, many molecules shuttle continuously 
between the nucleus and the cytoplasm through the nuclear pore complexes (NPCs), which 
penetrate the nuclear envelope. NPC consists of a central core with a ring-spoke structure 
exhibiting 8-fold radial symmetry. From this central ring, 50-100nm fibrils extend into the 
nucleoplasm and the cytoplasm (Akey and Radermacher, 1993; Pante and Aebi, 1994). It is 
estimated that the average mammalian nucleus contains approximately 5600 pores. Small 
proteins (<40-60kDa), and small molecules such as lipid, ions and metabolites passively diffuse 
through the NPC by following a concentration gradient. Macromolecules larger than 40-60 kDa 
are, in most cases, actively transported across the NPC. NPCs of higher eukaryotes have a mass 
of ~125MDa and are estimated to be composed of ~50-100 different proteins that are often 
collectively called nucleoporins (Gorlich and Kutay, 1999; Ohno et al., 1998). The active nuclear 
import and export of proteins is mediated by specific amino acid sequences, which are referred to 
as nuclear localization signals (NLSs) and nuclear export signals (NESs), respectively, and which 
are usually present within the primary structure of each cargo. 
Nuclear import signals are often characterized by essential basic amino acids, which lead to the 
proposal of consensus import signal. The basic types of NLS are mainly either monopartite or 
bipartite (Gorlich and Kutay, 1999). A monopartite NLS consists of a single short cluster of 
consecutive basic amino acids, while a bipartite NLS comprises two clusters of basic amino acids 
separated by a 10–12 amino acid spacer.  Many transporters belong to the importin superfamily, 
and, frequently, the interactions of importin with cargo protein via NLS and NPC proteins 
(nucleoporins) are orchestrated by the small GTP-binding protein Ran guanosine triphosphatase 
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(Ran GTPase). Because of the spatial distribution of its GAP and GEF proteins, cytoplasmic Ran 
is primarily in the GDP-bound state, whereas nuclear Ran is primarily in the GTP-bound state 
(Figure 1.13) (Weis, 2003). Cargo proteins destined for import are attached to importin-β via the 
importin-α adaptor protein (although a minority of cargo proteins bind to importin-β directly) 
(Wozniak et al., 1998). Importin-α consists of two functional domains, a short basic N-terminal 
importin-β binding domain (the IBB domain), and an NLS-binding domain built of armadillo 
(arm) repeats motifs (Kobe, 1999). Importin-α is autoinhibited by its N-terminal segment 
containing the IBB domain. Importin-β binding to importin-α removes the N-terminal 
autoinhibitory segment from the NLS-binding site in importin-α. This importin-α/β heterodimer 
is then active and importin-α binds to a NLS-containing cargo protein in the cytoplasm (Figure 
1.13). The passage of importin-β cargo complexes through NPCs is mediated by transient 
interactions with nucleoporins that have characteristic FG sequence repeats (Bayliss et al., 2000). 
Therefore, importin-α acts as an adapter molecule between the cargo and importin-β, and it is 
importin-β, which actually carries the cargo from the cytoplasm into the nucleus. After 
translocation of the cargo/importin complex through the NPC, nuclear RanGTP binds to 
importin-β, inducing release of its cargo and facilitating the recycling of both importins back to 
the cytoplasm (Gorlich et al., 1996). Importin-β, bound to RanGTP, returns to the cytoplasm. 
Whereas importin-α forms a trimeric complex within the nucleus with CAS (one of the importin-
β related molecules) and RanGTP, and then migrates into the cytoplasm (not shown in Figure 
1.13)(Kutay et al., 1997). For the next import cycle, in the cytoplasm, the GTP hydrolysis of Ran 
bound to importin-β or CAS triggers the dissociation of the complex, resulting in recycling of the 
carrier molecules.  
On the other hand, the leucine-rich NESs, which contain export cargoes, are complexed with their 
export receptor, CRM1 (Chromosomal Region Maintenance 1) and RanGTP in the nucleus. 
CRM1 (designated exportin 1) is also related to importin-β with Ran-binding activity and binds 
the export cargo cooperatively with RanGTP. The NES-cargo/CRM1/RanGTP trimeric complex 
is translocated through the NPC towards the cytoplasm without GTP hydrolysis of Ran (Fornerod 
et al., 1997; Fukuda et al., 1997; Stade et al., 1997). After the translocation, the trimer dissociates 
in the cytoplasm or on the cytoplasmic side of the NPC via the conversion of RanGTP to the 
GDP-bound form. The drug leptomycin B inhibits this pathway by binding to CRM1 (Kudo et al., 
1998). Therefore, this drug is very useful for the identification of CRM1-dependent export 
cargoes and for verifying whether proteins are shuttled continuously between the cytoplasm and 
the nucleus, when the proteins are exported in a CRM1-dependent manner.  
Ran GTPase cycle is regulated by various interacting proteins. The GEF of Ran (RanGEF), 
RCC1, accelerates the dissociation of guanine nucleotide from Ran, resulting in the conversion of 
RanGDP to RanGTP because of a higher levels of GTP compared with GDP in cells. RCC1 is a 
chromatin protein and is located in the nucleus. Thus, the generation of the GTP-bound form of 
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Ran occurs only in the nucleus. Ran GTPase activity is stimulated by the GAP of Ran (RanGAP) 
in the cytoplasm.  
  
Figure 1.13 Scheme for nuclear import and export of proteins.  Cargo proteins are transported by importin or 
exportin and Ran coordinates their transport. NLS: nuclear localization signal, NES: nuclear export signal.
A large number of proteins shuttle between the nucleus and the cytoplasm. The intracellular 
localization of these proteins is highly regulated and dependent on extra-cellular signals and the 
cell cycle. Extra-cellular signal-regulated kinases1 and 2 (ERK1/2) translocate into the nucleus 
after activation of the cells with epidermal growth factor (EGF), and phosphorylate specific 
transcription factors such as Jun and Fos that control cell proliferation, differentiation and 
apoptosis (Thomson et al., 1999). Essential cell cycle regulators such as cyclins and cyclin-
dependent kinases (CDKs) shuttle continuously between the nucleus and cytoplasm, and the final 
localization of these proteins regulates the cell cycle progression (Yoneda, 2000). Overexpression 
studies demonstrated that LIMKs are found not only in the cytoplasm but also in the nucleus. The 
cytoplasmic localization of LIMK1 is due to the presence of two functional leucine rich NESs, 
which are sensitive to LMB (Yang and Mizuno, 1999). Therefore, LIMK1 shuttles between the 
nucleus and the cytoplasm. However, the mechanism by which the nucleocytoplasmic shuttling 
occurs is completely unknown. 
1.6. Cellular functions of LIMK-kinases 
Overexpression of LIMKs in a variety of cultured cell types resulted in actin stabilization and 
subsequent aggregation of F-actin (Amano et al., 2001; Arber et al., 1998). This effect of LIMKs 
can be explained by cofilin phosphorylation at Ser-3 (inactivation of cofilin) and inhibition of 
actin depolymerization (Arber et al., 1998). Overexpression studies of LIMKs also observed that 
LIMKs play an important role in stress fiber formation, stabilization of focal adhesion, and ruffle 
formation in various cells (Amano et al., 2001).  
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Furthermore, evidence is accumulating that LIMKs are involved in transducing signals from 
extracellular stimuli to cytoskeletal networks that regulate various functions, such as cell division, 
motility, and the maintenance of specialized structures in differentiated cells.  
For example LIMK1 interacts with the tail region of BMPR-II (Bone Morphogenetic Proteins 
Receptor); a transmembrane serine threonine protein kinase phosphorylates BMPR1 and 
regulates the Smad transcription factor. This interaction between LIMK1 and BMPR-II inhibited 
LIMK1's ability to phosphorylate cofilin (Foletta et al., 2003). A BMPR-II mutant containing the 
truncation of the tail region described in the rare autosomal dominant disorder primary 
pulmonary hypertension (PPH), is characterized by the proliferation of pulmonary artery smooth 
muscle cells and endothelial cells, resulting in an increased blood pressure followed by heart 
failure. The level of LIMK1 protein is increased in PPH patients, and truncated BMPRII, which 
mimics the PPH patient’s mutants of BMPRII, failed to bind or inhibit LIMK1. These results 
together suggest that disregulation of LIMK activity could lead to the hyperproliferation of 
endothelial and smooth muscle cell, a characteristic of PPH. 
Various reports showed that LIMK1 is upregulated in adenocarcinomatous prostatic epithelium 
and prostate cancer cell lines, and that it is essential for the invasive property and growth of 
prostate cancer cells. Interestingly, this effect is not mediated through phosphorylation of cofilin 
(Davila et al., 2003; Yoshioka et al., 2003). These finding suggest a possible correlation of 
LIMK1 expression with prostate cancer progression. A recent study shows that LIMK1 cleaved 
by caspases at Asp-240, and that cleaved LIMK1 fragment induces membrane blebbing in 
apoptotic Jurkat and Hela cells. These results suggest that LIMK1 might play a critical role in 
membrane bleb formation during apoptosis (Tomiyoshi et al., 2004).  
In Williams syndrome, the chromosomal region containing the LIMK1 gene is deleted, a 
neurodevelopmental disorder characterized by mental retardation, difficulties in visuospatial 
constructive cognition, and skeletal abnormalities. This syndrome raised the questions regarding 
a specific neuronal function of LIMK1 (Frangiskakis et al., 1996). LIMK1- and LIMK2-deficient 
mice have been developed, to explore the function of LIMK in vivo. LIMK1-deficient mice 
developed quite normally, but they showed abnormalities in the hippocampal dendritic spine 
structure (Meng et al., 2002). In addition, these mice showed a significant deficit in relearning 
spatial information, strongly suggesting that LIMK1 might be implicated in Williams syndrome. 
Somewhat surprisingly, the LIMK1-deficient mice, and the LIMK2-deficient mice, which have 
all three LIMK2 isoforms disrupted, did not exhibit embryonic lethality. In addition, there was no 
marked phenotypic abnormality in postnatal growth and development in these mice (Takahashi et 
al., 2002). Apart from a smaller testis size, LIMK2-deficient mice older than two years showed 
no pathological symptoms, abnormal behavior, or significant increase in tumor development. A 
possible explanation for these normal phenotypes may be a functional redundancy of the two 
LIMKs i.e. LIMK1 fulfills the function of LIMK2 and vice versa. LIMK1- and LIMK2-double- 
deficient mice might answer this question.  
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2. Aim of the study 
The activation of the endothelium with various stimuli such as thrombin leads to cell shape 
change, migration, and proliferation that involve dynamic changes of the actin cytoskeleton. The 
Rho family GTPases activate Rho-kinase and PAK, which stimulate LIM-kinases. LIM-kinases 
regulate the actin cytoskeleton through phosphorylation of cofilin. Only very few studies reported 
about other functions of LIM-kinases, such as its possible role in cell cycle regulation. The 
function of the LIM-kinases is unknown in endothelial cells.  
The aim of the present study was to answer the following two major questions: 
A) Which LIM-kinase(s) are expressed in endothelial cells? What is the role of LIM-kinases and 
cofilin phosphorylation in thrombin-induced stress fiber formation and contraction of endothelial 
cells? How is the LIMK/cofilin pathway regulated in endothelial cells? 
B) Does LIMK2 shuttle between the cytosol and the nucleus in endothelial cells? If yes, which 
are the responsible nuclear localization signals (NLSs) and nuclear export signals (NESs)? How 
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3. Materials and methods 
Protocols were adapted from standard methods (Sambrook and Russell, 2001) unless otherwise 
mentioned. 
All solutions and media were prepared with ultra-pure water (Milli-Q Plus ultra purification pak, 
Milli-RO Plus purification pak; Millipore, Molsheim, France). 
3.1. General equipments 
Autoclave Autoclave 23; MELAG Medizintechnick (Berlin, Germany) 
Bioclav; Schütt Labortechnik GmbH (Göttingen, Germany) 
Centrifuges Biofuge pico, Omnifuge 2.OR, Megafuge 1.ORS, Heraeus 
(Osterode, Germany) Centrikon H-401, with Rotors A8.24 and 
A6.9; Kontron-Hermle (Gosheim, Germany) 
Chromatography System Automated Econo System; Biorad (Hercules, CA) 
Electroporation apparatus Gene pulser II; Biorad (Hercules, CA) 
Freezer, -70°C ULT1706; Revco Scientific (Asheville, NC),  
Gel documentation camera Polaroid MP-4 land camera; Polaroid USA 
Gel Electrophoresis   Biorad (Hercules, CA) 
Hera freeze; Heraeus (Osterode, Germany) 
Incubators   WTB Binder (Tuttlingen, Germany), Forma Scientific (USA) 
JULABO Labortechnik GmbH 
Liquid nitrogen tank  BT40; L’air liquide (Champigny, France) 
LSM 510META confocal microscope; Zeiss (Jena Germany) 
Magnetic stirrer  MR3001; heidolph (Kelheim, Germany) 
Microscope   IX50; Olympus Optical GmbH (Hamburg, Germany) 
Model RI60P; Sartorius (Göttingen, Germany) 
pH meter   Model 765 Calimatic; Knick (Berlin, Germany) 
Scales    Model BP 2100S; Sartorius (Göttingen, Germany) 
Sonicator   SONOPLUS Bandelin electronic GmbH (Berlin, Germany) 
Spectrophotometer  UVICON 930; Kontron instruments (Echingen, Germany) 
Thermocycler   Mastercycler gradient; Eppendorf (Hamburg, Germany) 
Thermomixer   Thermomixer compact; Eppendorf (Hamburg, Germany) 
Ultracentrifuge OptimaTM TLX, with rotor TLA 100.4; BeckMan Instruments 
Fullerton, CA 
Vortexer   REAX top; Heidolph (Kelheim, Germany) 
Water baths   GFL GmbH (Burgwedel, Germany) 
Densitometer   Pharmacia LKB (Sweden) 
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UV illuminator  Model N90M; UniEquip (Martinsried, Germany) 
3.2. Materials 
3.2.1. Chemicals 
Acryl/Bis 37.5:1; 40% (w/v) Solution AMRESCO Inc. USA 
Acetic acid     Merck Biosciences GmbH, Schwalbach, Germany 
Agar       Mo Bio Laboratories, USA 
Agarose      Sigma, Munich, Germany 
Ammonium persulphate    Sigma, Munich, Germany 
Ampicillin     Sigma, Munich, Germany 
Aprotinin      Sigma, Munich, Germany 
ATP       Amersham Biosciences, Freiburg, Germany 
BrdU      Sigma, Munich, Germany 
Bromophenol blue     Sigma, Munich, Germany 
BSA (bovine serum albumin)   Sigma, Munich, Germany 
G250 Brilliant Blue     Serva, Heidelberg, Germany 
Dideoxynucleotides    Stratagene Inc USA
DMSO      Sigma, Munich, Germany 
DTT       Sigma, Munich, Germany  
EDTA       Sigma, Munich, Germany 
Ethanol     Merck Biosciences GmbH, Schwalbach, Germany 
Isopropanol     Sigma, Munich, Germany 
Ethidium Bromide     Sigma, Munich, Germany 
Formamide      Fluka AG, Neu-Ulm, Germany 
G418 (Geneticin)     Invitrogen, Karlsruhe, Germany 
Glycerol     Merck Biosciences GmbH, Schwalbach, Germany 
Glutathione-Sepharose    Amersham Biosciences, Freiburg, Germany 
HEPES      Sigma, Munich, Germany 
Hoechst 3342     Molecular Probe,  USA 
IPTG       peqLab Biotechnologie, Erlangen, Germany 
Lipofectamine®     Invitrogen, Karlsruhe, Germany 
L-Glutamine      Invitrogen, Karlsruhe, Germany  
Leptomycin B     Sigma, Munich, Germany 
Kanamycin      Sigma, Munich, Germany 
Methanol     Merck Biosciences GmbH, Schwalbach, Germany 
Protein A Sepharose CL-4B    Sigma, Munich, Germany 
SDS       Sigma, Munich, Germany 
Sodium Azide     Serva, Heidelberg 
Sodium Fluoride     Sigma, Munich, Germany 
Sodium Orthovanadate         Aldrich, Steinheim, Germany 
PMA      Sigma, Munich, Germany  
PMSF       Sigma, Munich, Germany 
Ponceau S      Sigma, Munich, Germany 
Propidium Iodide    Sigma, Munich, Germany 
TEMED      Sigma, Munich, Germany 
Triton X-100      Sigma, Munich, Germany 
Tryptone      Sigma, Munich, Germany 
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Tween 20      Sigma, Munich, Germany 
Yeast extracts      Sigma, Munich, Germany 
3.2.2. Enzymes and reagents for molecular biology 
Restriction enzymes   New England Biolabs GmbH, Frankfurt, Germany  
Taq DNA polymerase   New England Biolabs GmbH, Frankfurt, Germany  
Pfu Ultra HF DNA polymerase Stratagene, Netherlands 
Thermoscript reverse transcriptase Invitrogen GmbH, Karlsruhe, Germany 
Calf Intestine alkaline phosphatase Roche Diagnostic, Mannheim, Germany 
T4 DNA ligase   New England Biolabs GmbH, Frankfurt, Germany 
RNaseA     Sigma, Munich, Germany 
DNase I    Roche Diagnostic, Mannheim, Germany 
DNase (RNase free)   Qiagen, Hiden, Germany 
Lysozyme    Sigma, Munich, Germany 
dNTP     Stratagene, Netherlands 
T4 Polynucleotide kinase  New England Biolabs GmbH, Frankfurt, Germany 
3.2.3. Antibodies 
3.2.3.1. Primary antibodies 
LIM-kinase 1 Rabbit IgG, directed against KLH conjugated synthetic peptide 
corresponding to the C-terminal residues of LIMK1 
Western Blotting 1:1000, Immunoprecipitation 1:25 
LIM-kinase 2 Rabbit IgG, directed against KLH conjugated synthetic peptide 
corresponding to the C-terminal residues of LIMK2 
Western Blotting 1:1000, Immunoprecipitation 1:25 
Phospho-LIM-kinase Rabbit IgG, directed against KLH conjugated synthetic phospho-
peptide corresponding to residues surrounding Thr508 of LIMK1. 
Western Blotting 1:1000, Immunoprecipitation 1:25 
Cofilin Rabbit IgG, directed against KLH conjugated synthetic peptide 
corresponding to residues surrounding Ser3 of human cofilin. 
Western Blotting 1:12000  
Phospho-Cofilin Rabbit IgG, directed against KLH conjugated synthetic phospho-
peptide corresponding to residues surrounding Ser3 of human 
cofilin. Western Blotting 1:1000. 
Phospho-MYPT1 Rabbit IgG, directed against KLH conjugated synthetic peptide 
corresponding to residues 848-858 of human MYPT1. 
Western Blotting 1:3000. 
Phospho-(Ser) PKC  Rabbit IgG, directed against synthetic phospho-PKC substrate 
Substrate   PKC peptides consensus sequences library. 
                                                Western Blotting 1:1000 
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3.2.3.2. Secondary antibodies 
Anti-rabbit IgG HRP conjugated F(ab’)2 fragment, from donkey, Amersham Biosciences, 
Freiburg, Germany. Western blot 1:5000 
Anti-mouse IgG HRP conjugated F(ab’)2 fragment, from sheep, Amersham Biosciences, 
Freiburg, Germany. Western blot 1:5000 
3.2.3.3. IgG isotype controls and sera 
Rabbit IgG    Sigma, Munich, Germany 
Mouse IgG    Sigma, Munich, Germany 
Donkey serum    Sigma, Munich, Germany 
Goat serum    Sigma, Munich, Germany 
3.2.4. Inhibitors 
Y27632 (Rho-kinase)   Merck Biosciences GmbH, Schwalbach, Germany 
Gö6976 (PKC isoforms)  Merck Biosciences GmbH, Schwalbach, Germany 
Gö6983 (PKC isoforms)  Merck Biosciences GmbH, Schwalbach, Germany 
Gö6950 (PKC isoforms)  Merck Biosciences GmbH, Schwalbach, Germany 
Phosphatase inhibitor cocktail Roche Diagnostic, Mannheim, Germany 
Proteases inhibitor cocktail  Roche Diagnostic, Mannheim, Germany 
3.2.5. Ligands 
Thrombin    Sigma, Munich, Germany 
LPA     Avanti polar lipids Inc. USA 
PMA     Sigma, Munich, Germany 
3.2.6. Commercial Kits and other materials 
QIAquickTM PCR-Purification kit   Qiagen, Hiden, Germany 
QIAquickTM Gel-extraction kit   Qiagen, Hiden, Germany 
QIA®Spin Miniprep kit    Qiagen, Hiden, Germany 
Endofree® Plasmid Maxi kit    Qiagen, Hiden, Germany 
RNeasy® mini kit     Qiagen, Hiden, Germany 
QuickChange® XL Site directed mutagenesis kit Stratagene, Netherlands 
Rapid DNA ligation kit    Roche Diagnostic, Mannheim, Germany 
Expend High Fidelity PCR system   Roche Diagnostic, Mannheim, Germany 
ThermoscriptTM RT-PCR system   Invitrogen GmbH, Karlsruhe, Germany 
Zero Blunt®TOPO®PCR cloning kit   Invitrogen GmbH, Karlsruhe, Germany 
DotMetricTM-1μl Protein assay kit   Genotech Inc. USA 
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Lowry Protein assay kit    Sigma, Munich, Germany 
HybondTM-C extra blotting membrane  Amersham Biosciences, Germany 
SuperSignal®West Pico chemiluminiscent   Pierce, Rockland, USA 
Substrate   
Photographic film     Polapan; Polaroid, Offenbach, Germany 
3.2.7. Primers 
3.2.7.1. For preparation of cDNA inserts 
 























* Restriction sites are shown in red.  
 
Sense, EcoR1   
Sense, EcoR1  
Sense, EcoR1   
Antisense, Sal1  
Sense, Xho1 
Antisense, Age1 
Sense, EcoR1  
Sense, EcoR1   
Antisense, Sal1 
3.2.7.2. For deletion mutation 
 























Sense, LIM2 deletion 
Sense, LIM1 deletion 
Antisense LIM1 and N-term 
of kinase domain deletion 
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3.2.7.3. For site directed mutagenesis 
Primer Sequence* Description (position of 




































































* The mutated bases are shown in red 
 
Sense (451 to A) 
Antisense (451 to A) 
Sense (505 to A) 
Antisense (505 to A) 
Sense (505 to EE) 
Antisense (505 to EE) 
Sense (283 to A) 
Antisense (283 to A) 
Sense (283 to EE) 
 
Antisense(283 to EE) 
 
Sense (494 to A) 
Antisense (494 to A) 
Sense (494 to EE) 
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3.2.7.4. Primers for gene expression analysis  




















3.2.8.1. Original plasmids 













Expression vector, EGFP tag 
at the N-terminal of the gene, 
CMV promoter, Kanr, Neor 
Expression vector, EYFP tag 
at the C-terminal of the gene, 
CMV promoter, Kanr, Neor 
Expression vector, GST tag at 
the N-terminal of the gene, 
Tac promoter, Ampr 
Expression vector, dsRed tag 
at the C-terminal of the gene, 
CMV promoter, Kanr, Neor
Clontech, Palo Alto, USA 
 





Clontech, Palo Alto, USA 
 
 
3.2.8.2. Plasmid with insert 












Human cytoplasmic β-actin gene cloned 
in pEGFP-C1 
Wild type human LIMK2 gene 
 
Full length (amino acids1-638) LIMK2 in 
pEGFP-C1 
LIM1 domain truncated LIMK2 in 
pEGFP-C1 (amino acids 69-638) 
LIM2 domain truncated LIMK2 in 
pEGFP-C1 (deleted amino acids 72-124) 
PDZ and kinase domain of LIMK2 in 
Clontech, Palo Alto, 
USA 
Dr. K. Mizuno, univ. 



















pEGFP-C1 (amino acids 142-638) 
Kinase domain of LIMK2 in pEGFP-C1 
(amino acids 315-638) 
LIMs and PDZ domains of LIMK2 in 
pEGFP-C1 (amino acids 1-239) 
PDZ and kinase domain of LIMK1 in 
pEGFP-C1 (amino acids 146-647) 
Kinase domain of LIMK2 in pEGFP-C1 









3.2.8.3. Plasmid with mutated insert 




























Amino acid 451 mutated to alanine 
 
Amino acid 505 mutated to alanine 
 
Amino acid 505 mutated to two glutamic 
acid 
Amino acid 283 mutated to alanine 
 
Amino acid 283 mutated to two glutamic 
acid 
Amino acids 283 and 494 were mutated to 
alanine 
Amino acids 283 and 494 were mutated to 
two glutamic acids 
Amino acid 283 mutated to alanine 
 
Amino acid 283 mutated to two glutamic 
acid 
Amino acid 494 mutated to alanine 
 
Amino acid 494 mutated to two glutamic 
acid 
Amino acids 283 and 494 were mutated to 
alanine 
Amino acids 283 and 494 were mutated to 
two glutamic acids 
























































two glutamic acids and alanine respectively 
Amino acids 494 and 283 were mutated to 
two glutamic acids and alanine respectively 
Amino acids 500-503 were mutated to 
alanines 
Amino acids 496-497 were mutated to 
alanines  
Amino acids 491-493 were mutated to 
alanines 
Amino acids 480-482 were mutated to 
alanines 
Amino acids 496-497 and 500-503 were 
mutated to alanines 
Amino acids 491-493 and 500-503 were 
mutated to alanines 
Amino acids 480-482 and 491-493 were 
mutated to alanines 
Amino acids 491-493, 496-497 and 500-
503 were mutated to alanines 
Amino acids 500-503 were mutated to 
alanines 
Amino acids 496-497 were mutated to 
alanines 
Amino acids 491-493 and 500-503 were 
mutated to alanines 
Amino acids 491-493, 496-497 and 500-
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3.3. Work with E.coli 
3.3.1. Bacterial strains 
Escherichia coli DH5α F−φ80dlacZΔM15 Δ(lacZYA-argF)U169 deoR recA1 
endA1 hsdR17(rk−, mk+) phoA supE44λ−thi-1 
XL10-Gold TetR ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173endA1 supE44 
thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZ∆M15 
Tn10 (TetR) Amy CamR] 
3.3.2. Media for bacterial culture 
LB-medium     1.0 % tryptone 
0.5 % yeast extract 
1.0 % NaCl 
pH 7.2 
 
Terrific Broth   1.2 % tryptone 
     2.4 % yeast extract 
     0.4 % glycerol 
17mM KH2PO4  
72mM K2HPO4 
1.5 % agar was added to the media for production of agar plates. 
The following concentrations of the antibiotics were used if required: 




100mg/ml in water 
10mg/ml in water 




Table 3.1 Antibiotic stock solutions and its working concentration 
3.3.3. General 
E. coli were cultured at 37°C with LB medium or terrific broth. Bacteria transformed with an 
antibiotic resistance-conferring plasmid were selectively propagated by supplementing the LB 
medium with respective antibiotic (see Table 3.1). All solutions and supplements used for work 
with E. coli were autoclaved for 20 min at 121°C or filter-sterilized. Bacterial strains were long-
term stored at –70°C in LB medium supplemented with glycerol to a final concentration of 15 %. 
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3.3.4. Culturing bacteria 
3.3.4.1. Growth on solid media 
Dry LB agar plates were used as solid media. Single bacterial colony or bacterial suspension was 
inoculated by spreading with a sterile inoculation loop or a glass spreader, respectively, to 
achieve single colony growth. The plates were incubated inverted overnight at 37°C. 
3.3.4.2. Growth of liquid cultures 
For small liquid culture, 5-10 ml LB or LB/antibiotic medium was inoculated with a single 
bacterial colony and incubated overnight at 37°C on a shaking platform. Starter culture was 
incubated for 8-12h and used to inoculate fresh liquid medium. For large liquid culture 100-250 
ml LB or LB/antibiotic medium was inoculated with a starter culture to a dilution of 1:50-1:100 
and incubated overnight at 37°C with shaking. Bacteria were harvested by centrifugation. 
3.3.4.3. Monitoring the bacterial growth 
The growth of the bacteria in liquid culture was measured at a wavelength of 600 nm (OD600) in 
plastic cuvettes against pure medium as a blank in a spectrophotometer. Each 0.1 OD600 unit 
corresponds to approx. 108 cells/ml for OD600 < 1. 
3.3.5. Transformation of plasmid in E.coli 
3.3.5.1. Preparation of competent cells by CaCl2 method 
LB medium (100 ml) was inoculated with an overnight culture of E. coli DH5α and grown at 
37°C with shaking to an OD600 of 0.4. This culture was transfer to sterile, disposable, ice-cold 50-
ml plastic tubes and store on ice for 10 minutes. After incubation, cells were centrifuged at 4,000 
rpm for 15 min at 4°C. The pellet was resuspended in 50 ml ice-cold 100 mM MgCl2, incubated 
for 30 min on ice, and centrifuged at 4°C. The cells were resuspended in 2 ml ice-cold 100 mM 
CaCl2, incubated for 24 h at 4°C, supplemented with ice-cold 0.6 ml glycerol and 2.4 ml 100 mM 
CaCl2 and stored in 200µl aliquots at –70°C. 
3.3.5.2. Heat shock transformation of the plasmid 
Treatment of competent bacterial cells with a brief heat shock enables transformation of DNA. 
Plasmid DNA or a plasmid ligation reaction (not more than 15ng or in a volume 2.5μL) was 
mixed with 50µl thawed competent bacteria and incubated for 30 min on ice. The bacteria were 
treated for 90sec by heat shock of 42°C, placed on ice for 1-2 minutes, diluted with 950 µl LB 
medium and incubated for 1 h at 37°C with shaking. An aliquot of 50-200 µl or resuspended 
pellet was spread on LB/antibiotic agar plate and incubated overnight at 37°C to select for 
transformed bacteria. In case of ligation mixture, the transformed cells were pelleted by 
centrifugation at 13,000rpm for 30 seconds, and the pellet was resuspended in 100μl of LB 
medium. The whole suspension was spread on the agar plate. 
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3.4. Recombinant DNA processing and manipulation 
3.4.1. DNA amplification of LIMK1 and LIMK2 cDNA 
The polymerase chain reaction (PCR) constitutes an enzymatic in vitro amplification of specific 
cDNA segments. Amplification occurs in automated, temperature-controlled cycles of 
denaturation, annealing and elongation in a thermal cycler. Initially, double-stranded template 
DNA is separated into its complementary single strands by heating (denaturation). At a lower 
temperature two oligonucleotides primers, flanking the DNA region to be amplified, hybridize to 
their respective complementary sequences on opposite strands (annealing) and serve as primers 
for DNA synthesis in a 5'→3' direction (elongation). Primer extension is catalyzed at a slightly 
increased temperature by a thermostable DNA polymerase that add deoxyribonucleotide 
triphosphates (dNTPs) to the recessed 3'-hydroxyl end of extending strands, thereby generating 
new double-stranded DNA across the primer-flanked region. The products of each reaction cycle 
are then denatured to permit a new amplification cycle. Theoretically, for n cycles a 2n-fold 
amplification of a specific DNA sequence is obtained.  
Primers for amplification of LIMK1 and LIMK2 cDNA were commercially synthesized (MWG 
Biotech, Ebersberg, Germany). They were designed corresponding to the DNA segment to be 
amplified, provided with restriction sites for endonuclease digestion. Pairs of primers were 
designed to have equivalent melting temperatures (Tm), calculated according to the formula1 Tm 
[°C] = (A+T)x2 + (G+C)x4. The annealing temperature for each PCR was typically estimated by 
experimentally. For preparative DNA amplification as part of cloning strategies, High fidelity 
DNA polymerase was used in preference to Taq DNA polymerase, due to its 3'→5' proofreading 
exonuclease activity which minimizes the risk of nucleotide misincorporation during elongation. 
PCR reaction composition for DNA amplification was as follows: 
Template DNA  20-50ng (Plasmid PUC-SRα-LIMK2 or cDNA of LIMK1) 
Sense primer (forward) 100 pmoles 
Antisense primer (reverse) 100 pmoles 
dNTPs    200μM each 
PCR reaction buffer  1x 
DMSO    5-10% (Optional, to increase yield, specificity, consistency)  
DNA polymerase  1-2.5 units 
Final reaction volume  100μl (preparative PCR), 20-50μl (analytical PCR) 
The PCR amplified products of LIMK1 and LIMK2 gene were analyzed by agarose gel 
electrophoresis, they were further proceed for cloning into the EGFP-C1 vector. 
                                                 
1 A, T, G, C: number of the 2’-deoxyribonucleosides adenosine (A), thymidine (T)guanosine (G) and cytidine (C) 
with in the primer sequence 
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Thermal cycle parameters for PCR were as follows: 
Lid temperature  105°C 
Initial denaturation  94°C, 5 minutes 
Denaturation   94°C, 30 seconds 
Annealing   50-55°C (primer pair and template specific), 1minute 
Elongation   72°C, 1 minute/kb 
Cycles    30 
Final elongation  72°C, 10 minutes 
3.4.2. Buffers and solutions 
TBE buffer (5X)   Tris-base 54 g 
(Working solution 0.5X)  boric acid 27.5 g 
     EDTA 20 ml of 0.5 M, pH 8.0       Final volume 1 Liter 
TE     10mM Tris (pH 7.6), ImM EDTA (pH8.0) 
DNA loading buffer (6X)  0.25% (w/v) bromophenol blue 
     0.25% (w/v) xylene cyanol 
     30% (v/v) glycerol 
     50 mM EDTA 
Ethidium bromide   1% (w/v) in water 
DNA standard    SmartLadderTM Eurogentec GmbH, Germany 
3.4.3. Restriction endonuclease digestion of DNA 
Type II restriction endonucleases were used to digest double-stranded DNA for analytical or 
preparative purposes. These restriction enzyme bind to short, specific nucleotides sequence and 
cleave the DNA within this region by hydrolyzing a phosphodiester bond in each strand. The 
recognition sequences (palindromes) possess twofold rotational symmetry. Staggered cleavage 
generates complementary, cohesive 5' and 3' ends (sticky ends). Cleavage in the axis of symmetry 
yields blunt ends. 
For preparative purposes, 1-5 µg PCR amplified DNA and EGFP-C1 vector were digested with 
1-20 U of restriction enzymes (see section 3.2.7.1) in a volume of 10-50 µl of reaction buffer. 
Complete digestion was confirmed by agarose gel electrophoresis. For analytical purposes, 0.2-1 
µg DNA were digested with 1-5 U of enzyme in a volume of 10-20 µl of reaction buffer. In both 
cases digests were incubated for 3h at 37°C. Reaction buffers were supplied by the manufacturer. 
Enzymes were heat-inactivated as recommended by the supplier or removed by purification of 
the digested DNA by column chromatography. 
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3.4.4. Purification of the digested DNA 
To inactivate and remove the proteins e.g. restriction enzymes, digested DNA was purified by 
using the QIAquick PCR purification kit (Qiagen) according to the manufacturer’s instructions 
with slight modification. Buffers were provided in the kit and all centrifugation steps were carried 
out at 13,000 rpm at RT in a tabletop microcentrifuge. The 5 volume of the buffer PB and one 
volume of isopropanol were added to the DNA solution. The sample was then applied to 
QIAquick spin column (Qiagen) and centrifuged for 1 min in order to bind DNA to the column. 
For washing of DNA on the column, 0.75 ml of buffer PE was added to the column and spun 
down for 1 min. The flow-through was removed and the column was centrifuged for an additional 
1 min to remove the residual ethanol. The column was then placed into a clean 1.5 ml tube and 
the DNA was eluted by the addition of 30-50 µl of buffer EB (10 mM Tris/HCl, pH 8.5) or dH2O 
to the column followed by centrifuging for 1 min. If needed the DNA could be concentrated by 
precipitating with ethanol. 
3.4.5. Ethanol precipitation of DNA 
In the presence of relatively high concentrations of monovalent cations, ethanol induces a 
structural transition in nucleic acid molecules, which causes them to aggregate and precipitate 
from solution. Ethanol precipitation was used to concentrate and/or desalt DNA solutions and to 
remove any residual impurity. 
5 M NaCl solution was added to the DNA sample to a final concentration of 250 mM. Three 
volumes of ethanol (-20°C) were added to the solution and stored on ice for 30 min and then 
centrifuged at 13,000 rpm for 15 min at 4°C. The pellet was washed with one volume of ice-cold 
70 % ethanol, recentrifuged for 5 min and dried at room temperature on desk. The DNA was 
dissolved in water or TE (pH 8) for 20 min at 37°C at an appropriate concentration. 
3.4.6. Dephosphorylation of linearized plasmid DNA by CIP 
In order to prevent self-ligation of vector ends in cloning strategies linearized plasmid DNA was 
treated with calf intestine alkaline phosphatase (CIP). CIP catalyzes the hydrolysis of 5'-
phosphate residues to 5'-hydroxyl ends. Since T4 DNA ligase requires 5'-phosphate residues to 
catalyze new phosphodiester bonds, ligation is only possible between vector ends and inserts, but 
not between vector ends themselves. Dephosphorylation was carried out directly following 
plasmid linearization. CIP was added to the digestion mixture at a concentration of 1 U per pmole 
linearized vector DNA. After 45 min incubation at 37°C, CIP and the restriction enzymes were 
removed as described previously. 
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3.4.7. Ligation of DNA fragments 
DNA fragments of bearing either sticky or blunt ends can be ligated in vitro with bacteriophage 
T4 DNA ligase. This enzyme catalyzes the formation of new phosphodiester bonds between a 5'-
phosphate residue of one and a 3'-hydroxyl residue of another double-stranded DNA fragment 
generated by restriction endonucleases. 
Ligation was carried out using Rapid DNA ligation kit (Roche) according to the manufacturer’s 
instructions with slight modification. All the buffers were provided with the kit. The insert DNA 
(LIMK1 or LIMK2 PCR amplified DNA) was employed at a 2-5 molar excess relative to the 
linearized and dephosphorylated EGFP-C1 vector DNA. The vector DNA and insert mixture 
were diluted in dilution buffer to a final volume of 10μl. 10μl of ligation buffer was added in 
diluted DNA mixture. 5unit of T4 DNA ligase was added and mix thoroughly. The ligation 
reaction mixture was incubated 5-10 minutes at 15-25°C. Ligation reaction mixture (5μl) was 
used directly for transformation of the 200μl competent cells. 
3.4.8. Miniprep: small-scale preparation of plasmid DNA 
Plasmid DNA was purified from bacteria cultures by alkaline lysis of the bacterial cells by using 
QIAprep Spin miniprep kit according to the manufacture instructions. In brief, a small culture 
(10ml) of bacteria was grown in order to amplify the plasmid of interest in vivo. The bacteria 
were harvested by centrifugation at 13,000 rpm for 1 min at room temperature. This pellet was 
resuspended in 250µl buffer P1 (50 mM Tris·Cl pH 8.0, 10 mM EDTA, 100 µg/ml RNase A). 
Lysis buffer P2 (250µl; 0.2 N NaOH, 1 % SDS) was added in resuspended pellet followed by 
gently mixing and incubated for 5 minutes at room temperature. It causes denaturation of the 
DNA by NaOH and of the bacterial proteins by SDS. The alkaline mixture was neutralized by 
350µl of buffer N3 (containing guanidine hydrochloride, 3M potassium acetate, pH 5.5) causing 
reannealing of plasmid DNA and precipitation of SDS. The white precipitate, containing proteins, 
chromosomal DNA, SDS and cell debris was removed by centrifugation for 10 minutes at 13,000 
rpm while the plasmid DNA was left in solution. The supernatant was passed through the spin 
column by centrifugation at 13,000 rpm for 1 minute. After washing of the column with 0.75ml 
buffer PE, the column was additionally centrifuged for 1 minute to remove residual buffer. The 
DNA was eluted by adding 50µl water or TE and centrifugation of the column at 13,000 rpm for 
1 min. 
3.4.9. Endofree Maxiprep: Large scale preparation of plasmid DNA 
Endotoxins or Lipopolysaccharides (LPS) are cell membrane components of Gram-negative 
bacteria (e.g., E.coli). During lysis of bacterial cells for plasmid preparations, endotoxin 
molecules are released from the outer membrane into the lysate. There tendency to form micellar 
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structures lead to co-purification of endotoxins with the plasmid DNA. Endotoxins strongly 
influence transfection of DNA into primary cells like endothelial cells and increased endotoxins 
levels leads to sharply reduced transfection efficiencies. To solve this problem, Endofree Plasmid 
maxi kit was used for large-scale purification. 
Bacterial culture (100 ml) was centrifuged at 4,000 rpm for 15 min at 4°C. The pellet was 
resuspended in 10 ml of P1 (50mM Tris.Cl, pH 8.0; 10mM EDTA; 100μg/ml RNase A). The 
resuspended pellet was lysed with 10 ml P2 (200mM NaOH, 1% SDS) by incubating for 5 min at 
room temperature. The lysis was stopped by adding 10 ml ice-cold P3 (3M potassium acetate, pH 
5.5) and the white precipitated mixture was poured into the barrel of QIAfilter cartridge and 
incubated. After 10 minutes, the plunger was inserted into the QIAfilter cartridge and the cell 
lysate was filtered into a 50ml tube. 2.5ml of buffer ER (endotoxin removal buffer) was added to 
the filtered lysate and incubated on ice for 30 minutes. The ER buffer treated lysate was loaded 
on an equilibrated anion exchange column that was subsequently washed twice with 30 ml of 
buffer QC (1.0M NaCl, 50mM MOPS, pH7.0; 15% isopropanol). The bound DNA was eluted 
with elution buffer QN (1.6M NaCl, 50mM MOPS, pH7.0; 15% isopropanol) by gravity flow. 
The eluted DNA was precipitated by adding 0.7 volumes isopropanol at room temperature and 
subsequent centrifugation at ≥15,000xg for 30 min at 4°C. The pellet was washed with 5 ml 70 % 
ethanol, re-centrifuged for 10 min, dried under vacuum and re-dissolved in 1ml of endothelial 
electroporation buffer or TE. 
3.4.10. Quantification of DNA and RNA solutions 
The concentration of nucleic acid solutions was determined by spectrophotometry. The ultraviolet 
(UV) absorption was measured at a wavelength of 260 nm (OD260) using a quartz cuvette of 1 cm 
width. For double-stranded DNA an OD260 =1.0 corresponds to approximately 50 µg DNA/ml. 
For RNA an OD260 = 1.0 corresponds to approximately 40 µg RNA/ml. In addition the OD260 was 
measured to estimate the purity of the nucleic acid sample. A ratio OD260/OD280 of significantly 
less than 1.8-2.0 indicates protein contamination.  
3.4.11. Agarose gel electrophoresis 
Agarose gel electrophoresis was used for analytical and preparative purposes. The method is 
based on the migration of negatively charged DNA towards the anode in an electric field. The 
fragments migrate through the gel matrix at rates inversely proportional to the logarithm (log10) of 
the number of base pairs. DNA bands were visualized within an agarose gel by staining with the 
intercalating fluorescent dye ethidium bromide and subsequent illumination under UV light. The 
length of a DNA fragment is determined by comparison of its mobility to that of DNA standards. 
For casting gel, 1-2 % (w/v) agarose was melted in 0.5xTBE electrophoresis buffer and 
supplemented with 0.5 µg/ml ethidium bromide and casted in a tray of desired size. The gel was 
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placed in an electrophoresis tank and submerged in 0.5xTBE buffer. The DNA samples were 
mixed with DNA loading buffer and loaded into the gel wells. In addition 5 µl of a DNA standard 
was loaded in parallel with the samples. Horizontal electrophoresis was carried out at 
approximately 100 V. The stained gel was photographed under UV light. 
3.4.12. DNA recovery from agarose gel 
For preparative purposes DNA fragments of interest were cut out from stained agarose gels with 
a razor blade under UV illumination. The gel slices were solubilized and DNA was purified by 
using the QIAquick Gel extraction kit (Qiagen) according to the manufacturer’s instructions. 
Agarose gel slices were weighed (= 1 volume) and dissolved each slice in 3 volumes of 
solubilization buffer QG by incubation for 10 min at 50°C. 1 volume isopropanol was added and 
the solution was applied to a silica-gel QIAquick spin column. The column was centrifuged at 
13,000 rpm for 1 min, washed with washing buffer PE and centrifuged again. The extra 
centrifugation was done to remove residual buffer. DNA was eluted by adding 30-50µl water or 
TE on the column and centrifugation of the column at 13,000 rpm for 1 min. All the buffers were 
provided by the manufacturer. 
3.4.13. DNA sequencing 
The sequence of specific target regions in recombinant plasmid DNA was determined by a 
commercial sequencing service (Agowa GmbH Berlin, Germany). The sequence data were 
verified on the basis of the corresponding fluorescence electropherogram and subjected to 
computer analysis. 
3.5. Mutagenesis of the LIMK2 gene 
3.5.1. PCR based site-directed mutagenesis  
The QuikChange™ Site-Directed Mutagenesis method (QCS) developed by Stratagene (La Jolla, 
CA, USA) is a widely used PCR-based site directed mutagenesis system that eliminates the 
necessity to subclone the amplified mutated DNA fragment. This procedure starts with a 
supercoiled, dsDNA vector with an insert of interest and two synthetic oligonucleotide primers 
containing the desired mutation (see section 3.2.7.3). The oligonucleotide primers, each 
complementary to opposite strands of the vector, are extended during temperature cycling by 
PfuUltra® high-fidelity DNA polymerase. After incorporation of the oligonucleotide primers, a 
mutated plasmid containing staggered nicks is generated. After temperature cycling, the product 
is treated with Dpn1. Dpn1 is used to digest the parental DNA template and select for the 
synthesized DNA containing mutations. Since DNA isolated from most E. coli strains is dam 
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methylated, it is susceptible to Dpn1 digestion, that will cut only fully or hemimethylated 5′-
Gm6ATG-3′ DNA sequences2. The nicked vector DNA incorporating the desired mutations is 
then transformed into the commercial XL10-Gold cells3. This method is very rapid and generates 
mutants with the efficiency greater than 80%. 
 
Figure 3.1 The QuickChange® One-Day Site-Directed Mutagenesis Method: 1. Mutant strand synthesis. 2. Dpn1 
Digestion of parental DNA template. 3. Transformation of the resulting annealed double-stranded nicked DNA 
molecules. After transformation, the XL-1 Blue E. coli cell repairs nicks in the plasmid. 
The mutant strands synthesis reaction was setup for PCR according to the manufacturer’s 
instructions. The PCR reaction composition and PCR cycling parameter were as follows. 
Template DNA   30ng (EGFP-LIMK2 plasmid) 
Sense primer4 (forward)  125ng 
Antisense primer (reverse)  125ng 
dNTPs     200μM each or 1μl (supplied with the kit) 
PCR reaction buffer   1x 
Quick solution reagent  3μl (supplied with the kit) 
Water was added to a final volume of 50μl 
 
 
                                                 
2 While plasmid DNA isolated from almost all the commonly used E.coli strains such as DH5α (dam+) is methylated 
and is suitable for mutagenesis, plasmid DNA isolated from the exceptional dam- E.coli strains, including JM110 and 
SCS11, is not suitable. 
3The DH5α chemical competent cells prepared in our lab also worked well with this protocol. 
4 The primers were design according to the mutagenic primer design rules, which were given in instruction manual. 
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Then 1μl of PfuUltra HF DNA polymerase was added and PCR was done with the following  
thermal cycling parameters. 
Lid temperature  105°C 
Initial denaturation  94°C, 2 minutes 
Denaturation   94°C, 50 seconds 
Annealing   60°C, 1minute 
Elongation   68°C, 1 minute/kb 
Cycles    18 
Final elongation  68°C, 10 minutes 
After the PCR the reaction mixture was cooled to ≤37°C on ice. 1μl of Dpn1 was added directly 
to reaction mixture and kept for 2 hours for digestion at 37°C. 2.5μl of the digested reaction 
mixture was transformed into competent cells and the mutant clone was selected and confirmed 
by DNA sequencing. 
3.5.2. Deletion mutagenesis 
This is the modified method of the QuikChange™ Site-Directed Mutagenesis kit with additional 
steps to generate deletion or insertion mutation. The reaction composition for PCR and the 
thermal cycling condition is the same as described before except primer amount and designing 
rules. The specific primer design consideration was applied as follows. 
1. Both the primers must anneal to different strands of the plasmid. 
2. Primers should be >22 bases in length  
3. The mismatched portions should be at or near the 5´ end of one or both of the primers 
with 15 or more bases of correct sequence on the 3´ end. 
4. For deletion, the primers should be designed in frame of the coding sequence of the 
gene. The forward primer and reverse primer should be designed at 3′ and 5′end of the 
deletion sequence, respectively. 
 
Figure 3.2 Primer design considerations. Mutagenesis primer oligonucleotides can be designed individually 
according to the desired mutation. Based on primer design, the ExSite mutagenesis method can allow for the 
mutagenesis of dsDNA templates resulting in large or small deletions and/or 5´-end oligonucleotide-directed base 
insertions.  
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5. One or both of the primers must be 5´ phosphorylated. T4 polynucleotide kinase used 
for the 5´ phosphorylation of an oligonucleotide primers. 
The reaction composition of the phosphorylation reaction is as follows 
Primer    1μl (100pmole)  
Kinase buffer   0.5μl (1x) 
T4 polynucleotide kinase 1μl (10 units) 
Water    2.5μl 
The reaction mixture was incubated for 1 hour. The 1.25μl of the reaction mixture was directly 
used for PCR. 
The PCR product was digested with Dpn1 and purified by PCR purification kit as described 
before. Purified PCR product (5μl) was ligated using rapid DNA ligation kit and transformed into 
DH5α cells. The positive clone was confirmed by DNA sequencing. 
3.6. Gene expression analysis at the RNA level using RT-PCR 
Gene expression analysis at the RNA level, i.e. determination of target-specific mRNA 
transcripts in the cell, includes isolation of total RNA, reverse transcription of mRNA to cDNA 
and amplification of the target cDNA by PCR. 
3.6.1. RNA isolation from HUVEC5 
The total cellular RNA was purified by RNeasy mini kit. In the RNeasy procedure, biological 
samples are first lysed and homogenized in the presence of a highly denaturing guanidine 
isothiocyanate (GITC)-containing buffer, which immediately inactivates RNases to ensure 
isolation of intact RNA. A specialized high-salt buffer system allows up to 100 µg of RNA longer 
than 200 bases to bind to the RNeasy silica-gel membrane. Ethanol is added to provide 
appropriate binding conditions, and the sample is then applied to an RNeasy mini column where 
the total RNA binds to the membrane and contaminants are efficiently washed away. High-
quality RNA is then eluted in water.  
Cells (5x106) were harvested and washed with PBS and resuspended in 600μl of buffer RLT 
containing β-mercaptoethanol (supplied with the kit). The cell lysate was homogenized by using 
QIAshredder spin column. The cell lysate was loaded on QIAshredder and centrifuged at 
maximum speed for 2 minutes. One volume of 70% ethanol was added in homogenized sample 
and loaded on the RNeasy spin column and centrifuged at high speed for 15seconds. The flow-
through was discarded and the column was washed with 350μl RW1 buffer. Then 80μl of DNAse 
                                                 
5 All the RNA work was done in RNase free conditions. All the precautions were taken during the work with RNA. 
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(10μl DNAse I stock solution (30 units) + 70μl RDD buffer) was added onto the column and kept 
for 15 minutes at room temperature. After DNA digestion the column was again washed with 
350μl RW1 buffer and then the column was finally washed two times with 700μl of RPE buffer 
and centrifuged for one minute at high speed to remove residual buffer. Finally, total RNA was 
eluted in 50μl RNase free water. 
3.6.2. Gel electrophoresis of RNA 
3.6.2.1. Buffers and solutions 
10x MOPS electrophoresis buffer  200 mM 3-[N-morpholino]propanesulfonic acid 
(MOPS) (free acid) 
50 mM sodium acetate 
10 mM EDTA 
 DEPC-treated water, pH to 7.0 with NaOH 
1x MOPS Gel Running Buffer  100 ml MOPS electrophoresis buffer 
20 ml 37% (12.3 M) formaldehyde 
880 ml DEPC-treated water6
5x RNA Loading Buffer   16 µl saturated bromophenol blue solution 
80 µl 500 mM EDTA, pH 8.0 
720 µl 37% (12.3 M) formaldehyde* 
2 ml 100% glycerol 
3084 µl formamide 
4 ml 10 x MOPS electrophoresis buffer 
DEPC-treated water to 10 ml 
Stability: Approximately 3 months at 4°C 
The integrity and the size distribution of total RNA were checked by denaturating-agarose gel 
electrophoresis and ethidium bromide staining. 1.2 g agarose was dissolved in 72 ml H2O by 
boiling in microwave. The solution was cooled to about 60 °C, and 10 ml 10x MOPS 
electrophoresis buffer, ethidium bromide, and 18 ml of formaldehyde were added. The gel was 
cast in chemical hood, and was equilibrated in 1x MOPS electrophoresis buffer for at least 30 
min. RNA sample (2-5 μg total RNA) was prepared in RNA loading buffer (1x in final volume) 
by incubating at 65 °C for 5 min. The samples were then loaded onto the gel. The gel was run at 
5-7 V/cm (running buffer 1x MOPS electrophoresis buffer) until the bromophenol dye has 
migrated two-thirds the length of the gel. The RNA was visualized by placing the gel on UV 
transilluminator.  
                                                 
6 The water was supplemented with DEPC to final 0.1% (v/v), incubated overnight at room temperature and 
autoclaved. The utilized glassware was baked overnight at 140°C prior to use. 
 
Materials and methods 48 
3.6.3. Synthesis of cDNA from total RNA and analysis of LIMK gene 
expression 
Total RNA (~3μg) and Oligo(dT)20 primers (1μL, 50 pmole) were mixed with RNase-free water 
to a final volume of 12 µl and incubated for 10 min at 70°C. Master reaction mix (8 μl, 
composition as shown below) was added to the denatured RNA tube and the RT-PCR was 
performed for 60 min at 50°C. The enzyme was heat-inactivated for 15 min at 85°C and the first 
strand cDNA samples were stored at –20°C. 
Master reaction mix composition for one RNA tube 
5x cDNA synthesis buffer  4μl 
0.1M DTT    1μl 
RNaseOUTTM (40U/μl)  1μl 
DEPC-treated water   1μl 
ThermoscriptTM RT (15U/μl) 1μl 
In the negative control, 1μl of DEPC treated water was added to the master mix instead of reverse 
transcriptase enzyme  
Subsequently, for gene expression analysis of LIMK1 and LIMK2, 10% of a cDNA-containing 
first strand reaction mix (with negative control) was subjected to analytical PCR in order to 
amplify cDNA fragments derived from expressed target gene-specific mRNA transcripts, i.e. 
LIMKs–related cDNA and as a control β-actin cDNA. Primers used for amplification of LIMK1 
and LIMK2 cDNA and β-actin cDNA were shown in section (see section 3.2.7.4). β-actin primers 
allowed amplified β-actin fragments derived from genomic DNA contamination or spliced 
mRNA transcripts to be distinguished. 
3.7. Protein analysis 
3.7.1. Buffers and solutions 
SDS sample buffer (2x)   100 mM Tris·Cl (pH 6.8) 
20 % (v/v) glycerol 
4 % (w/v) SDS 
0.01 % (w/v) bromophenol blue 
10% β-mercaptoethanol 
acrylamide/bis-acrylamide 40% (w/v) acrylamide/bis-acrylamide (ratio 37.5:1) 
Stacking gel buffer   0.5 M Tris-HCl, pH 6.8 
Resolving gel buffer   1.5 M Tris-HCl, pH 8.8 
APS     10% (w/v) APS in water, (aliquots were stored at -20°C) 
SDS     10% (w/v) SDS in water 
Electrophoresis Buffer (10x)  30g Tris-base 
     142g glycine 
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     10g SDS  
     Water was up to 1 liter  
Transfer buffer   5.82g (48mM) Tris-base 
     2.93g (39mM) glycine 
     200ml methanol 
     Water was added up to 1 liter 
TBST buffer    10mM Tris-base (pH 7.6) 
     150mM NaCl 
     0.05% (v/v) Tween 20 
Blocking solution   5% blocking milk (BioRad) in TBST 
Cell lysis buffer (2x)   2 % NP-40 
     300mM NaCl 
     20 mM Tris (pH 7.5) 
     2 mM EGTA 
     5 mM Na3VO4
     Complete mini protease inhibitor tablet (Roche) 1/5ml 
     Phosphatase cocktail (1:100) 
     0.1% SDS 
Coomassie staining solution  0.25% Coomassie Brilliant Blue R-250 
     10%Acetic acid  
     40% methanol in water (filtered) 
Coomassie destaining solution 10%Acetic acid  
     40% methanol in water 
3.7.2. Measurement of protein concentration 
3.7.2.1. Enhanced alkaline copper (Lowry) protein assay 
The method is based on Peterson’s modification of the micro-Lowry method (Peterson, 1977). 
An alkaline cupric tartrate reagent (Lowry reagent) complexes with the peptide bonds of proteins 
and becomes reduced to cuprous (Cu+). The Cu+ as well as the R groups of tyrosine, tryptophan, 
and cysteine residues then react with the Folin reagent. The reagent reacts by first producing an 
unstable product which is slowly reduce to become molybdenum/tungsten blue color complex. 
The absorbance is read at a suitable wavelength between 500 nm and 800 nm (preferably 750nm) 
for spectroscopic quantification of proteins in aqueous solution.  
Lowry protein assay kit (Sigma) was used for protein quantification according to the 
manufacturer instructions. Using BSA stock solution (400 μg/ml), a set of protein standards with 
0-300 μg/ml was prepared. The protein samples (containing with or without 1% SDS) were dilute 
to 1.0 ml with water. To each set of protein standards and samples, 1 ml of Lowry reagent was 
added and incubated for 20 minutes at room temperature. With rapid and immediate mixing, 0.5 
ml of Folin & Ciocalteu’s phenol reagent was added in each tube and the color was allowed to 
develop for 30 minutes. The absorbance was measured at the wavelength of 750 nm in a 
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spectrophotometer. Based on the absorption values of the protein standards a calibration curve 
was calculated and used for determination of the protein concentrations in the samples. All 
protein standards and samples were prepared in duplicate. 
3.7.2.2. dotMETRICTM 1μl Protein assay 
This is in effect a chromatographic capture method where the flat surface of the test strip acts as 
the solid matrix or support. Protein solution is applied on a specific protein binding test strip by 
point of contact capillary action. Under a specific buffer condition as the protein enters into the 
matrix of the test strip it binds instantly and saturates as protein solution diffuses into the test strip 
in a circular manner. A circular protein imprint is produced which is developed into visible 
protein spots with a protein specific dye. The diameter of the protein spot is proportional to 
protein concentration. By measuring the diameter of the protein spots with a pre-developed 
measuring gauge the amount of protein in the spot can be estimated (Figure 3.3). This method 
requires only 1μl of the sample and is resistant to most common laboratory reagents such as 
Triton-X100, Triton-X114, Tween-20, NP-40 and SDS, reducing agents such as beta-
mercaptoethanol and DTT, sugars, cobalt, EDTA, Tris buffers, and others. This assay is 
independent of protein-to-protein variation and can be performed even if the protein sample is in 
a SDS-PAGE gel-loading buffer. 
                                            
Figure 3.3 A) Method of spotting of the protein sample on the test strip. B) Steps involved in protein estimation. 1-
5μl protein solution is applied to the test strip (1), it produces compact and symmetrical spots on the strip; the 
diameter of protein spots is proportional to their protein concentration (2). Thus, by measuring the diameter of 
protein spots with the dotMETRICTM scale, supplied with each kit, protein amount can be estimated. 
The protein was estimated by dotMETRICTM 1μl Protein assay kit according to the 
manufacturer’s instructions. 2 μl of protein sample was diluted in 10 μl of dilution buffer 
(provided in the kit). 2 μl and 4 μl of diluted samples were spotted on the test strip by using the 
common pipette man with ultra fine tip. The loaded protein sample was fixed on test strip by 
incubating the strip in diluted fixer (0.8 ml of Fixer-A stock + 7 ml water) for 2 minutes at room 
temperature. The fixed strip was transferred into diluted developer (0.8 ml of developer-B stock + 
7 ml water) and shake gently for 30 seconds and incubated for 2-4 minutes or longer at room 
temperature to develop the spot. The spots were read by using dotMETRICTM scale to match the 
diameter of each spot to its corresponding protein concentration. 2-3 spot were produced from 
each sample and the mean average was calculated.  
 
Materials and methods 51
3.7.3. Whole cell lysates 
Endothelial cells were washed with ice cold PBS. Approximately 1.5x106 cells (25mm2 flask) 
were lysed in 500µl of cell lysis buffer (1x, see section 3.7.1) for 45 minutes on ice. To remove 
the insoluble part, the lysate was collected in eppendorf tube and centrifuged at 16000xg 4°C for 
15 minutes. The clear lysate was immediately processed for immunoprecipitation or kinase assay. 
3.7.4. Immunoprecipitation 
The underlying strategy behind the immunoprecipitation is to use the high affinity of antibodies 
for their antigens as a method to locate and bind target molecules in the proteins mixture. Once 
the antibody-antigen complexes are formed in solution, they are collected and purified by using 
small agarose or polyacrylamide beads with covalently attached protein A or protein G. Both 
protein A and protein G specifically interacts with conserved regions of the antibodies, thus 
forming an immobilized complex of antibody-antigen bound to beads. Irrelevant molecules in the 
starting protein mixture are removed by washing the beads. 
For immunoprecipitation, the clear whole cell lysate of endothelial cells was prepared as 
described above.  To remove the nonspecific sepharose bind proteins, 50% protein A sepharose 
slurry was added to clear lysate in the ratio 1:20 respectively and incubated at 4°C for one hours 
end over end mixing. A-sepharose was prepared by incubating the beads in swelling buffer 
(20mM NaH2PO4, 0.15M NaCl, and 0.1% NaN3) containing 2% BSA to block unspecific 
binding. The beads were removed by centrifugation at 13,000prm for 20 seconds and the pre-
cleared supernatant was further processed. The specific antibody was added in supernatant in 
appropriate amount (see section 3.2.3) and was incubated overnight at 4°C with end over end 
mixing. 50% slurry of protein a sepharose was added (1:10), and incubated for 2 hrs at 4°C with 
end over end mixing. The antigen-antibody bound beads were purified by centrifugation at 
13,000 rpm for 30 seconds and the beads were washed 2 times with 1 ml ice-cold cell lysis buffer 
(without protease and phosphatase inhibitor) followed by two washing with 1 ml ice cold PBS. 
The pellets containing antigen-antibody bound beads were solubilized in 1x SDS-sample buffer 
and heated at 95°C for 5 minutes and stored at -20°C. 
3.7.5. SDS-PAGE 
Protein samples were resolved for analytical purposes by polyacrylamide gel electrophoresis 
(PAGE). The use of the anionic detergent sodium dodecyl sulfate (SDS) enables separation 
according to the molecular mass of the proteins. It binds to the polypeptides and confers a 
negative charge, which is in direct proportion to their mass. The gel matrix is prepared by 
polymerization of acrylamide and N,N'-methylenebisacrylamide via free radicals. Initial radicals 
arise from chemical decay of ammonium persulphate (APS) catalyzed byN,N,N',N'-
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tetramethylethylenediamine (TEMED). The electrophoresis towards the anode is carried out in a 
discontinuous buffer system that first concentrates SDS-protein complexes within a stacking gel 
before they migrate into the resolving gel. The size of proteins is determined by comparing their 
mobility with that of a protein standard. 
The resolving gel solution was prepared, poured between two clean glass plates and overlaid with 
water or butanol. After polymerization, the top of the gel was washed with water and the residual 
water was removed by filter paper. Freshly prepared stacking gel solution was filled and allowed 
to polymerize. The plastic comb was inserted in poured stacking gel to prepare the wells for 
sample loading. After polymerization the comb was removed and the wells were washed with 
water to remove unpolymerized acrylamide Subsequently the gel was placed in a vertical 
electrophoresis apparatus filled with 1x electrophoresis buffer. SDS-PAGE protein samples were 
prepared by mixing protein samples with 2x SDS sample buffer in the ratio of 1:1, if not already 
prepared with 1x SDS sample buffer. The SDS-PAGE protein samples and a protein standard 
were denatured at 95°C for 5 min and loaded onto the gel. Electrophoresis was carried out at 200 
V. The resolving gel was subsequently subjected to western blot analysis or gel staining. 
 
Components Stacking gel 5% 
(5ml final vol.) 
Resolving gel 10% 
(10ml final Vol.) 
Resolving gel 12% 
(10ml final vol.) 
Water 
Acrylamide mix 
1.5M Tris (pH8.8) 
1.0M Tris (pH6.8) 
10% SDS 























Table 3.2 Composition of stacking and resolving gel.  
3.7.6. Detection of protein on gel 
3.7.6.1.  Silver staining of the polyacrylamide gels 
Silver staining of polyacrylamide gels allows the detection of proteins separated by SDS-PAGE 
to a limit of 2-5ng protein/band. The staining relies on differential reduction of silver ions bind 
various chemical groups such as sulfhydryl, carboxyl moieties in proteins. 
The various steps involved are as follows: 
Fixation   2 x 30 min   CH3OH/H2O/glacial acetic acid (4:3:1) 
2 x 10 min   H2O wash 
Extra fixation  1 x 15 min   2.4 g sodium tetraborate (Na2B4O7) decahydrate 
ad 148 ml H2O 
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2 ml 25 % glutaraldehyde 
3 x 30 min   H2O wash 
Incubation   1 x 15 min   merge in order as indicated: 
24 ml H2O 
2.3 ml 1 M NaOH 
2.5 ml 25 % NH3 solution 
5 ml 20 % (w/v) AgNO3
ad 125 ml H2O 
2 x 5 min   H2O wash 
Development      until desired staining level with: 
13 ml ethanol 
750 µl 1 % (w/v) citric acid 
90 µl 37 % formaldehyde 
ad 150 ml H2O 
Reduction termination 
1 x 10 min  3.7 g Tris·Cl 
2.5 g Na2S2O3
ad 100 ml H2O 
Background destaining    exposure until desired background attenuation 
with Farmer’s Reducer: 
2.5 ml 20 % (w/v) Na2S2O3
2.5 ml 1 % (w/v) K3[Fe(CN)6] 
ad 220 ml H2O 
3 x 10 min   H2O wash 
For storage purpose the stained polyacrylamide gel was incubated in 20 % glycerin for 2 h. The 
gel was then placed between a wet Whatman 3MM paper and cellophane sheet on the top and 
dried under vacuum for 2 h at 85°C. 
3.7.6.2. Coomassie staining of the polyacrylamide gels 
Coomassie Brilliant Blue is an aminotriarylmethane dye that forms strong covalent complexes 
with proteins, most probably by a combination of van der Waals forces and electrostatic 
interactions with NH3+ groups. The uptake of dye is approximately proportional to the amount of 
protein.  
The polyacrylamide gel was immersed in at least 5 volumes of the coomassie staining solution 
and placed on a slowly rotating plateform for 15-30 minutes at room temperature. The gel was 
destained in coomassie destaining solution on a slowly rotating plateforms, changing the 
destaining solution three to four times. The rapid destaining can also achieved by keeping the 
staining gel in hot water (80°C). The reaming background was removed by leaving the gel 
overnight in water. 
3.7.7. Western blot analysis 
Western blotting consists of the transfer of electrophoretically separated proteins from a SDS-
PAGE gel to a nitrocellulose membrane by electroblotting. The membrane-immobilized target 
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protein is identified by an appropriate primary antibody and a horseradish peroxidase (HRP)-
conjugated secondary antibody directed against the primary antibody. Detection of the antigen-
antibody-antibody complex occurs by HRP-mediated oxidation of the chemiluminescent 
substrate luminol, a cyclic diacylhydrazide. The reaction product exhibits an excited state which 
decays to ground state via a light emitting pathway, and is detectable by exposure of the 
membrane to an autoradiography film. 
After SDS-PAGE, the gel, nitrocellulose membrane pads and electrode papers were equilibrated 
with pre chilled transfer buffer. The gel cassette was placed with the gray side down on a clean 
surface. The fiber pad, electroblotting papers (7papers on each side), gel and nitrocellulose 
membrane were arranged in the cassette as shown in Figure 3.4. 
 
Figure 3.4 Arrangement of the gel and the membrane in the cassette. 
The firmly closed cassette was put into the blotting module and then placed into the 
electroblotting buffer tank with ice cooling unit. The proteins were transferred to the membrane 
towards the anode at 200 mA for 1 h at 4°C in ice-cooled transfer buffer with continuous stirring. 
Non-specific binding sites on the blotted membrane were blocked by shaking in blocking solution 
for 2 h at room temperature. After blocking, the membrane was washed thrice with TBST for 5 
minutes each wash. The washed membrane was sealed in polybag along with the primary 
antibody and incubated at 4°C for over night with an end-to-end shaking. The membrane was 
washed thrice for minutes each washing and incubated with the secondary antibody in blocking 
solution for 45 minutes. The membrane was washed thrice for 5 minutes each washing. The 
freshly prepared chemiluminescent substrate working solution was added to the surface of the 
membrane (approx. 0.2 ml/cm2) and incubated for 4 min at room temperature. The membrane 
was wrapped in plastic foil and exposed in the darkroom for 10 s to 30 min to an 
autoradiographic film that was subsequently developed in dark room conditions. 
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3.7.8. Densitometric analysis of immunoblots 
Densitometric analysis of the proteins was done using the public domain of National Institutes of 
Health (NIH) ImageJ (1.32j) software. Using as reference image of the Kodak step tablet, the 
calibration to an optical density scale of scanner was performed. The densitometric values of 
phosphorylated proteins were divided by the corresponding values of unphosphorylated proteins 
respectively. Absorption of proteins in unstimulated control samples was set to 100%. Data are 
presented as mean±SEM of three independent experiments. 
3.8. Endothelial cells 
3.8.1. Buffers and solutions 
Endothelial growth medium  Endothelial cell basal medium with supplement mix 
Supplement Mix ECGS/H 0.4 %, ECGS/H 0.4 %, FCS 2 %, Epidermal 
Growth Factor 0.1 ng/ml, Hydrocortison 1 µg/ml, basic 
Fibroblast Factor 1 ng/ml Amphotericin B 50 ng/ml, 
Gentamicin 50 µg/ml 




6mM D-Glucose final pH 7.0 
Freezing medium   10% DMSO in heat inactivated FCS 
Trypan blue    0.4% trypan blue solution 
PBS Dulbecco’s phosphate buffered saline, w/o calcium and 
magnesium; PAA Laboratories (Linz, Austria)  
Collagen solution   Collagen G, 75μg/ml in PBS 
PHEM buffer    60mM Pipes pH 6.1 
     25mM Hepes 
     10mM EGTA 
     3mM MgCl2
Trypsin/EDTA   0.5 g porcine trypsin  
0.2g EDTA  
1 liter of Hanks' Balanced Salt Solution with phenol red 
3.8.2. General 
Cell culture work was performed in sterile conditions under a laminar flow hood using sterile 
disposable plastic ware. Unless purchased sterile, all media, solutions and supplements used in 
cell culture work were sterilized with a vacuum-driven 0.2-µm filter membrane filtration system 
or a 0.2-µm syringe filter. They were stored at 4°C and prewarmed to 37°C prior to use. 
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3.8.3. Isolation of human umbilical vein endothelial cells (HUVECs) 
Human ECs were isolated from the veins of umbilical cords according to (Jaffe et al., 1973). 
From each end of the freshly obtained umbilical cord (obtained from Frauenklinik, Roten Kreuz, 
Munich) 1 cm was cut off, and the cord was hung up vertically. The upper end of the umbilical 
vein was cannulated and than sealed with artery clips. The vein was perfused with sterile PBS to 
wash out blood and sealed at the remaining end. α-chymotrypsin (approx. 5 ml 0.1 % w/v in 
PBS) was infused to slight flatulence in order to detach the HUVECs from the interior vein wall. 
After 20 min of incubation at 37°C and a short cord massage the solution was flushed from the 
vein by perfusion with 10 ml PBS into 2ml FCS or in endothelial complete growth medium that 
neutralizes α-chymotrypsin activity.  
HUVECs were harvested by centrifugation at 1000 rpm for 5 minutes at room temperature, and 
resuspended in 15 ml of endothelial growth medium, and cultured at 37°C in collagen-coated 75-
cm
2 
flasks as described below. After 3 h, the blood residuents were removed from adherent cells 
by washing with PBS and the fresh medium was added to the flask. The medium was changed 
after 24 h and cells were grown to confluence (passage 0) and then subcultured. 
3.8.4. Culturing 
HUVECs were placed in polystyrene culture flasks provided with 0.2-µm hydrophobic vent caps 
and maintained in a humidified 5 % CO2 atmosphere in an incubator at 37°C. Endothelial growth 
basal media were supplemented to complete media with growth factors, FCS and antibiotics (see 
section 3.8.1) to avoid bacterial contamination. The medium was changed twice a week. 
Adherent cells were grown to confluence and then detached by trypsinization by using 
trypsin/EDTA-treatment (3ml per 75-cm2 culture flask) for 1-2 minutes. After incubation, the cell 
suspension was diluted with 1 volume of complete medium to inactivate the trypsin. 
Subsequently, the cells were harvested by centrifugation at 1,000 rpm for 5 min at room 
temperature. The supernatant was removed, and cells were resuspended in fresh medium and 
reseeded in culture flasks at a density of approx. 6x104ells/ml. Endothelial cells of passage 1-4 
were used for experiments. 
3.8.5. Collagenization 
For adhesive growth, all cell culture flasks, and petri-dishes, subjected to HUVEC monolayer 
seeding, were collagen-coated by incubation with a sterile collagen G solution of final (75 µg/ml 
in PBS) for 30 min at room temperature. 
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3.8.6. Cell number determination 
If cell density was to be determined, 50 µl of the cell suspension was mixed with 50 µl 0.4 % 
trypan blue solution to visualize non-viable cells. The cell numbers in four 0.1-mm3volumes 
chamber were counted in a Neubauer hemacytometer under a binocular microscope and used to 
determine the mean cell density (cells/ml) by multiplying 10,000 with average cell 
number/chamber and dilution factor. 
3.8.7. Freezing and thawing of endothelial cells 
Endothelial cells of passage 1 were stored in 2-ml cryovials in a liquid nitrogen storage freezer. 
Cells were harvested at a concentration of 106-107
 
cells/ml, washed with PBS and resuspended in 
freezing medium. Before use of FCS in freezing medium, FCS was treated for 30 min at 56°C to 
inactivate complement and stored at –20°C. The cryovials were insulated with Styrofoam cloth 
(to avoid rapid cooling) and placed in a –70°C freezer overnight and transferred to liquid nitrogen 
for long-time storage.  
Cryopreserved cells were thawed rapidly in a 37°C water bath, transferred in 5 volumes of 
prewarmed medium and seeded in collagen-coated flask. After 3-5 hours the DMSO-containing 
medium was removed and fresh endothelial growth medium was added into the flask. 
3.8.8. Transfection of endothelial cells 
3.8.8.1. Electroporation method 
The technique of electroporation is widely used as a means to transfect cells. It consists in 
applying a brief electric field across a cell which leads to the polarization of the plasma 
membrane. The resulting difference in potential induces reversible loss of plasma membrane 
integrity, as long as a critical threshold has been reached, resulting in the formation of pores large 
enough to allow the diffusion of macromolecules such as DNA and Dextran. However, in the 
absence of optimized combinations of field strength (V/cm), time constant (determined by the 
resistance and capacitance in the complete circuit) and electroporation buffer composition, 
irreversible damage to the plasma membrane will occur and lead to cell death. 
Adherent endothelial cells were removed from 100-mm Petri dishes by trypsin/EDTA treatment 
as described above and washed with PBS. Endothelial cells (1.4x106 cells/400μl) were suspended 
in electroporation buffer. 20 μg of plasmid (EGFP-LIMK2 or its constructs) in electroporation 
buffer (30–60 μl) was mixed with the cell suspension and incubation was done for 10 min at 
room temperature. The final volume of incubation mixture was exactly 400 μl in all experiments. 
The cell suspension was placed in a 4 mm gap electroporation cuvette. Cells were electroporated 
at a fixed capacitance of 1000 μF and, 210V using a BioRad Gene Pulser instrument. Instrument 
readings showed that the time constant varied between 20 and 30 ms. Prewarmed endothelial 
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growth basal medium supplemented with 2x supplements (400 μl; without antibiotics) was added 
to each cuvette then transferred to glass bottom petri dishes (4 Petri dishes of 10mm diameter/per 
transfection) for confocal microscopy and placed in the incubator. After 30 minutes, fresh 
endothelial growth medium was added to the Petri dishes and the medium was replenished after 
24 h. 
3.8.8.2. NupherinTM-neuron mediated transfection 
Lipofection mediated transfection of primary cells is inefficient because much of the transfected 
DNA is retained in endosomes, and that which escapes to the cytoplasm, enters the nucleus at low 
rates. NupherinTM-neuron is a peptide-based reagent that combines a non-classical nuclear 
localization signal (NLS) containing the M9 sequence of heterogeneous nuclear 
ribonucleoprotein (hnRNP) A1, with a cationic peptide scaffold derived from a scrambled 
sequence of the SV40 T-antigen consensus NLS (ScT). The ScT was added to improve DNA 
binding of the M9 sequence. This reagent helps to transport DNA into the transfected cell's 
nucleus. NupherinTM-neuron with lipid mediated transfection protocol dramatically enhances the 
transfection efficiency of primary cells such as HUVECs. 
HUVECs were grown in 6-well plate up to the 90-100% confluency. The following solutions 
were prepared for transfection of HUVECs in each well. 
Solution A For each transfection, 2µg of DNA was diluted into 150µl serum-free medium OPTI-
MEM®I. 20µl (60µg) of the NupherinTM-neuron reagent was added to tube A and gently mixed 
by pipetting (do not vortex). The solution was incubated for 15 min at room temperature before 
mixing with solution B. 
Solution B 10μl cationic lipid lipofectinTM was added to a final volume of 150μl of OPTI-
MEM®I medium. 
The solutions A and B were mixed gently by pipetting (do not vortex) and incubated at room 
temperature for 40 minutes. After incubation 500μl of OPTI-MEM®I medium was added. The 
final volume of transfection solution was 800μl. Cells were washed twice with OPTI-MEM®I 
medium and then overlayed with transfection solution (800μl). Cells were centrifuged at 100xg 
for 5 minutes at room temperature and were incubated for 4 hours in CO2 incubator. The fresh 
endothelial complete medium was replaced after incubation. 
3.8.9. Actin staining 
HUVECs in 8-chamber Falcon® culture slide or in glass bottom dishes (for transfected cells) 
were either left untreated or stimulated with LPA (20μM) or thrombin (1U/ml) for different times 
(0-45 min) in the presence or absence of Rho-kinase inhibitorY27632 (20μM). Rho-kinase 
inhibitor Y27632 was added to the cells 40 min before stimulation. Cells were washed two times 
with PBS and fixed with 3.7% paraformaldehyde in PHEM buffer for 10 min at room 
 
Materials and methods 59
temperature. After washing twice with PBS, cells were permeabilized for 5 min with 0.1% Triton 
X-100 at room temperature, and washed again three times with PBS. In the case of transfected 
cells, cells were fixed and permeabilized with 50μl of BD Cytofix/cytopermTM buffer with an 
incubation of 15 minutes at 4°C and washed three times with PBS. Cells were incubated with a 
1% solution of BSA (30 min) at room temperature, and stained with rhodamine-phalloidine or 
Alexa 546-phalloidine (1:100 dilution) for 20 min at 4°C in the darkness. After washing, stained 
F-actin was visualized using a Zeiss Axiovert 25 microscope or confocal microscope Zeiss 
LMS510 Meta. 
3.9. Microscopy 
3.9.1. Live cell imaging by confocal microscopy 
Most cellular processes occur in three dimensions overtime. To get a complete picture, we need 
to image cells in four dimensions. In 4D microscopy, time-lapse observations of fluorescent 
molecules are collected as three-dimensional data sets rather than as one image in a single focal 
plane. Live-cell imaging technology using fluorescent proteins (green fluorescent protein and its 
homologues) and confocal microscopy has revolutionized the study of cellular dynamics because 
an auto fluorescent molecule can be genetically encoded by fusion of GFP with the cDNA of 
interest.  
 
Figure 3.5 Beam path in the confocal laser scanning microscope
In confocal laser scanning microscopes, a light beam with short wave length generated by laser is 
reflected by a beamsplitter/diachronic mirror and is led by flexible mirrors over the object field to 
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scan a custom region. Excited chromophores scatter light of a longer wavelength back through 
the beamsplitter/diachronic mirror and produce in the focal plane a characteristic diffraction 
pattern from which the center, the so called “Airy disc” is selected by a detector pinhole. Because 
light beams projected from regions above and below the focal plane will not pass the detector 
pinhole (red line path in Figure 3.5), this step leads to a strong suppression of out–of-focus 
information, known as the confocal principle. A laser beam scans the specimen pixel-by-pixel 
and line-by-line. The pixel data are then assembled into an image that is an optical section 
through the specimen, distinguished by high contrast and high resolution in x, y and z. A number 
of images generated with the focal plane shifted in small steps can be combined into a 3-
dimensional image stack, which is available for digital processing. 
Successful observations of living cells under the microscope depend on several requirements: (a) 
for optimal growth, most mammalian cell types have to be kept within a distinct temperature 
range (36.5 to 37°C). (b) The pH value of the medium should be kept within the physiological 
range (pH 7.2 to 7.4). In most growth media this is accomplished by a CO2-NaHCO3 based buffer 
system requiring a 5% CO2 atmosphere. In addition, media may contain HEPES buffer to 
increase the buffer capacity. (c) Evaporation of water leading to a harmful increase of the ion 
concentration has to be prevented. (d) The microscope should be able to record time series of 3D 
image stacks automatically with a high aperture objective (optical surface should be uniform and 
thin). (e) Focus drift should be automatically corrected. Vibrations during imaging should be 
carefully avoided. (f) Light exposure of the cells should be kept to the possible minimum to avoid 
phototoxic effects. 
   
 
 
Figure 3.6 A) Side and top view of glass bottom dishes. A glass coverslip was attached to the bottom of the dish. 
The dimensions of the dish are sown.  The thickness of the bottom glass is 0.085-0.13mm. B). This solid heating 
element is made of one piece of aluminium with uniform heat distribution and a high thermal conductivity.  
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To minimize these artifacts, the cells were grown on glass bottom culture dishes (Figure 3.6). 
After 24 hrs of transfection cells were washed with OPTI-MEM®I medium and kept for two 
hours in the same medium. To keep the temperature constant, after incubation, the culture dishes 
were placed in heating elements (Figure 3.6), set at 37°C and left for 15 minutes to equilibrate the 
temperature so that the focus drift is minimized. The cells were focused on a microscope using 
the Xenon light source. The microscope functions were controlled by light manager through the 
software LSM 510 Meta. The desired lasers were switched on. After focusing on the cells of 
interest, the parameters of laser intensity and detectors gains were optimized to reduce the photo-
damage and to acquire the good quality images. For Z-stacking the top and the bottom position 
were selected and the number of slices was determined according to the pinhole size and 
scanning time. After adjusting all the parameters live cell imaging was done on the microscope 
3.9.2. Photobleaching techniques 
Photobleaching techniques were used in combination with green fluorescent protein (GFP) 
chimeras to analyze protein dynamics in living cells. Photobleaching is the photoinduced 
alteration of a fluorophore that abolishes the fluorophore's fluorescence signal. The diffusive 
characteristics of fluorescently tagged proteins or organelles in the cell can be studied by 
photobleaching a selected region of a fluorescently labeled cell with intense light and then 
quantitating the movement of nonbleached fluorescent molecules into the photobleached area 
using an attenuated light source. In this study, two photobleaching techniques of confocal laser 
scanning microscope were used to study the nucleocytoplasmic shuttling of LIMK2: FRAP 
(fluorescence recovery after photobleaching) and FLIP (fluorescence loss in photobleaching). 
3.9.2.1. FRAP 
In FRAP, a distinct region of interest in a cell expressing a GFP chimera is briefly photobleached 
with a high-intensity laser, and the movement of unbleached fluorescent molecules into the 
bleached region is followed with low-intensity laser light. 
Establishing FRAP conditions 
This protocol was adapted from Snapp et al., 2003. The cells were prepared on glass bottom with 
phenol red free medium (OPTI-MEM®I medium) at 37°C. The cell of interest was selected. The 
whole cell image was scanned at the desired excitation light intensity, line averaging, zoom, and 
other parameters (modify pinhole and detector gain for maximal fluorescence signal with no pixel 
saturation (pixel intensities that exceed the detector scale, i.e., >255 for an 8-bit image). The 
region-of-interest (ROI) for the photobleaching was selected which is usually a 2- to 4-µm strip 
across the width of the cell. The photobleaching conditions (i.e., scan speed, zoom, laser power, 
microscope objective, and the minimal number of laser iterations required for photobleaching) 
were empirically determined so that after photobleaching, the fluorescent signal of the 
photobleached ROI decreases to background intensity levels. The imaging software LSM 510 
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META or NIH J was used to quantitate fluorescence intensity in the photobleached ROI and the 
whole cell prior to bleaching. For acquisition of fluorescence recovery time points, those imaging 
conditions that do not significantly photobleach were empirically determined. 
Note: ROI. Recommended conditions for photobleaching with 25mW argon laser are 45% to 
60% power with 100% transmission. For acquisition of recovery time points, use the same power 
with 0.1% to 1.0% transmission. For quantitative FRAP, the whole cell is usually scanned at scan 
speed 8 to 10 (0.798 to 3 sec per 512 × 512 frame) with either two-line averaging or no-line 
averaging. In qualitative FRAP experiments, where the goal is to obtain high-quality images, the 
intervals at which images are collected during recovery are longer.  
Collecting FRAP data 
To perform data analysis of a FRAP experiment, the prebleach image of the cell, a series of 
postbleach images of the whole cell that extend from an immediate postbleach image to several 
images after the bleach ROI fluorescence intensity reaches a plateau, and a table of fluorescence 
intensity values including the photobleach ROI, the whole-cell ROI, and a background ROI were 
collected. Multiple prebleach images were collected to establish the prebleach fluorescence 
intensity and to confirm that the prebleach fluorescence intensities of the cell and the bleach ROI 
do not fluctuate significantly. 
Using the predetermined conditions; the ROI was photobleached with intense laser illumination. 
The whole cell imaging was continued at low laser illumination (the same conditions as the 
prebleach images) until the recovery process has reached a steady state. At least 10 to 20 data 
sets were collected for each fluorescently labeled protein for statistical analysis. 
Note: A fraction of the data sets are usually discarded because of problems that potentially bias 
imaging results (e.g., recovery was not complete, the focal plane shifted, or the recovery curve-
fitting method failed). 
The postbleach intensity was corrected for overall loss of fluorescence determined from total 
fluorescence in the whole-cell images taken at the beginning and the end of the experiment. 
Overall loss of fluorescence is given by (IΣ0- IΣ∞)/ IΣ0 with IΣ0 = total cumulative pixel values in 
pre bleach whole cell image; IΣ∞ = total cumulative pixel values in post bleach whole cell image. 
Due to this loss, postbleach fluorescence intensities in the ROI can never reach 100% of the 
prebleach value and need to be corrected by multiplication with IΣ0/IΣ∞. The mean fluorescence 
intensities per area over time were plotted. 
3.9.2.2. FLIP 
This technique provides a powerful means for examining the boundaries of a compartment, 
whether it is the endoplasmic reticulum, nucleus, or cytoplasm. Using this method, a ROI is 
bleached repeatedly and fluorescence loss outside the ROI is monitored over time. The extent of 
which areas outside the ROI lose fluorescence overtime describes the boundaries over which the 
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fluorescent molecule is capable of diffusing. Three to five prebleach images were collected to 
establish the prebleach fluorescence intensity and to confirm that the prebleach fluorescence 
intensity does not significantly fluctuate. The cell of interest was identified. The ideal situation is 
to have two adjacent cells of similar fluorescence intensity in the imaging field. The cell that is 
not bleached provides a control to ensure that the imaging conditions do not cause nonspecific 
photobleaching. The imaging conditions were determined as described in FRAP. A region-of-
interest (ROI) for the photobleach was defined which was between 5% and 20% of the structure 
of interest. The imaging conditions photobleaching conditions (i.e., scan speed, zoom, laser 
power, number of laser iterations required for photobleaching, and microscope objective) were 
determined that photobleach 90% or more of the fluorescent signal in the ROI, without causing 
significant photobleaching outside of the ROI. The photobleaching module in Zeiss LSM 510 
Meta software was used to automate these processes. 20-40 iterations were set to photobleach the 
ROI to reduce the intensity to background level. Images were collected after photobleaching the 
area. Image were Collected at least three to five data sets for each fluorescently labeled protein 
and treatment. A fraction of data sets may be unusable because the focal plane shifted, the cell 
moved, or other reasons. 
3.9.3. Fluorescence data analysis 
All experiments were done from cells of at least three different independent cell preparations. 
The fluorescent intensity measurements were carried out with 20 cells randomly selected in each 






4.1. Expression of LIMKs in endothelial cells 
Protein sequences of LIMK1 (Entrez accession no. NP_002305) and LIMK2 (Entrez accession 
no. NP_005560) were aligned using ClustalW multi sequence alignment tool (Thompson et al., 
1994). The homologies of LIM1 domains and LIM2 domains of human LIMK1 and LIMK2 were 
found to be 50% and 62%, respectively. The homology between the PDZ domains of human 
LIMK1 and LIMK2 was 48%. The highest homology (71%) was found between their kinase 
domains. 
The information on the expression of human LIMK1 and LIMK2 genes was obtained from 
Unigene database (http://www.ncbi.nlm.nih.gov/UniGene/). 119 ESTs (Expressed Sequence 
Tags) were found for the human LIMK1 gene. The ESTs for human LIMK1 were obtained from 
tissues like brain, placenta, colon and different organ tumors (lung tumor, neuroblastoma, and 
retinoblastoma). 400 ESTs were found for human LIMK2, which are present in most of the body 
organs such as spleen, testis, ovary, skin, brain, heart, liver, and kidney. LIMK2 ESTs were also 
found in various cells such as human lung epithelial cells, T cells (Jurkat cell line), and B cells 
(Ramos cell lines). In endothelial cells, no ESTs of LIMK1 and LIMK2 were found using these 
databases.  
Therefore, the expression of LIMKs in endothelial cells was analyzed at the transcriptional level 
by reverse transcriptase polymerase chain reaction (RT-PCR) using total RNA isolated from 
human umbilical cord vein endothelial cells (HUVECs).  
Agarose gel electrophoresis of the PCR products revealed fragments of the expected size for 
human LIMK1 (405bp) and LIMK2 (490bp). Therefore, endothelial cells express a transcript for 
both LIMKs (Figure 4.1A). These amplified products of LIMKs were confirmed by DNA 
sequencing. Possible DNA contamination of RNA preparation leading to false-positive detection 
of genomic LIMKs sequences instead of in vivo transcribed LIMKs mRNA, was excluded by 
designing the LIMKs specific primers at exon boundaries (exon-intron informations of LIMK1 
and LIMK2 were obtained from Ensembl database http://www.ensembl.org/), and by using 
negative controls of RT-PCR samples (reverse transcriptase polymerase enzyme was excluded 
during the RT-PCR). No amplification was obtained in negative RT-PCR controls. No additional 
amplification of LIMKs genomic fragments including the introns between exon 13 and 16 
sequences (5.37kb with LIMK1 sets of primers MS3 and Limk1_3’and 5.86kb with LIMK2 sets 
of primers LIMK2_13 and Limk2_3’; data not shown) was obtained in addition to the fragments 





Figure 4.1 A) Expression of LIMKs in endothelial cells. (A) 490bp PCR product was amplified with LIMK2 
specific primers (lane 3) and a 405bp PCR product was amplified with LIMK1 specific primers (lane4). No PCR 
products were obtained in the negative controls of LIMK1 (lane5) and LIMK2 (lane2). B) Expression analysis of the 
β-actin RNA transcript (446bp) in endothelial cells (lane1). DNA contamination was excluded by the absence of a 
longer 652-bp fragment amplified from the intron-containing genomic β-actin DNA (lane1). No PCR product was 
seen in negative control (lane2). DNA molecular weight marker is shown in lane1 (A) and lane3 (B). 
 
 
Figure 4.2 LIMK1 and LIMK2 protein expression in endothelial cells (EC) and platelets. Confluent 
unstimulated or stimulated (thrombin, 1U/ml) endothelial cells (1.8×106 cells) and platelets (2×105 platelets/μl) were 
lysed in 500μL SDS PAGE sample buffer. A) The ~100kDa (27kDa EGFP + 72 kDa LIMK2) and ~85kDa (27kDa 
EGFP + 56.5 kDa PDZ-kinase (PDZK) of LIMK2) bands were detected in EGFP-LIMK2 (lane2; and lane3) and 
EGFP-PDZK (lane1) transfected cells respectively. The faint endogenous LIMK2 (~72 kDa) bands were also seen in 
the same blot. B) Endogenous LIMK2 protein (~72 kDa) was detected in endothelial cells but not in platelets C) No 
bands were detected in EGFP-LIMK2 transfected cells by blotting with the anti-LIMK1 antibody. Endogenous 
LIMK1 (~72kDa) was detected in untransfected cells (EC, lane 4). D) Endogenous LIMK1 protein was detected in 
both endothelial cells and platelets.  
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A PCR of negative RT-PCR controls and the RT-PCR samples was also performed with the 
primers of housekeeping gene β-actin (Figure 4.1B). In the case of the DNA contamination, PCR 
would lead to an additional amplification of a genomic β-actin fragment including the intron 
sequence (652bp) in addition to the fragments (446bp) derived from spliced β-actin mRNA 
transcripts. PCR with the β-actin primers showed only a fragment of 446bp (Figure 4.1B). These 
results indicate that the RNA preparation was free from genomic DNA contamination.  
The expression of LIMK1 and LIMK2 proteins in endothelial cells was also analyzed by western 
blotting using LIMK1 and LIMK2 specific antibodies. Anti-LIMK2 specific antibody identified a 
band of ~72kDa in endothelial cells (lane 4, Figure 4.2A; Figure 4.2B) but not in platelets. In 
endothelial cells, a specific lower band (~55kDa) was also observed in immunoblots with a 
specific anti-LIMK2 antibody (Figure 4.2B). The anti-LIMK1 specific antibody identified the 
72kDa band in both endothelial cells and platelets (lane 4 Figure 4.2; lane 1 and 2, figure 1.2D).  
The specificity of the LIMK1 and LIMK2 antibodies was analyzed by immunoblotting of 
endothelial cells that had been transfected with different EGFP constructs of LIMK2 (pEGFP-
LIMK2, pEGFP-PDZK). The anti-LIMK2 antibody but not the anti-LIMK1 antibody identified 
the specific bands of EGFP-LIMK2 and EGFP-PDZK (Figure 4.2A, C). The anti-LIMK1 and 
anti-LIMK2 antibodies but not specific IgG control antibody recognized specific bands of 72kDa 
in untransfected endothelial cells indicating the expression of both LIMKs in these cells (Figure 
4.2B, and D, data not shown). LIMK2 was not expressed in platelets (Figure 4.2B). The 
endogenous proteins of LIMK1 and LIMK2 were barely detected in transfected cells (Figure 
4.2A, and C). Possible reasons for this observation are that 1) the total proteins amount of the 
transfected cells loaded was approximately 50% of the amount of the non-transfected cells, 2) 
that the exposure time of the film after western blotting was less due to the high expression of 
EGFP-LIMK2 constructs in endothelial cells, and 3) that the transfection suppresses expression 
of the endogenous LIMKs. 
4.2. LIMKs regulate actin dynamics in thrombin-stimulated 
endothelial cells 
4.2.1. Thrombin induces stress fiber formation by Rho-kinase activation  
The effect of thrombin on actin dynamics in endothelial cells was studied by live cell imaging. 
After 30 hours of transfection with EGFP-β-actin plasmid, endothelial cells were serum starved 
for two hours and then activated with thrombin 
In the control state, ruffle formation at the cell periphery and few stress fibers were observed. The 
EGFP-β-actin protein was diffusively distributed throughout the cytoplasm, and also found in the 
ruffles as small aggregates.  
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Within 5 minutes of activation by thrombin, the transfected cells started contracting. After 15 to 
22 minutes, the contracted cells were often rounded and a F-actin ring was seen at the periphery 
of cells. In addition, thrombin stimulated ruffle formation. In the upper cell, that did not contract, 
stress fiber formation was prominent. Some of the cell-cell contacts were disrupted and the F-
actin fibers connecting the two cells were broken, possibly due to the contraction of the 
contractile F-actin rings (Figure 4.3 and supplementary movie 1). 
 
Figure 4.3 The effect of thrombin on actin dynamics in endothelial cells. The images show the same cells at 0 
minute (control), 15 minutes, and 22 minutes after thrombin (1U/ml) activation. The white arrows indicate actin ring 
formation. The red arrow shows the place where the cells separated and actin fibers broke leading to cellular gap 
formation.  
To investigate whether thrombin activates Rho-kinase in endothelial cells, Rho-kinase activation 
was measured by MYPT1 phosphorylation (Myosin Phosphatase Targeting Subunit1). The 
myosin light chain phosphatase (MLCP) consists of the delta isoform of type 1 protein 
phosphatase and the regulatory subunit (MYPT1). MYPT1 is phosphorylated at Thr696 and 
Thr853 by Rho-kinase (Ito et al., 2004). Thrombin-stimulated MYPT1 phosphorylation was 
increased within 2 minutes, reaching a maximum (2.4 fold) after 5 minutes. MYPT1 
phosphorylation subsequently decreased (Figure 4.4A). In the presence of the Rho-kinase 
inhibitor Y-27632, MYPT1 phosphorylation in control cells was drastically decreased (Figure 
4.4A) and the increase of MYPT1 phosphorylation after thrombin stimulation was inhibited. 
These data indicate that Rho-kinase is already active in unstimulated cells and further activated 
by thrombin. Furthermore, thrombin-induced stress fiber formation is dependent on Rho-kinase 
activation; since it was completely blocked by pretreatment of the cells with Y-27632 (Figure 
4.4B). 
4.2.2. Rho-kinase stimulates phosphorylation of LIMK leading to subsequent 
cofilin phosphorylation in thrombin-stimulated endothelial cells 
Cofilin is an actin binding protein, which promotes actin depolymerization. Its function is 
inhibited by phosphorylation at Ser-3 by LIM-kinase. In studies of cell lines, it has been shown 
that Rho-kinase can phosphorylate LIMK1 at Thr508, and LIMK2 at Thr505, leading to the 





Figure 4.4 Thrombin stimulates Rho-kinase and stress fiber formation in endothelial cells. Endothelial cells, 
pretreated with or without the Rho-kinase inhibitor Y27632 (20μM, 45 minutes), were stimulated with thrombin 
(1U/ml) and immunoblotted with specific anti-phospho-MYPT1 (Thr853) specific antibody. A) The activation of 
Rho-kinase was measured by MYPT1 phosphorylation and plotted against time. B) Stress fiber formation was 
analyzed 15 minutes after thrombin stimulation using rhodamine-phalloidin staining.  
To analyze the activation of LIMK1 and/or LIMK2 in thrombin-stimulated endothelial cells, 
LIMK-kinase phosphorylation was measured by a specific anti-phospho-LIMK antibody.  
LIM-kinase phosphorylation was rapidly stimulated (7.3 fold). The maximum level was reached 
2 minutes after thrombin activation. Subsequently, LIM-kinase phosphorylation decreased slowly 
(Figure 4.5A). LIMK phosphorylation was completely absent in Y27632-treated unstimulated 




Figure 4.5 Effect of Rho-kinase activation on LIMK activation and cofilin phosphorylation in thrombin-
stimulated endothelial cells. Endothelial cells pretreated without or with Y27632 (20μM; 45 minutes), were 
stimulated with thrombin (1U/ml) for different times. A) LIMK phosphorylation was analyzed by blotting with anti-
phospho-LIMK antibody. B) Cofilin phosphorylation was analyzed by blotting with a specific anti-phospho cofilin 
antibody. Values represent mean±SEM of 3 experiments. 
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To investigate whether LIM-kinase activation might phosphorylate cofilin in thrombin–
stimulated endothelial cells, cofilin phosphorylation was measured by using a specific anti-
phospho cofilin antibody. In thrombin-stimulated cells, cofilin phosphorylation gradually 
increased up to 15 minutes and then decreased until 45 minutes after activation (Figure 4.5B). In 
the presence of the Y27632, cofilin phosphorylation was drastically reduced in unstimulated and 
stimulated cells (Figure 4.5B).  
These results show that in thrombin-stimulated endothelial cells, Rho-kinase activates LIM-
kinase, leading to cofilin phosphorylation.  
4.2.3. Role of LIMKs in stress fiber formation  
To demonstrate the functional relevance of LIM-kinase activation for stress fiber formation, a 
kinase negative mutant (D451A) of EGFP-LIMK2 was prepared and transfected in endothelial 
cells. For comparison, endothelial cells were transfected with wild type EGFP-LIMK2. These 
cells were stimulated with thrombin for 10 minutes and analyzed for actin staining along with 
EGFP fluorescence by confocal microscopy. 
In non-transfected cells and in wild type EGFP-LIMK2 transfected cells, dense and thick stress 
fibers were observed after thrombin stimulation. In contrast, in cells transfected with dominant 
negative mutant of EGFP-LIMK2, actin stress fiber formation was absent; instead actin 
aggregates were observed (Figure 4.6). These data suggest that the Rho-kinase/LIMK/cofilin 
pathway regulates stress fiber formation in thrombin-stimulated endothelial cells.  
               
Figure 4.6 The effect of dominant negative mutant of LIMK2 on stress fiber formation in thrombin-stimulated 
cells. Endothelial cells transfected with wild type EGFP-LIMK2 and dominant negative EGFP-LIMK2 (D451A) 
were activated with thrombin for 10 minutes. Stress fiber formation was analyzed using F-actin staining after 
thrombin stimulation (red). EGFP fluorescence of wild type and mutant LIMK2 is shown in green. 
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4.3. Primary sequence analysis of LIM-kinase 
4.3.1. Prediction of nuclear localization signals and nuclear export signals 
 
Figure 4.7 Protein sequence alignment of human LIMK1 and LIMK2. The LIM1 domains (red), LIM2 domains 
(green), PDZ domain (cyan) and the kinase domains (magenta) show homologies of 50%, 62%, 48% and 71%, 
respectively. The unique basic amino acid-motifs in the kinase domains, representing a potential nuclear localization 
signal (NLS), are shaded in red and the basic amino acids are shown in yellow. The conserved amino acids are 
marked with asterisk. The positively substituted amino acids are marked with dots. The known nuclear export signal 
(NES) sequences of LIMK1 and the two predicted NES of LIMK2 are shaded in yellow. The conserved leucine, 
isoleucine and valine residues in the NES sequences are shown in red. A Ser/Pro rich region lies between the PDZ 
domain and the kinase domain. The different domains were separated for clear visualization. 
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The unique basic amino acid-rich motifs of LIMK1 and LIMK2 in the kinase domain are shown 
in Figure 4.7 (amino acids, yellow). The basic nature of these motifs suggests that they may 
function as a nuclear localization signal (NLS). The basic amino acid-rich motif of LIMK2 has 
more arginine and lysine residues than LIMK1. To characterize the functional NLS in LIMK2, 
the basic amino acids-rich motif of LIMK2 was scanned in the Prosite database 
(http://www.expasy.org/prosite/ (Hulo et al., 2004) and compared with known NLSs of different 
proteins. Three types of unique potential NLSs were predicted which were designated as NLS1, 
NLS2, and NLS3 (Figure 4.8A). 
NLS1 was predicted by comparing the motif of LIMK2 with well-characterized monopartite 
NLSs (consisting of a single short consecutive basic amino acids) of different proteins. The 
alignment with selected monopartite NLSs of different proteins is shown in Figure 4.8B (Jans and 
Hubner, 1996). NLS2 and NLS3 were predicted based on bipartite NLSs. Bipartite NLSs have 
two series of basic residues separated by a 10 to 12 amino acid spacer (Robbins et al., 1991). 
 
Figure 4.8 Prediction of the nuclear localization and nuclear export signals in LIMK2. A) The location of 
different predicted NLSs (NLS1, NLS2, and NLS3) in basic amino acid-rich motif of LIMK2. The basic amino acid-
rich motifs of LIMKs were aligned with monopartite NLSs from different proteins (B) and bipartite NLSs of the 
Polo-like kinase family members (C). The numbering of amino acids in the Plk sequences is based on human Plk1. 
The basic amino acids are shown in red. D) NES in LIMK1 and LIMK2. The leucine rich regions of LIMK2 were 
aligned with LIMK1 NESs and other selected known NESs from different proteins. Leucine, isoleucine, and valine 
are shown in red. 
Polo-like kinase 1 (Plk1), a mammalian ortholog of Drosophila Polo, is a serine-threonine protein 
kinase involved in the regulation of multiple aspects of mitosis. Plk1 bipartite NLS has an 
unusually short spacer (6 amino acids) sequence between two clusters of basic amino acids 
(Taniguchi et al., 2002). NLS2 was determined by aligning Plk1 with the basic amino acid motifs 
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of LIMK1 and LIMK2 (Figure 4.8C). In LIMK2, the 6 amino acid spacer is uniquely interrupted 
by two basic amino acids (RK). The bipartite NLS3 with an 8 amino acid spacer was predicted in 
LIMK2 by analyzing the Prosite database. In LIMK1, no bipartite type of NLS sequence (NLS2 
or NLS3) was found. The predicted NLS1, NLS2, and NLS3 in LIMK2 are shown in Figure 
4.8A. 
LIMK1 has two nuclear export signals in the PDZ domain (NES1 and NES2) as shown in Figure 
4.7 and Figure 4.8D (Yang and Mizuno, 1999). The two NESs in LIMK2 were predicted based 
on alignment with LIMK1 and the consensus sequences (ψ-X2-3-ψ- X2-3-L-X- (LI), ψ represent 
any hydrophobic amino acid) of NES (Figure 4.7 and Figure 4.8D) The putative NES1 of the 
LIMK2 is present at the C-terminal of the PDZ domain and NES2 is localized immediately after 
the PDZ domain. The numerous NLSs and NESs in LIMK2 suggest that this kinase may actively 
shuttle between the nucleus and the cytoplasm. 
4.3.2. Prediction of PKC phosphorylation sites in LIMK2 
Besides the LIM-, PDZ-, and the kinase-domains, LIMKs have structurally flexible or 
“intrinsically disordered”7 regions. The majority of known disordered proteins or domains are 
involved in cell signaling or transcriptional or translational regulation via non-catalytic 
interactions with DNA, RNA or other proteins (Iakoucheva et al., 2002). Disordered regions have 
a much higher frequency of known phosphorylation sites than ordered regions (Iakoucheva et al., 
2004). 
LIMK1 LIMK2 PONDR 























Table 4.1Prediction of disordered regions in LIMKs. PONDR VL-XT predictor shows that LIMK1 and LIMK2 
have two highly disordered regions (>30 amino acids). LIMK2 has shorter disordered regions than LIMK1. PONDR 
XL1-XT analysis of LIMK2 shows the same results as before. In contrast, it did predict any disordered region 
(longer than 30 amino acids) in LIMK1. 
                                                 
7 Disordered regions (DRs) are entire proteins or regions of proteins, which lack a fixed tertiary structure, essentially 
being partially or fully unfolded. 
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To predict the disordered regions, LIMKs protein sequences were analyzed by using PONDR 
(Predictors Of Natural Disordered Regions) VL-XT and XL1-XT predictors 
(http://www.pondr.com/). The accuracy of predictions by PONDR is highest in the predicted 
regions of > 30 amino acids length. The results are summarized in Table 4.1.  
The regions longer than 30 amino acids were selected for the further analysis The disordered 
regions in LIMKs might be potential targets for phosphorylation that leads to their transition into 
an ordered region, and might control the functions of these enzymes. 
To predict the phosphorylation sites in LIMKs other than Thr505 (LIMK2) or 508 (LIMK1) 
(target for Rho-kinase, refer introduction for details), Scansite (Obenauer et al., 2003), a motif 
based bioinformatics tool was used . The amino acid sequences of LIMK1 and LIMK2 were 
analyzed by using high stringency settings8. Two potential PKC phosphorylation sites (Ser283, 
and Thr494) were found in the predicted disordered regions of LIMK2 (Table 4.2). These sites 
were absent in the same corresponding regions of LIMK1. Interestingly, the second PKC 
phosphorylation site (Thr494) was found in the predicted NLS2 region. The two PKC sites have 
the consensus sequences of substrates of specifically the PKC-α and PKC-β isoforms 
(Brinkworth et al., 2003). The positions of NLS, NES and PKC sites in LIMK2 are shown in 
Figure 4.9. 
 
Disordered region PKC site Sequence 
VL-XT XL1-XT 
PKCI 278TLRRR283SLRRSNSI 267-307 269-310 
PKCII 489TTKKR494TLRKNDRK (NLS2) 473-506 474-507 
 
Table 4.2 The positions of predicted PKC phosphorylation site in LIMK2. Two phosphorylation sites in the 
disordered regions of LIMK2 were predicted by Scansite program. The phosphorylation target sites are shown in red. 
The PKCII site is present in NLS2.  
 
Figure 4.9 Localization of NES, NLS, PKCI and PKCII sites in LIMK2. The predicted NES and NLS are shown 
in green and dull yellow respectively. The putative PKC phosphorylation sites are shown in sky blue.  
                                                 
8 High stringency setting is the most restrictive and reports a ‘hit’ only if the score falls within the top 0.2% of scores 
when the motif matrix of interest was applied to the vertebrate subset of SWISS-PORT. 
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4.4. Nucleocytoplasmic shuttling of LIMK2 in endothelial cells 
In order to analyze whether the predicted NLSs and NESs in LIMK2 are functional, the full-
length LIMK2 cDNA was cloned into the pEGFP-C1 plasmid and the sub-cellular distribution 
were examined in live cells by confocal fluorescence microscopy.  
The EGFP protein was diffusely distributed throughout the cytoplasm and the nucleus (Figure 
4.10A), probably reflecting the unfacilitated diffusion of EGFP (~27kDa) through the nuclear 
pore. The EGFP-LIMK29 protein was mainly localized in the cytoplasm (92±2%, Mean±SEM) 
and only 6±2% was in the nucleus (Figure 4.10C). The intensity of EGFP-LIMK2 expression in 
the nucleus and the cytoplasm was measured by ImageJ software (http://rsb.info.nih.gov/ij) and 
LSM 510 META confocal software. The measurements were carried out in three independent 
experiments with 20 cells randomly selected in each experiment. The same approach was 
followed in all the subsequent experiments. 
 
Figure 4.10 Nucleocytoplasmic shuttling of EGFP-LIMK2 but not EGFP. Endothelial cells were transfected with 
plasmid EGFP-C1 or plasmid containing the full length LIMK2 gene. EGFP was diffused throughout the cell (I) and 
EGFP-LIMK2 protein was mainly localized in the cytoplasm (III). After inhibition of nuclear export with leptomycin 
B (LMB; 10ng/ml; 60 minutes), the distribution of EGFP was not affected (II), but EGFP-LIMK2 was located 
exclusively in the nucleus (IV).  
The nuclear export of many proteins is governed by the exportin protein CRM1. CRM1 
dependent nuclear export is blocked specifically by the Streptomyces metabolite leptomycin B 
(LMB) (Kudo et al., 1998; Wolff et al., 1997). To determine whether LIMK2 is continuously 
                                                 
9 The correct expression of the different EGFP-constructs of LIMK2 was controlled by immunoblotting with anti-
LIMK2 antibody (shown in Figure 4.2).  
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shuttled between the nucleus and cytoplasm in resting endothelial cells and whether its export is 
dependent on CRM1, EGFP-LIMK2 transfected endothelial cells were treated with LMB 
(10ng/ml). It was found that EGFP-LIMK2 was located exclusively in the nucleus (Figure 
4.10D). The cytoplasmic distribution of EGFP was not affected by the LMB treatment. These 
results indicate that the cytoplasmic EGFP-LIMK2 continuously goes into the nucleus, and that 
CRM1 transports EGFP-LIMK2 actively and continuously out of the nucleus. The continuous 
nucleocytoplasmic shuttling of LIMK2 is likely to be regulated by its NLSs and NESs. 
4.4.1. LIM domains of LIMK2 regulate its cytoplasmic localization 
Since LIMK2 is found mainly in the cytosol in resting endothelial cells, the NLS of LIMK2 
might be masked. It has been found that LIM domains bind with the kinase domain of LIMK1 
containing the NLS (Nagata et al., 1999). Therefore, the cytoplasmic localization of LIMK2 may 
be due to the interaction of LIM domains and the kinase domain. This interaction may be either 
intramolecularly or intermolecularly and may block the NLS function. To investigate this, 
different constructs of LIMK2 were made with EGFP in which either one or both LIM domains 
were deleted. The nuclear localization of ΔLIM1-LIMK2 (LIM1, amino acids 1-62 were deleted) 
protein was approximately 2 times (15±3%) higher than the wild type EGFP-LIMK2 (Figure 
4.11A). This indicates that LIM1 partially inhibits the NLS and plays a role in the cytoplasmic 
localization of LIMK2. In contrast, the ΔLIM2-LIMK2 protein (LIM2 domain, amino acids 72-
124 were deleted) was localized mainly in the cytoplasm similarly to the full length EGFP-
LIMK2 protein (Figure 4.11B). 
The nuclear localization of EGFP-PDZK (both LIM domains, amino acids 1-141 were deleted) 
was drastically increased in the nucleus (40±5% of the total protein) (Figure 4.11C). This result 
suggests that both LIM domains contribute to the cytoplasmic localization of LIMK2. This might 
be due to the partial inhibition of NLS by the interaction between both the LIM domains and the 
kinase domain. 
It was found that EGFP-LIMK1 after LMB treatment of endothelial cells was also localized in 
the nucleus (data not shown). However, in contrast to LIMK2, deletion of the two LIM domains 
of LIMK1 did not enhance the nucleus localization of LIMK1. The EGFP-PDZK (amino acids 
146-647) of LIMK1 was still localized in the cytoplasm (Figure 4.11). This indicates that the 
LIM-domains of LIMK1 do not regulate the nucleocytoplasmic shuttling of LIMK1. 
After 30 hrs of EGFP-PDZK of LIMK2 plasmid transfection, the endothelial cells were treated 
with LMB, and the nuclear accumulation of the protein was observed at different time intervals. 
Ten minutes after LMB treatment, 80±6% of the total protein was shifted to the nucleus (Figure 
4.12). After 30 minutes, almost all the EGFP-PDZK was localized in the nucleus. EGFP-PDZK 
entered the nucleus faster than the full length EGFP-LIMK2 (data not shown). These results 
suggest that LIMK2 rapidly shuttles between the nucleus and cytoplasm, and that cytoplasmic 
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localization of LIMK2 is due to the partial inhibition of the NLS by the two LIM domains and 
due to the active CRM1 dependent nuclear export of LIMK2. 
 
 
Figure 4.11 The LIM-domains of LIMK2 inhibit nuclear localization of LIMK2, but not LIMK1. A) Deletion 
of LIM1 domain (EGFP-ΔLIM1-LIMK2, amino acids 1-62 deleted) of LIMK2 partially enhanced the nuclear 
localization of EFGP-LIMK2. B) The deletion of LIM2 domain ((EGFP-ΔLIM2-LIMK2, amino acids 72-124 
deleted) did not affect the cytoplasmic localization of LIMK2. C) Deletion of both LIM1 and LIM2 domains (EGFP-
PDZK, amino acids 1-141 deleted) of LIMK2 drastically increased its localization in the nucleus. D) EGFP-PDZK of 
LIMK1 (amino acids 146-647) was localized exclusively in the cytoplasm. 
 
Figure 4.12 Time course of nuclear accumulation of EGFP-PDZK after LMB treatment. After 30hrs of 
transfection, cells were treated with LMB (10ng/ml) for different times, and the localization of EGFP-PDZK in the 
nucleus was observed by confocal microscopy. 
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4.4.2. PDZ-kinase domain of LIMK2 is localized in the nucleus and cytosol: 
Analysis of shuttling by FRAP and FLIP 
The shuttling of EGFP-PDZK of LIMK2 between the nucleus and the cytoplasm was analyzed by 
FRAP and FLIP. Fluorescence Recovery After Photobleaching (FRAP) is a tool to study the 
diffusive properties of molecules in living cells (Lippincott-Schwartz et al., 2003). Using this 
technique, a region of interest is selectively photobleached with high–intensity of laser light. The 
recovery that occurs as the fluorescent-labeled molecules move into the bleached region is 
monitored over time with low intensity laser light. EGFP-PDZK plasmid transfected cells were 
used for FRAP as described in materials and methods.  
 






























Figure 4.13 Nuclear FRAP analysis of EGFP-PDZK in the endothelial cells. The transfected endothelial cells 
were pretreated for 30 minutes with cycloheximide (10μg/ml) before the experiment to inhibit new EGFP-PDZK 
synthesis. A) The target cell expressing EGFP-PDZK protein is shown before bleaching. The green fluorescence was 
specifically photobleached in the nucleus (red circle). B) Image immediately after photobleaching. C) Final image of 
the bleached cell at the end time point (534 seconds) of the experiment. D) The recovery of the nuclear fluorescence 
(fluorescence intensity, control 100%) was measured in the graph at different times after photobleaching. The images 
A, B, and C are also indicated at the respective time points of the graph  
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The nucleus region was selected as the “region of interest” (ROI) and photobleached with high 
intensity laser light.  The recovery was monitored in the same ROI. A graph was plotted as shown 
in Figure 4.13. The time for 50% recovery (τ1/2) of fluorescence was determined form the graph. 
The τ1/2 of EGFP-PDZK was calculated as 205 seconds. This means that after 3.5 minutes half of 
the total nuclear accumulating fluorescent EGFP-PDZK proteins have entered the nucleus. These 
results suggest that the NLS within the kinase domain drive the EGFP-PDZK into the nucleus. In 
addition, it was observed that the recovery in the ROI could not reach 100%. One possible 
explanation is that part of the cytosolic EGFP-PDZK is not free to move into the nucleus, perhaps 



























Figure 4.14 FLIP analysis of EGFP-PDZK transfected endothelial cells. Two regions of the cytosol of the lower 
cell (marked as red squares) were repeatedly photobleached (as described in Materials and Methods). Images were 
scanned before photobleaching (A), immediately after photobleaching (B) and at the final time point (C). D) 
Fluorescence in the nucleus of the lower bleached cell (blue diamond), and in the nucleus of the upper control cell 
(pink square) was measured at the indicated times. Cells were pretreated with cycloheximide for 30 minutes before 
starting the FLIP experiment. 
In order to study whether EGFP-PDZK was exported from the nucleus to the cytoplasm, the 
technique Fluorescence Loss In Photobleaching (FLIP) was used. An area of the cytoplasm of a 
cell expressing the EGFP-PDZK protein was photobleached, and fluorescence intensity in the 
nucleus of the photobleached cell was monitored. As control, the fluorescence intensity in the 
nucleus of an adjacent unbleached cell was measured. The level of nuclear fluorescence in the 
photobleached cell gradually decreased over time (Figure 4.14C). In contrast, the nuclear 
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fluorescence in the adjacent cell (unbleached) was unaffected. (D) This indicates that EGFP-
PDZK was exported from the nucleus in endothelial cells. 
4.4.3. EGFP-kinase of LIMK2 is localized in nucleus and nucleolus: 
comparison with the EGFP-kinase of LIMK1 
The kinase domain of LIMK2 has several predicted NLSs (NLS1, NLS2, NLS3; Figure 4.8). A 
NES consensus sequence was not detected in the kinase domain, suggesting that the kinase 
domain of LIMK2 should localize into the nucleus. To confirm this prediction, the EGFP-kinase 
domain (amino acids 315-638) construct was transfected into the endothelial cells. As expected, 
more than 95% protein accumulated in the nucleus (Figure 4.15A). Notably, EGFP kinase was 
also concentrated as dense bodies in the nucleus (white arrow Figure 4.15A), indicating that 
EGFP-kinase might associate with specific nuclear sub-compartments. The mammalian nucleus 
has various sub-compartments such as the nucleolus, the cajal bodies and nuclear speckles. Of 
these sub-compartments, the nucleolus is a highly dense nuclear compartment that can be easily 
detected by phase contrast microscopy. The phase contrast image of EGFP-kinase transfected 
endothelial cells (Figure 4.15B) showed an exact overlap of the nucleoli with the intensely 
stained EGFP-kinase dense bodies (Figure 4.15). This indicates that the EGFP-kinase not only 
accumulated in the nucleus but also in the nucleolus. To ensure that the EGFP-kinase stained 
dense bodies are not nuclear membrane bulge or bleb like structures, the cell was scanned by 
confocal microscopy. This revealed that the EGFP-kinase dense bodies were inside the nucleus 
(data not shown). 
 
Figure 4.15 Sub-cellular localization of EGFP-kinase of LIMK1 and LIMK2. The EGFP-kinase domains of 
LIMK1 (amino acids 302-647) and LIMK2 (amino acids 315-638) mainly localized in the nucleus of the transfected 
endothelial cells. The fluorescence and phase contrast images of the respective EGFP-kinase transfected cells are 
shown. The nucleolus is indicated by white arrow. The dense fluorescent bodies of EGFP-kinase of LIMK2 exactly 
overlay with the nucleolus. EGFP-kinase of LIMK1 is absent in the nucleolus (white arrow). 
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The nuclear localization of the kinase domain of LIMK2 was compared with localization of the 
kinase domain of LIMK1. In LIMK1, the basic amino acid motif in the kinase of domain has less 
arginine and lysine than the respective sequence of LIMK2 (Figure 4.7) that may affect the 
nuclear localization of the LIMK1. In contrast to the results obtained with LIMK2, only about 
75% of the EGFP-kinase of LIMK1 was localized in the nucleus. However, it did not localize to 
the nucleolus Figure 4.15).  
These results suggest that the LIMK2 has more potential of being localized to the nucleus than 
LIMK1. They also show that the kinase domain of LIMK2, but not LIMK1, has a specific 
nucleolar localization signal (NoLS). 
4.4.4. Site directed mutagenesis of the unique basic amino acid-rich motif in 
LIMK2  









Mutant 6 (NLS2) 
Mutant 7 (NLS3) 
Mutant 8 (NLS2 + RK) 
 
                                                    NLS2 
480RKRAPMEKATTKKRTLRKNDRKKR503









Mutants of EGFP-PDZK Amino acid sequence 
 
Mutant 9 (NLS1) 
Mutant 10 
Mutant 11 (NLS2) 






Table 4.3 Mutants of EGFP-kinase and EGFP-PDZK constructs. In the wild type sequence, the putative NLS1, 
NLS2, and NLS3 were underlined. The basic amino acids are shown in blue, and were mutated to alanine (red). 
Mutant 1 (9 of EGFP-PDZK), 6 (11 of EGFP-PDZK) and 7 are generated to inhibit the function of the putative 
NLS1, NLS2 and NLS3 respectively.  
The unique basic amino acid-rich motif within the kinase domain of LIMK2 has three putative 
nuclear localization signals (Figure 4.8), and the results in the previous section show that it may 
also contain a nucleolus localization signal. These NoLS are also generally built by sequences 
rich in arginine and lysine. In contrast to the NLS, the sizes of NoLS are highly variable, ranging 
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5 amino acids to 100 amino acids. Therefore, amino acid sequence analysis fails in predicting 
putative NoLS especially also because they overlap with NLS. 
The unique basic insert of LIMK2 may thus have both functional NLS and NoLS. Therefore, 
different mutants of EGFP-kinase and EGFP-PDZK were generated in which the basic amino 
acids were mutated into alanine. The characteristics of the mutants are shown in Table 4.3.  
4.4.4.1. Site directed mutagenesis in EGFP-kinase domain of LIMK2 
The different mutants of EGFP-kinase constructs were transfected in endothelial cells, and their 
sub-cellular localization was studied. Mutant 1 affecting NLS1 (RKKR, amino acids 500-503) 
was mainly localized in the nucleus similarly as the wild type kinase domain of LIMK2. 
However, the nucleolus staining was drastically reduced (Figure 4.16A I, IV). The nuclear 
localization of mutant 2 (RK, amino acids 496-497) and 3 (KKR, amino acids 491-493) was 
decreased by 20±6%, and the nucleolus localization was absent similarly to the mutant 1 (Figure 
4.16A II, III and its corresponding phase contrast images V and VI respectively). These results 
indicate that NLS1 (RKKR) and the basic amino acids RK and KKR are an important part of the 
NoLS.  
Mutant 4 (RKR, amino acids 480-482) was mainly in the nucleus as the wild type kinase (Figure 
4.16A VII and X). The nucleolar localization of mutant 4 was slightly reduced, and any distinct 
green fluorescent dense bodies could not be observed in the nucleus. This indicates that the basic 
amino acids 480-482 are not an important part of the NLS and NoLS.  
Mutant 7 (NLS 3, amino acid 480-482 and 491-493 were mutated) was absent in the nucleolus 
and the nuclear localization of mutant 7 was more reduced (25±5%) than of mutant 3 (Figure 
4.16A and B). This confirms that the basic amino acids 480-482 play a minor role in nuclear 
localization signal (mutant 4).  
These results together suggest that the basic amino acid-rich motif 491-503 (KKRTLRKN 
DRKKR) is the functional nucleolar localization signal. NLS1 and NLS3 are not active nuclear 
localization signals. To explore the NLS further, basic amino acids of NLS 2 were mutated in 
sequence in mutant1 (Table 4.3). The additional mutation of basic amino acids RK (mutant 5) 
and KKR (mutant 6, NLS2) in mutant 1 affected the nuclear localization of the mutant proteins. 
The nuclear localization of mutant 5 and 6 was decreased by 25±2% and cytoplasmic staining 
was increased. These proteins were also absent in the nucleolus (Figure 4.16A). Finally, all the 
additional basic amino acids RK of NLS2 were mutated in mutant 6 and mutant 8 was prepared. 
The nuclear localization of this mutant protein was drastically reduced in the nucleus (20±4%). 
these results indicate that the basic amino acids RK (amino acids 496-497) KKR (amino acids 
491-493) and RKKR (amino acids 500-503) may all be part of the NLS of LIMK2.  








Figure 4.16 The effect of different mutations in the basic amino acid motif of EGFP-kinase on nucleus and 
nucleolus localization. A) The fluorescence images of mutant 1-6 expressions in endothelial cells are shown in 
figure I-III and VII-IX. The corresponding phase contrast images are shown in figure IV-VI and X-XII respectively. 
B) The expression of mutant 7 and 8 and its corresponding phase contrast images are shown in Figure I, III and 
figure II, IV, respectively. 
The nuclear localization of the mutant 8 was not completely inhibited. This may be due to the 
remaining basic amino acids 480-482 being a part of NLS.  
 
Sub-cellular localization in % Mutants 
Nucleus N/C Nucleolus 





































Table 4.4 The summary of the mutation data of EGFP-kinase. The sub-cellular distribution was measured as 
described in materials and methods and calculated as % of total expressed recombinant protein. The values of sub-
cellular expression of the recombinant protein are the Mean±SEM (n=3 experiments, 20 cells per experiment were 
selected) N/C indicates the nuclear localization versus cytoplasmic localization of the EGFP-kinase. 
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4.4.4.2. Site directed mutagenesis in EGFP-PDZK of LIMK2 
In addition to the three NLSs in the kinase domain, PDZ-kinase contains two predicted NES, 
which are C-terminal of the PDZ domain. These NESs might be responsible for the decreased 
localization of EGFP-PDZK (40%) as compared to EGFP-kinase (95%). In comparison with the 
high molecular weight protein EGFP-PDZK (~84kDa), the EGFP-kinase (~62kDa) may passively 
diffuse into the nucleus. After LMB treatment, the wild type EGFP-PDZK completely 
accumulated in the nucleus. In order to explore the respective function of NLS1, NLS2 and NLS3 
in the nuclear import of PDZ-kinase, specific mutants (mutants 9-12) were made. Mutant 9 (NLS 
1) and mutant 11 (NLS2) were mainly in the cytoplasm (98%, Figure 4.17). The nuclear 
localization was increased to 20% after LMB treatment for 40 minutes.  
The nuclear localization of mutant 10 was slightly higher then mutant 9. After LMB treatment, 
the nuclear localization of mutant 10 was only 40±6%. This indicates that the mutation of the 
basic amino acids 496-497 slightly reduced the rate of nuclear import, resulting in reduction of 
the nuclear localization of mutant protein.  
The nuclear localization of mutant 12 (NLS2+RK) was mainly in the cytoplasm (98%). After 
LMB treatment, this sub-cellular distribution was barely affected. only 7% of mutant 12 was in 
the nucleus.  
These results of mutation in EGFP-PDZK clearly show that the NLS2 (basic motif 491-503) is 
the nuclear localization signal of LIMK2. The nuclear localization of mutant 8 in contrast to 
mutant 12 may be due to the passive diffusion of the protein in to the nucleus. The results further 
show that NLS1 (RKKR, amino acids 500-503) is the most important for the nuclear localization 
of PDZ-kinase (reduction of the nuclear localization of mutant 9 to 20% after LMB treatment). 
The two amino acids 496-497 (RK) contributed also to the nuclear localization (see results of 
mutant 10 with LMB), whereas the amino acids 491-493 (KKR) were apparently not as important 
for the nuclear localization of PDZ-kinase (compare results of mutant 9 with mutant 11). The 
summary of the results is shown in Table 4.5. 
Together all these mutational data from EGFP-kinase and EGFP-PDZK show that the basic motif 
491-503 is the functional NLS of LIMK2 and is also the functional NoLS. 
Sub-cellular localization in % Mutants 
Nucleus Cytoplasm Nucleolus 
Control +LMB  































Figure 4.17 The sub-cellular expression of different mutants of EGFP-PDZK transfected into endothelial cells. 
The cells transfected with mutant 9, 10, 11 and 12 plasmids are shown These transfected cells were treated with 
LMB (10ng/ml, 40 minutes) to block the nuclear export. 
4.4.5. Sub-cellular localization of EGFP-Δkinase-LIMK2 
The functional NLS sequence identified above lies within the kinase domain. To explore, whether 
there might be a further NLS present in LIMK2, the kinase domain was deleted and a EGFP-
Δkinase-LIMK2 (amino acids 1-314) construct was prepared. As expected from the mutation 
analysis shown before, EGFP-Δkinase-LIMK2 protein was localized in the cytoplasm and not in 
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the nucleus. After one hour of treatment with LMB, to inhibit the nuclear export, the EGFP-
Δkinase-LIMK2 protein was distributed equally in the nucleus and the cytoplasm suggesting the 
presence of a NLS in this construct. There is a possible monopartite NLS at position 280-286 
(RRRSLRR) in LIMK2. To analyze this further, the basic amino acids 280-282 (RRR) were 
mutated to alanine in EGFP-Δkinase-LIMK2. The sub-cellular distribution of the mutant protein 
was however similar to that of the wild type construct in untreated or pretreated cells with LMB. 
The presence of the EGFP-Δkinase-LIMK2 protein in the nucleus might be explained by the 
diffusion of this low molecular weight protein (60kDa) into the nucleus. In addition, the two 
putative CRM1 dependent NESs of LIMK2 localized at the end of the PDZ domain are present in 
the EGFP-Δkinase-LIMK2 (Figure 4.7).  
 
Figure 4.18 Possible NLS of LIMK2 situated between PDZ and kinase domain is not functional. The wild type 
and mutant EGFP-Δkinase-LIMK 2 plasmids of LIMK2 were transfected into endothelial cells. The expressed 
EGFP-Δkinase-LIMK2 protein was mainly localized in the cytoplasm. After LMB treatment the NLS mutant and 
wild type protein were equally distributed in the cytoplasm and the nucleus. The mutant EGFP-Δkinase-LIMK2 was 
also localized mainly in cytoplasm and was equally distributed in the nucleus and cytoplasm after LMB treatment 
4.5. Regulation of nucleocytoplasmic shuttling of LIMK2 by PKC-
dependent phosphorylation 
4.5.1. Effect of PMA on sub-cellular localization of LIMK2 
Two putative PKC phosphorylation sites are present in the disordered regions of LIMK2 (Table 
4.2). One (site I) is present between the PDZ and the kinase domain (amino acids 280-286), and 
the other (site II) is in the kinase domain within the functional NLS2 (amino acids (492-497). To 
study the effect of phosphorylation by PKC, EGFP-LIMK2 and EGFP-PDZK transfected cells 
were stimulated with phorbol-12-myristate-13-acetate (PMA), a potent PKC activator.  
Within 30 minutes of stimulation with PMA, the nuclear EGFP-LIMK2 was shifted to the 
cytoplasm (Figure 4.19A and D). The amount of nuclear EGFP-LIMK2 (6±2%) was decreased to 
1±0.5%. The nuclear fluorescence of EGFP-PDZK (40%) also disappeared after PMA 
stimulation, and EGFP-PDZK was exclusively localized in the cytoplasm (Figure 4.19B and E). 
There was no effect of PMA on the nuclear localization of EGFP-kinase (Figure 4.19C and F) 
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indicating that phosphorylation of the second PKC site within NLS-2 does not alter the function 
of this nuclear localization signal. The effect of PKC activation on the exclusive cytoplasmic 
localization of EGFP-LIMK2 and EGFP-PDZK must then be due to phosphorylation of the PKC 
I site and might be explained either by acceleration of the nuclear export or by indirect inhibition 
of the nuclear localization.  
 
Figure 4.19 PKC activation by PMA regulates the sub-cellular distribution of EGFP-LIMK2 and EGFP-
PDZK, but not EGFP-kinase. Endothelial cells transfected with EGFP-LIMK2, EGFP-PDZK and EGFP-kinase 
were treated with 200nM PMA for 30 minutes. EGFP-LIMK2 is mainly present in the cytoplasm, but approximately 
6±2% of total expressed protein was in the nucleus (A). After treatment with PMA, the nuclear fluorescence 
disappeared in the nucleus (D). The nuclear fluorescence of EGFP-PDZK was higher as observed and discussed 
before (40%, B) and also drastically reduced to 3% by PMA treatment (E). The treatment of PMA did not affect the 
nuclear localization of EGFP-kinase (C and F). 
4.5.2. The PKC-α and PKC-β isoforms regulate nucleocytoplasmic 
translocation of LIMK2  
PKC, a serine/threonine kinase, has various isoforms (Shirai and Saito, 2002). To find out which 
specific isoforms of PKC regulate the shuttling of LIMK2, the cells transfected with EGFP-
PDZK were incubated with isoform specific inhibitors. Subsequently the cells were activated 
with PMA. Go6983, a potent PKC inhibitor, specifically inhibits PKC-α, PKC-β, PKC-γ, PKC-δ 
and PKC-ζ in nanomolar range, but not other PKC-isoforms (Gschwendt et al., 1996; Peterman et 
al., 2004). The PMA-stimulated translocation of EGFP-PDZK to the cytoplasm was completely 
blocked (Figure 4.20 C).  
The specific inhibitor Go6976 only inhibits the PKC isoforms PKC-α, PKC-β, and PKC-μ. It 
does not affect other PKC isoforms even at micro-molar range in vitro (Martiny-Baron et al., 
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1993). EGFP-PDZK protein translocation to the cytoplasm by PMA stimulation was also 
inhibited by Go6976. These results indicate that the PMA-induced translocation of LIMK2 from 
the nucleus to the cytoplasm is mediated specifically by the PKC isoforms PKC-α and PKC-β.  
 
 
Figure 4.20 The effect of different PKC inhibitors on the PMA induced translocation of EGFP-PDZK. 
Endothelial cells transfected with EGFP-PDZK were incubated with the PKC inhibitor Go6976 (2μM) or Go6983 
(500nM) and then stimulated with PMA for 30 minutes. PMA-treatment shifted the protein from the nucleus to the 
cytoplasm ( A). This translocation was completely blocked by the PKC inhibitors (B, C). 
4.5.3. Ser283 (site I) in LIMK2 is phosphorylated in PMA-stimulated 
endothelial cells 
Phospho-specific antibodies are powerful tool to analyze protein phosphorylation. To investigate 
the potential PKC phosphorylation site I in LIMK2, a specific anti-phospho-Ser PKC substrate 
antibody was used. This antibody has been generated against a degenerate peptide library of the 
PKC substrate motif CXXX(K/R)(K/R)S*(F/L/V)(K/R)(K/R)XXX (X representing any amino 
acid except Trp and Cys, and S* is phosphoserine) (Zhang et al., 2002) and was found to bind 
with high affinity to the consensus peptide sequence (XXRRRS*LRRXX) present in LIMK2 
(Table 4.2, amino acids 280-286). 
To analyze, whether endogenous LIMK2 was phosphorylated, endothelial cells were untreated 
(control) or treated with PMA. LIMK2 in endothelial cell lysates was specifically 
immunoprecipitated with a specific anti-LIMK2 antibody and blotted with anti-phospho-Ser PKC 
substrate antibody. The phosphorylation of LIMK-2 was increased about 4.5 fold after PMA 
treatment (Figure 4.21A, lanes 1 and 2 and Figure 4.21B). Both PKC inhibitors Go6976 and 
Go6983 inhibited LIMK2 phosphorylation in control cells and PMA-stimulated cells. Go6983 
was more potent then Go6976 (Figure 4.21A and B). These results strongly suggest that 
endogenous LIMK2 was phosphorylated on Ser283 by the PKC isoforms PKC-α, and PKC-β in 
PMA-stimulated endothelial cells. 
In addition to the PKC site at Ser283, there is a second possible PKC phosphorylation site in 
LIMK2 at Thr494. To confirm the specificity of the anti-phospho-Ser PKC substrate antibody, 
mutants of EGFP-PDZK were prepared in which Ser283, Thr494 or both sites were mutated to 
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alanine. The mutants were transfected into endothelial cells, which were stimulated with PMA. 
The anti-phospho-Ser PKC substrate antibody detected both the wild type EGFP-PDZK and the 
T494A mutant (Figure 4.21C lane 1-4). There was no signal on the immunoblots of the S283A 
mutant and the S283A/T494A double mutant in PMA stimulated or control cells (Figure 4.21 
























































Figure 4.21 PKC phosphorylates endogenous LIMK2 at position Ser283 in PMA-stimulated endothelial cells. 
A) Cells were incubated at 37°C for 30 minutes with or without PKC-inhibitors (Go6983 500nM, Go6976 2μM) and 
then stimulated with PMA (200nM). LIMK2 in the endothelial cell lysates was immunoprecipitated with a specific 
anti-LIMK2 antibody. The LIMK2 immunoprecipitated samples were blotted against anti-phospho-Ser PKC 







Figure 4.22 Specificity of anti-phospho-Ser PKC substrate antibody. Anti-phospho-Ser PKC substrate antibody 
recognized the EGFP-PDZK (lane 1 and 2), and threonine 494 mutated EGFP-PDZK proteins (lane 3 and 4) from 
both PMA treated and untreated cells. This antibody failed to recognize the protein in which Ser283 was mutated to 
alanine. 
4.5.4. PKC-mediated Ser283 phosphorylation inhibits the nuclear import of 
LIMK2 
In order to examine whether S283 phosphorylation is responsible for the translocation of LIMK2 
from the nucleus to the cytoplasm in PMA activated cells, Ser283 was modified to either alanine 
(S283A) or to two glutamic acids (S283EE). Substitution of the phosphorylation site with two 
acidic amino acids (EE) mimics the phosphorylation of that site. LIMK2 constructs containing 
the S283EE mutation should be constitutively active, whereas constructs containing the S283A 
mutation should be inactive. The wild type EGFP-PDZK and EGFP-LIMK2 left the nucleus after 
PMA treatment (Figure 4.23 I, II and IV, V). After PMA stimulation of cells transfected with the 
S283A mutants of EGFP-PDZK and EGFP-LIMK2, the translocation of the recombinant mutant 
proteins to the cytoplasm was completely blocked (Figure 4.23 III, VI). In control cells, more 
EGFP-LIMK2 (S283A) (10%) was in the nucleus than the wild type LIMK2 (data not shown). In 
the cells transfected with the active S283EE mutants of EGFP-PDZK and EGFP-LIMK2, the 
proteins were completely localized in the cytoplasm similar to the PMA-stimulated cells (Figure 
4.23B). These results indicate that PKC regulates the nucleocytoplasmic shuttling of LIMK2 in 
resting endothelial cells and in cells after PMA activation through phosphorylation of Ser283.  
To investigate whether the S283 phosphorylation blocks the nuclear entry or accelerates the 
nuclear export, cells transfected with the S283EE mutant plasmid were treated with LMB. The 
nuclear accumulation of mutant EGFP-LIMK2 was drastically reduced (Figure 4.23B IV). More 
mutant EGFP-PDZK was in the nucleus and less in the cytoplasm as compared with the results of 
the mutant EGFP-LIMK2 (Figure 4.23B). As shown previously, wild type EGFP-LIMK2 and 
EGFP-PDZK accumulated in the nucleus completely in the presence of LMB. These results 
indicate that S283 phosphorylation inhibits nuclear accumulation of LIMK2 by reducing the rate 




       
Figure 4.23 Effect of S283 mutation on the nucleocytoplasmic shuttling of LIMK2. The serine283 was either 
mutated to alanine (inactive mutation; A III and VI) or to two glutamic acids (active mutation; B). In cells transfected 
with the wild type EGFP-LIMK2 and EGFP-PDZK, the proteins leave the nucleus within 30 minutes of PMA 
treatment (II and V). S283A mutation of LIMK2 and PDZK stopped this translocation (III and VI). B) No nuclear 
localization of the active S283EE mutants of LIMK2 and PDZK was observed (III and VI). After LMB treatment 
(10ng/ml), the nuclear accumulation of these active mutants was reduced as compared to the results with the wild 
type of these constructs.  
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4.5.5. Mutation analysis of the putative PKC phosphorylation site at Thr494 
(siteII) 
There is a putative second phosphorylation site by PKC: in LIMK2 at Thr494 ( 
Table 4.2). To analyze the possible function of the phosphorylation of T494 in vivo, T494 was 
mutated to alanine (inactive mutant) or to two glutamic acids (active mutant). The T494A mutant 
of EGFP-PDZK was localized both in the nucleus and the cytoplasm of control cells (Figure 
4.24A). After 40 minutes of PMA treatment, the T494A mutant protein was shifted to the 
cytoplasm similar to cells transfected with wild type EGFP-PDZK (Figure 4.24B compare with 
Figure 4.12).  However, rate of translocation was slower than the wild type protein (30 minutes). 
These results suggest that the possible phosphorylation of Thr494 does not play major role in the 
inhibition of nuclear accumulation of EGFP-PDZK by PKC.  
We also studied the sub-cellular distribution of the active mutant (T494EE) of EGFP-PDZK. 
LIMK2 might be also phosphorylated at this site. The results show that the active mutant of 
EGFP-PDZK is mainly localized in the cytoplasm not in the nucleus (Figure 4.24C) similar to the 
localization of S283EE mutant of EGFP-PDZK. After LMB treatment, only part of the active 
(T494EE) EGFP-PDZK mutant was in the nucleus. These results suggest that phosphorylation of 
LIMK2 at Thr494, if it was phosphorylated in endothelial cells, can also inhibit nuclear import. 
 
Figure 4.24 The effect of Thr494 mutation on nucleocytoplasmic shuttling of EGFP-PDZK. Thr494 was 
mutated to alanine or two glutamic acids. The inactive mutant (T494A) of EGFP-PDZK was distributed both in 
nucleus and the cytoplasm (A), and shifted to the cytoplasm within 40 minutes of treatment with PMA (B). The 
active (T494EE) mutant of EGFP-PDZK was mainly localized in the cytoplasm of the control cells (C) and was 
partially localized in the nucleus after one hour of LMB treatment of endothelial cells.  
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4.5.6. Phosphorylation of both Ser283 and Thr494 blocks the shuttling of 
LIMK2 
To study whether the phosphorylation of both PKC sites in LIMK2 (Ser283, Thr494) affects the 
sub-cellular distribution of LIMK2 more than the phosphorylation of one PKC site only, several 
double mutants of EGFP-PDZK and EGFP-LIMK2 were prepared. The S283A/T494EE 
(inactive/active) and the S283EE/T494A (active/inactive) mutants behaved similar to each other 
and to the single mutant proteins, T494EE and S283EE, respectively. The mutant proteins were 
found mainly in the cytoplasm (Figure 4.25A I, II) and did not completely accumulate in the 
nucleus after LMB treatment of the endothelial cells (Figure 4.25A IV, V). These results show 
that either one of the two sites reduce nuclear import of LIMK2 and regulate the 
nucleocytoplasmic shuttling.  
 
 
Figure 4.25 Effect of double mutations of the two PKC sites on nucleocytoplasmic shuttling of LIMK2. A) The 
S283A/T494EE and S283EE/T494A mutants of EGFP-PDZK mainly localized in the cytoplasm of the control cells 
(I and II). They partially accumulated in the nucleus after LMB treatment (IV and V). The mutant S283EE/T494EE 
of EGFP-PDZK was also mainly localized in the cytoplasm of the control cells (III), but failed to localize to the 
nucleus after LMB treatment (VI). B). The double mutant S283EE/T494EE of EGFP-LIMK2 was mainly localized 
in the cytoplasm, and after LMB treatment, did not accumulate in the nucleus  
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To analyze, whether phosphorylation of both sites inhibits the nuclear import completely, 
S283EE/T494EE double mutants of EGFP-PDZK and the EGFP-LIMK2 were prepared. 
S283EE/T494EE mutants of EGFP-PDZK and EGFP-LIMK2 were localized in the cytoplasm of 
control cells (Figure 4.25A III and Figure 4.25B I) and also after LMB treatment (Figure 4.24A, 
VI; Figure 4.24, II). These double active mutants were not able to enter into the nucleus. These 
results suggest that both PKC sites might be functional in LIMK2, and that the phosphorylation 
of both sites is more effective than the phosphorylation of only one site: it completely stopped 
LIMK2 of entering into the nucleus.  
4.6. PMA-induced activation of endothelial cells does not stimulate 
LIMK-mediated phosphorylation of cofilin 
PKC-induced phosphorylation of LIMK2 might affect the kinase activity of LIMK2 for two 
reasons: a) Ser283 phosphorylation might induce conformational change, b) the probable 
phosphorylation of Thr494 in the kinase domain is close the Thr505 in LIMK2 which is 
phosphorylated by Rho-kinase. Phosphorylation of Thr505 is known activate the kinase activity 
of LIMK2  
 
Figure 4.26 Effect of PMA on cofilin phosphorylation in endothelial cells. Endothelial cells were activated with 
PMA (200nM) and Cofilin phosphorylation was analyzed by at different time points by western blotting. 
Endothelial cells were stimulated with PMA and LIMK-mediated phosphorylation of cofilin was 
measured. The results did not show a change of cofilin phosphorylation and also not of LIMK 
phosphorylation at Thr505 after PMA stimulation (Figure 4.26). Therefore the PKC mediated 





5.1. Expression of LIMKs in endothelial cells 
Contraction, migration, and proliferation of vascular endothelial cells are essential features of 
vascular permeability, endothelial repair after injury, and angiogenesis (Folkman and Shing, 
1992; Jackson et al., 1994), and regulated by coordinated changes of actin dynamics (Tang et al., 
1997; van Nieuw Amerongen et al., 2003). The LIMK family of proteins, a member of the class 
of serine/threonine protein kinases, consists of LIMK1 and LIMK2 that specifically 
phosphorylate and inactivate cofilin, an actin-depolymerizing protein, thereby regulating actin 
cytoskeleton rearrangement (Arber et al., 1998; Yang et al., 1998b). 
LIMK2 and as a recent study shows, also LIMK1 are ubiquitously expressed in mouse tissues 
(Foletta et al., 2004). The results from Unigene EST database also indicate that LIMK1 and 
LIMK2 are present in various tissues such as brain, placenta colon and different organ tumors. 
LIMK2 ESTs were also reported in various cell lines such as T cells, human lung epithelial cells. 
So far it has not been reported, which isoform of LIMKs is present in endothelial cells. By using 
RT-PCR and immunoblot, the present work demonstrates that both LIMK1 and LIMK2 are 
present in endothelial cells and monocytes (data not shown). However, only LIMK1 was present 
in platelets. In endothelial cells, an additional specific protein band of low molecular mass 
(~55kDa) was observed in anti-LIMK2 immunoblots. This result suggests that a low molecular 
mass splice variant of LIMK2 might be present in endothelial cells. Based on the AceView10 
database, eleven different isoforms of LIMK2 have been suggested to be present in human cells. 
A previous study has shown that LIMK2 has various splice isoforms in mouse tissues (Ikebe et 
al., 1997; Ikebe et al., 1998). The expression of LIMK2 isoforms is not yet reported in human, 
and the specific cellular distribution of human LIMK1 and LIMK2 is poorly studied. In the 
present study, only one type of endothelial cells (HUVECs) has been studied. It is possible that 
the expression of LIMK1, LIMK2 and their isoforms depends on the state of maturation of 
endothelial cells and their origin from different vascular beds. Endothelial cells in different 
vascular beds are heterogeneous. They show a highly different structure due to different gene 
expression and actin cytoskeleton rearrangement. For example, the brain and retina capillaries are 
lined by a layer of continuous endothelial cells connected by tight junctions that help to maintain 
the blood brain barrier.  
                                                 
10 AceView offers an integrated view of the human, nematode and Arabidopsis genes reconstructed by alignment of 
all publicly available mRNAs and ESTs on the genome sequence. AceView carefully computes co-alignment and 
clustering of experimental cDNA data, no prediction is involved. The resulting AceView genes and their alternative 
variants are analyzed in terms of expression, intron-exon structure, and alternative features. 
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5.2. Thrombin-induced stress fiber formation is regulated by Rho-
kinase/LIMK/cofilin pathway 
By using live cell imaging, the present study shows and confirms previous findings that thrombin 
induces stress fiber formation, ruffle formation and cell contraction in endothelial cells (Essler et 
al., 1998). This study also showed that cell-cell contacts were disrupted and F-actin fibers 
connecting two cells were broken after thrombin-stimulated endothelial cells. Increased 
permeability of endothelial monolayers results from both, disruption of tethering forces (arising 
from cell-cell junctions and cell-matrix interactions) and enhancement of cell retraction (Garcia et 
al., 1996; Lum and Malik, 1994).  
Rho-like small GTPases such as Rho, Rac, and Cdc42 regulate actin dynamics in stimulated 
endothelial cells. Rho-kinase, a kinase downstream of Rho, plays a major role in thrombin-
induced endothelial cell contraction (Goeckeler and Wysolmerski, 1995). In this study, activation 
of Rho-kinase in thrombin-stimulated endothelial cells was measured by a new approach; i.e. by 
quantifying the phosphorylation of the substrate MYPT on Thr696 or Thr853 (Hartshorne, 1998; 
Ito et al., 2004). The results show that MYPT phosphorylation was maximal 5 minutes after 
thrombin activation and decreased subsequently. This study also demonstrates that the Rho-
kinase inhibitor Y27632 could completely block thrombin-stimulated MYPT phosphorylation, 
stress fiber formation, and cell contraction suggesting that thrombin-induced stress fiber 
formation and cell contraction is mediated by Rho-kinase activation. These results are consistent 
with the findings of previous studies, and demonstrate that thrombin induces stress fiber 
formation and cell rounding in endothelial cells via the Rho/Rho-kinase pathway.   
The precise mechanism by which Rho-kinase regulates stress fiber formation in endothelial cells 
is unknown. Previous studies have shown that Rho-kinase in endothelial cells directly 
phosphorylates MYPT and inactivates myosin phosphatase, leading to an increase in myosin light 
chain phosphorylation (Essler et al., 1998). Phosphorylated myosin interacts with actin filaments, 
and develops actin-activated adenosine triphosphatase (ATPase) activity (Goeckeler and 
Wysolmerski, 1995). These properties of myosin are important for endothelial cell contraction, 
and may also be important for stress fiber formation. Based on transfection studies it has been 
proposed that Rho-kinase leads to LIMK activation and subsequent phosphorylation and 
inactivation of cofilin, resulting in the accumulation of actin filaments and stress fiber formation 
(Arber et al., 1998; Maekawa et al., 1999). In order to find out, whether in endothelial cells 
phosphorylation and inactivation of the actin depolymerizing protein cofilin was responsible for 
the F-actin increase and stress fiber formation, the LIM-kinase/cofilin pathway was analyzed in 
thrombin-stimulated endothelial cells. 
This study showed that both LIMK1 and LIMK2 are present in endothelial cells. LIMK1 and/or 
LIMK2 were rapidly phosphorylated and the phosphorylation was maximal within 2 minutes 
after thrombin activation. Previous studies have reported that LIMKs are not only activated by 
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Rho-kinase, but can also be phosphorylated and activated by Rac-activated PAKs (p21 activated 
kinases)(Edwards et al., 1999). A previous study has however, shown that the Rac1 activity was 
inhibited in thrombin-activated endothelial cells (Vouret-Craviari et al., 2002). It was found in the 
present study that the specific Rho-kinase inhibitor Y-27632, which does not effect the activity of 
PAK, even at high concentrations (100μM) (Uehata et al., 1997), inhibited completely LIMK 
activation in thrombin-stimulated of endothelial cells. Therefore, LIMK phosphorylation in 
thrombin-stimulated endothelial cells was entirely dependent on Rho-kinase. Moreover the 
increase of cofilin phosphorylation in thrombin-stimulated endothelial cells was drastically 
decreased by pretreatment of the cells with Y27632. These results indicate that in thrombin-
stimulated endothelial cells cofilin phosphorylation and inactivation is regulated by Rho-kinase 
mediated LIM-kinase activation.  
 
Figure 5.1 Proposed schema of Rho-kinase/LIMK/cofilin mediated stress fiber formation in thrombin-activated 
endothelial cells. 
To analyze more directly the role of LIMKs in stress fiber formation, a kinase inactive mutant 
(D451A) of LIMK2 was transfected into endothelial cells. This mutant binds to cofilin and 
inhibits cofilin phosphorylation by endogenous LIMKs. Stress fiber formation was blocked in 
these cells transfected with the dominant negative mutant of LIMK2, indicating that LIMKs play 
an essential role in stress fiber formation. 
Together theses results show that the Rho-kinase/LIMK/cofilin pathway is activated in thrombin-
stimulated endothelial cells and that this pathway plays -together with the Rho-kinase/MLC-Pase/ 
MLC phosphorylation pathway- a central role in stress fiber formation (see Figure 5.1). 
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5.3. Primary sequence analysis of LIMK 
Computational analysis of the primary sequence of a protein is a powerful method to predict the 
regulation of the protein function. It has been shown that the kinase domain of LIMKs has a 
unique basic sequence inserted between subdomain VII and VIII. The basic nature of this motif 
suggests a functional nuclear localization signal present in LIMKs. Of the two types of NLSs 
known, a monopartite NLS consists of a single short stretch of consecutive basic amino acids, 
like in SV40 large T-antigen (PKKKRKV), and a bipartite NLS comprises two clusters of basic 
amino acids separated by a 10-12-amino acid spacer, like in nucleoplasmin (KRPAATKKAGQA 
KKKKLDK) (Mattaj and Englmeier, 1998). Based on homology searches with NLS containing 
proteins and by software analysis, this study demonstrates that LIMK2 has a NLS sequence 
different than LIMK1. LIMK2 has three predicted NLS: one monopartite NLS (NLS1) and two 
bipartite NLS (NLS2, NLS3). In contrast, LIMK1 has only one monopartite NLS. This difference 
suggests a different mode of regulation of nuclear localization of LIMK2 and LIMK1. 
Concerning the nuclear export of LIMKs, a previous study showed two leucine rich NES 
sequences C-terminal of the PDZ domain of LIMK1 (Yang and Mizuno, 1999). These leucine 
rich NES-containing proteins are exported from the nucleus by CRM1/exportin 1 (Fornerod et al., 
1997). By searching homologies with NES containing proteins, two CRM1 binding NES 
sequences were predicted in LIMK2: one was C-terminal of the PDZ domain and the other was 
present immediately after the PDZ domain. These findings indicate that both LIMKs contain the 
signals to shuttle between the nucleus and the cytoplasm. Since LIMK1 and LIMK2 show 
differences in their nuclear export and import signal sequences, the two enzymes may have a 
different mode of regulation of nucleocytoplasmic shuttling. 
Primary sequence analysis also indicated that LIMKs have a Ser/Pro-rich region between the 
PDZ and the kinase domain. After extensive analysis of this region, the results show that these 
regions are intrinsically disordered. An additional disordered region was found in the kinase 
domain of LIMK2, but not in LIMK1. Proteins with intrinsically unstructured regions are 
frequently involved in specific cell processes such as transcriptional activation, cell-cycle 
regulation, membrane transport, molecular recognition and signaling (Wright and Dyson, 1999). 
Post-translational modifications such as phosphorylation occur often in disordered regions and 
then lead to transition into an ordered conformation thereby regulating the function of these 
proteins (Dunker et al., 2001; Tompa, 2002). Both LIMKs have many serine residues in the 
region between the PDZ domain and the kinase domain. The disordered region in the kinase 
domain of LIMK2, but not LIMK1 has many threonine residues. These amino acids are potential 
targets for phosphorylation. Indeed this study demonstrates that LIMK2, but not LIMK1 has two 
potential PKC phosphorylation sites: one is present between the PDZ and the kinase domain 
(Ser283, site I); the other is in the kinase domain (Thr494, site II). The primary sequence analysis 
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suggested a unique subcellular distribution of LIMK2 and a unique mechanism of regulation of 
nucleocytoplasmic shuttling of LIMK2.  
5.4. Nucleocytoplasmic shuttling of LIMKs 
Previous reports have shown that both LIMK1 and LIMK2 are present mainly in the cytoplasm, 
but also in the nucleus of cell lines such as NIH3T3, and mouse embryonic fibroblast cells, 
indicating that the NLS and NES sequences in these enzymes are functional (Foletta et al., 2004; 
Roovers et al., 2003). Indeed, after blocking the CRM1-dependent export with LMB, LIMK1 was 
predominantly localized in the nucleus indicating that it shuttles between the nucleus and the 
cytoplasm (Roovers et al., 2003; Yang and Mizuno, 1999). The present study shows that LIMK2 
similar to LIMK1 is also present mainly in the cytoplasm and less in the nucleus of endothelial 
cells. We observed that LIMK2 was completely shifted to the nucleus after treatment of 
endothelial cells with LMB. This indicates the existence of functional NES and NLS in LIMK2 
and also, that LIMK2 is exported via the CRM1-dependent nuclear export pathway.  
In order to directly visualize the nucleocytoplasmic shuttling of the PDZK construct of LIMK2, 
photobleaching experiments (FRAP and FLIP) were carried out. FRAP analysis indicated that 
EGFP-PDZK continuously entered the nucleus and has a functional NLS. The shape of the 
recovery curve (recovery of the fluorescence in the nucleus) is of complex type (Periasamy and 
Verkman, 1998). This can occur when a molecule undergoes binding and release from 
intracellular components, or exists as monomer and multimer. The PDZ domain generally 
functions as a protein-protein interacting domain (see Introduction for details), and the PDZ-
kinase domain of LIMK2 might interact with other proteins in the cytoplasm and the nucleus. To 
analyze the export of the EGFP-PDZK in endothelial cells, the photobleaching technique FLIP 
was used. After cytoplasmic photobleaching, the nuclear fluorescence gradually decreased with 
time. This result shows that the EGFP-PDZK protein was continuously exported from the nucleus 
to the cytoplasm indicating the presence of functional NES in LIMK2. 
5.5. Subcellular distribution of LIMKs and their domains 
In mouse tissues, various isoforms of LIMK2 showing a unique sub-cellular distribution have 
been reported (Ikebe et al., 1998; Nunoue et al., 1995). LIMK2a (full length LIMK2) and 
LIMK2b (LIM1domain deleted) were mainly found in the cytoplasm. The main LIMK2 isoform 
is tLIMK2, which lacks both LIM domains and is found mainly in the nucleus. The subcellular 
distribution of different domains of LIMK2 is not reported yet. This study shows that the full 
length LIMK2, ΔLIM1-LIMK2 (LIM1 deleted, similar to LIMK2b) and ΔLIM2-LIMK2 (LIM2 
domain deleted) were mainly found in the cytoplasm. Deletion of both LIM domains (the PDZ-
kinase construct, similar to tLIMK2) drastically enhanced the nuclear localization of LIMK2. In 
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contrast, deletion of both LIM domains of LIMK1 did not change its subcellular distribution: the 
PDZ-kinase construct of LIMK1 remained in the cytoplasm. These results demonstrate that the 
sub-cellular distribution of LIMK1 and LIMK2 is regulated differentially in endothelial cells. 
Studies from different groups demonstrated that the LIM domains of LIMK1 interact with the 
kinase domain, and that the LIM2 domain regulates its kinase activity (Edwards and Gill, 1999; 
Hiraoka et al., 1996). Our results suggest that the LIM domains bind to the kinase domain of 
LIMK2 and LIMK1 differently, masking the NLS of LIMK2 but not LIMK1.  
The kinase domain of LIMKs has NLS sequences, but no NES, suggesting a nuclear localization 
of the kinase domain. Indeed, the kinase domain of both LIMK1 and LIMK2 was present mainly 
in the nucleus. The nuclear localization of the kinase domain of LIMK2 was higher than the 
kinase domain of LIMK1. The three NLS sequences of LIMK2 in the kinase domain seem to 
have higher binding affinity with importin-α than the one NLS in the kinase domain of LIMK1.  
Interestingly, the kinase domain of LIMK2 but not LIMK1 was also present in the nucleolus 
suggesting a unique function of LIMK2 in this nuclear organelle. Unlike the nucleus and other 
membrane-bound organelles, there is no physical barrier between the nucleolus and the 
surrounding nucleoplasm. In principle any soluble protein should be able to diffuse in and out of 
the nucleoli. However, it has also become clear that many proteins that localize to the nucleolus 
typically possess a NoLS motif, and the NoLS usually overlaps with the NLS (Kubota et al., 
1999). This indicates that the basic amino acid-rich motif of LIMK2 may also function as a 
nucleolar localization signal (see section 5.6). 
The Δkinase-LIMK2 construct (kinase domain deleted) was exclusively present in the cytoplasm 
indicating the presence of functional NES. After LMB treatment of the cells, this construct was 
enriched in the nucleus but not in the nucleolus. This may be due to the presence of another NLS 
outside of the kinase domain. Indeed, a further basic amino acid cluster was found between the 
PDZ and kinase domain of LIMK2 (amino acids 280-286) which could be a monopartite NLS. 
However, site directed mutational analysis indicate that this possible monopartite NLS is not 
functional since the mutant protein behaved similar to the wild type protein after LMB treatment 
of endothelial cells. Another explanation for the presence of the Δkinase-LIMK2 construct in the 
nucleus after LMB treatment of the endothelial cells is that this construct may enter the nucleus 
by diffusion due to its low molecular mass (60kDa) after inactivation of CRM1 dependent export. 
5.6. Identification of functional NoLS and NLS in LIMK2 
Based on the primary sequence analysis 3 types of NLS sequences were predicted in the kinase 
domain of LIMK2. In this study, site directed mutagenesis was used to identify key amino acid 
residues involved in the nuclear and nucleolar import of LIMK2. Mutation of either one of the 
cluster of basic amino acids RKKR (amino acids 500-503), RK (amino acids 496-497), or KKR 
(amino acids 491-493) to alanine indicates that each of these clusters is important for nucleolar 
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localization. The basic amino acids RKR (amino acids 480-482) did not play a significant role in 
nucleolar localization. These results identify the 13 amino acids (491-503) motif in LIMK2 
containing three clusters of basic amino acids as the functional nucleolar localization signal. 
Analysis of the protein composition of the nucleolus in other studies did not lead to the 
identification of a general nucleolar localization signal (Andersen et al., 2002; Dundr and Misteli, 
2002; Leung et al., 2003). Nucleolar localizing properties of eukaryotic proteins were apparently 
due to cooperation of several domains of the protein suggesting a complex regulation of nucleolar 
localization (Michael and Dreyfuss, 1996; Russo et al., 1997; Schmidt-Zachmann and Nigg, 
1993). However, small NoLS sequence motifs have been identified mainly in retroviral RNA 
binding trans-regulator proteins. Aligning the LIMK2 NoLS with the published NoLS sequences 
(generally 20-40 amino acids long) (Guo et al., 2003; Horke et al., 2004; Kubota et al., 1999) 
revealed that all these sequences retain continuous stretches of basic residues: either one 
continuous stretch of three to four basic residues, or one to three  stretches of three to four basic 
residues interrupted by one non basic residue (Table 5.1). 
In some studies, it has been shown that mutation of one of these basic amino acid–rich clusters 
inhibited the nucleolar localization of the protein(Guo et al., 2003). In these NoLS motifs, I noted 
that the sequences between the basic amino acid clusters were rich in hydrophilic amino acids. 
However, each of these basic amino acids clusters was important, but not sufficient for nucleolar 
localization of the protein. The whole NoLS as shown in Table 5.1 was needed. The NoLSs 
described in these proteins may be regarded as members of the “compact NoLS family”.  
What might be the partner in the nucleolus interacting with these compact NoLS sequences? 
Nucleolar localization can be accomplished by three different types of interactions: a) with 
nucleolar or nucleolar-associated proteins, b) with rDNA and c) with nucleolar RNA consisting 
mainly r RNA (Carmo-Fonseca et al., 2000; Shaw and Jordan, 1995). LIMK2 should follow one 
of these mechanisms to enter the nucleolus. It is hypothesized that the kinase domain of LIMK2 
binds with rRNA. Arginine/lysine-rich RNA-binding domains are found in many viral proteins 
(Bartel et al., 1991; Dingwall et al., 1989; Lazinski et al., 1989; Slice et al., 1992). These proteins 
have a similar pattern of arginine distribution as in LIMK2 suggesting the binding of LIMK2 
with rRNA (Table 5.2). The binding of proteins to rRNA in the nucleolus is known to regulate 
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Table 5.1 Sequence alignment NoLS sequences of different human and viral proteins with LIMK2 NoLS 
sequence. Clusters of basic amino acids are highlighted in red. 
 















Table 5.2 Comparison of the Arginine/Lysine-rich RNA-binding domains of different proteins with the NoLS 
sequence of LIMK2. 
 
The present study also identified the functional NLS of LIMK2. Based on the mutational analysis 
of EGFP-kinase and EGFP-PDZ-kinase, it is shown that the NLS2 containing the NLS1 (amino 
acids 491-503), but not the NLS3 is the functional NLS in LIMK2. When all the basic amino 
acids of NLS1 or NLS2 in PDZ-kinase were mutated to alanine, the mutated proteins were 
mainly in the cytoplasm. PDZ-kinase mutated at NLS2 was unable to enter the nucleus after 
LMB treatment. Mutational analysis of the kinase domain also showed that NLS2 containing 
NLS1 and RK (amino acids 496-497) are important for nuclear localization.  
The functional NLS of LIMK2 (amino acids 491-503) is not the classical bipartite type NLS. It 
contains additional two basic amino acids within the sequence of 6 amino acids that separates the 
two clusters of basic amino acids, demonstrating a unique type of NLS.  
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5.7. Regulation of nucleocytoplasmic shuttling of LIMK2 by PKC 
dependent phosphorylation 
The results so far demonstrate that LIMK2 constitutively shuttles between the nucleus and the 
cytoplasm in resting endothelial cells. The nucleocytoplasmic shuttling is often regulated in 
response to specific cellular signals and influenced directly by posttranslational modifications 
such as phosphorylation of the cargo proteins (Kaffman and Shea, 1999). Phosphorylation often 
regulates the nuclear import of NLS cargo proteins by inhibiting the interaction of the cargo with 
the classic nuclear transport receptor importin-α (Harreman et al., 2004). Moreover, it has been 
shown that many nucleocytoplasmic shuttling proteins such as DAG kinase ζ, Ca2+/calmodulin-
dependent protein kinase II, NF-κB, and NF-AT contain a phosphorylation site within or adjacent 
to the NLS sequence, and that the phosphorylation of this site regulates nuclear localization of 
these proteins (Heist et al., 1998; Kaffman and O'Shea, 1999; Topham et al., 1998).  
Is nuclear transport of LIMK also regulated by phosphorylation? Only one phosphorylation site 
(Thr505/508) was previously reported in LIMKs, which is present very near the predicted nuclear 
localization signal. Previous studies showed that phosphorylation of Thr505 (LIMK2) or Thr508 
(LIMK1) is involved in the activation of the LIMKs, but did not affect their subcellular 
localization (Roovers et al., 2003; Sumi et al., 2001a).  
We predicted two potential PKC phosphorylation sites in LIMK2, one at Ser283 between the 
PDZ and the kinase domain, and the other at Thr494 in the kinase domain, near to the predicted 
NLS. These sites were absent in the same homologous region of LIMK1 suggesting that only 
LIMK2 but not LIMK1 may be regulated by PKC. Indeed, activation of PKC by PMA stimulated 
the translocation of LIMK2 and the PDZ-kinase construct of LIMK2 (PDZK) from the nucleus to 
the cytoplasm. However, no change in the sub-cellular localization of the kinase domain of 
LIMK2 was observed after PMA stimulation of endothelial cells. This differential regulation of 
the PDZK constructs and the kinase domain of LIMK2 suggests that PKC regulates the 
nucleocytoplasmic shuttling of LIMK2 most probably by phosphorylation of Ser283 (present 
between the PDZ and the kinase domain) and not Thr494 (present in the kinase domain). We 
found indeed that PKC phosphorylated LIMK2 at Ser283. This was shown for the endogenous 
LIMK2 in endothelial cells as well as for the transfected EGFP-LIMK2 constructs. The 
experiments with isoform specific PKC inhibitors indicate that PKC-α and PKC-β are the major 
PKC isoforms that regulate the translocation of LIMK2 from the nucleus to the cytoplasm. 
Due to unavailability of a specific phospho-Thr PKC substrate peptide antibody, it could not be 
determined whether the second potential PKC phosphorylation site at Thr494 was also 
phosphorylated by PKC. The subcellular distribution of the kinase domain of LIMK2 was not 
affected by PMA treatment indicating that Thr494 may not be essential for translocation of 
LIMK2 from the nucleus to the cytoplasm after PKC activation. 
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To gain further insight into the relative importance of PKC mediated phosphorylation of the two 
sites in LIMK2, active and inactive mutations were introduced into the PDZ-kinase construct and 
the full length LIMK2. The inactive S283A mutant of PDZ-kinase did not accumulate in the 
cytoplasm after PMA treatment, whereas the T494A mutant of PDZ-kinase behaved similarly to 
the wild type PDZ-kinase: it still accumulated in the cytoplasm after PMA treatment, but at a 
slower rate. These results indicate that phosphorylation of Ser283 is necessary for the PMA-
induced translocation of LIMK2 from the nucleus to the cytoplasm. However, phosphorylation of 
Thr494 is not needed, but may be involved in the nucleocytoplasmic shuttling of LIMK2. 
The results with PDZK and LIMK2 constructs containing the active mutant (S283EE) mimicking 
serine phosphorylation were the same as after PMA treatment of endothelial cells: the mutant 
proteins were not in the nucleus but in the cytoplasm in resting endothelial cells. Constitutive 
phosphorylation of Ser283 may either stimulate nuclear export or inhibit the nuclear import of 
LIMK2. To study these two possibilities further, the cells transfected with the S283EE mutant 
were treated with LMB, which inhibits nuclear export. The nuclear localization of the mutant 
proteins (PDZ-kinase, LIMK2) was highly reduced after LMB treatment, indicating that Ser283 
phosphorylation by PKC indeed partially inhibits the nuclear import of LIMK2. Surprisingly the 
T494EE mutant protein was also mainly localized in the cytoplasm; similar to the mutant 
S283EE.After LMB treatment the nuclear localization of T494EE mutant was also highly 
reduced suggesting that phosphorylation of this site might also partially inhibit the nuclear import 
of LIMK2.  
To explain these results, the following hypothesis is made: the NES and NLS are partially 
masked in the PDZ-kinase domain of LIMK2 leading to equal distribution of the protein in the 
cytoplasm and the nucleus of resting cells. In the first step after PMA induced PKC activation, 
Ser283 phosphorylation by PKC leads to a conformational change of the protein, which makes 
the NES fully accessible to the CRM1 export receptor and/or inhibits the NLS indirectly. The rate 
of export of LIMK2 from the nucleus to the cytoplasm would be increased. In the second step, 
the Thr494 site in the NLS is accessible for PKC, and phosphorylation of this site, located in the 
NLS of LIMK2, inhibits directly its interaction with importin-α.  
To further test this hypothesis, double mutants of both sites were studied. In active single mutants 
(S283EE, T494EE), the possibility of basal phosphorylation and the contribution of the other site 
cannot be ruled out. To eliminate this possibility, S283EE/T494A and T494EE/S283A double 
mutant proteins (active/inactive) were studied. These proteins behaved similar to the single active 
mutants of the same site. However, the S283EE/T494EE double active mutant remained 
completely in the cytoplasm after LMB treatment. These results suggest that the two 
phosphorylation sites are functional and by completing each other may affect nuclear import 
through different mechanism. Ser283 phosphorylation might through conformational change 
partially mask the NLS and inhibit nuclear import indirectly, whereas Thr494 phosphorylation 
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might direct inhibits NLS binding to importin-α. Phosphorylation of both the sites is required to 
block the nuclear import of LIMK2 completely.  
 
Figure 5.2 Proposed model of the regulation of nucleocytoplasmic shuttling of LIMK2. See text for details. 
14-3-3 is a protein which binds to pSer/pThr motifs present in many target proteins and 
modulates their subcellular localization by interfering with the function of nearby targeting 
sequences such as NES and NLS. Various nucleocytoplasmic shuttling proteins such as CDC25, 
and transcription factors such as FKHRL1, are phosphorylated at Ser/Thr present near or in the 
NLS sequences binds to with 14-3-3. These proteins are localized mainly in the cytoplasm after 
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phosphorylation (Muslin and Xing, 2000). It has been reported that LIMK1 can interact with 14-
3-3 (Birkenfeld et al., 2003). 14-3-3 binds as a dimer to proteins containing the consensus 
sequences a) R(S/Ar)XpSXP , b) RX(Ar/S)XpSXP and, c) RX1-2pSX2-3S in which pS denotes 
pSer/pThr and Ar denotes aromatic residues (Fu et al., 2000; Muslin et al., 1996; Yaffe et al., 
1997). LIMK2 at Ser283 has the same consensus sequence of 14-3-3 binding as in c): 
(RRRpS283LRRS). This result suggests that 14-3-3 could bind to LIMK2 after phosphorylation at 
Ser283. This binding may inhibit the NLS function partially.  
Based on these findings and considerations the following model of regulation of 
nucleocytoplasmic shuttling of LIMK2 by PKC is proposed. (Figure 5.2): 
LIMK2 adopts a close conformation in resting cells and the LIM domains interact with the kinase 
domain thereby masking the NLS and keeping the protein mainly in the cytoplasm. PDZ-kinase 
(similar to the tLIMK2 isoform in mice) is more localized in the nucleus, due to lack of inhibition 
of the NLS by LIM domains. Activation of PKC induces phosphorylation of LIMK2 at Ser283 
causing the binding of 14-3-3 to this site. This results in a partially locked conformation of 
LIMK2 with partial inhibition of NLS. PKC then phosphorylates LIMK2 at Thr494 and 14-3-3 
also binds to this site. The binding of 14-3-3 as a dimer locks the LIMK2 conformation and 
inhibits completely the binding of NLS to importin-α. LIMK2 in this locked conformation cannot 
enter the nucleus and is found completely in the cytoplasm. 
5.8. Possible nuclear function of LIMK2 
What is the possible function of LIMK2 in the nucleus? Nucleocytoplasmic shuttling of LIMK2 
in resting endothelial cells and its regulation by PKC mediated phosphorylation suggests that 
LIMK2 might have a function in the nucleus. 
It has been suggested that nuclear actin plays an important role in some nuclear functions, such as 
RNA transcription, RNA splicing, chromosome condensation, and chromatin remodeling 
(Bettinger et al., 2004; Percipalle et al., 2003; Rando et al., 2000), all of which are essential for 
cell survival and mitotic or meiotic division. Under conditions of  cellular stress such as heat, 
DMSO treatment, cofilin migrates into the nucleus and forms rod like inclusions with associated 
actin, and such nuclear accumulation of cofilin is inhibited by phosphorylation (Bamburg, 1999). 
Therefore, the LIMK-cofilin system-mediated actin cytoskeleton dynamics may play a crucial 
role in the formation and proper function of nuclear processes. Utilizing the Xenopus oocyte 
system, it has been demonstrated that ectopic expression of LIMK1 in the nucleus clearly 
impaired progression of the meiotic process (oogenesis), such as organization, maintenance, and 
migration of specific meiotic spindle precursors (Takahashi et al., 2002). In the Drosophila 
mutant twinstar (tsr, the gene encoding Drosophila cofilin), migration and separation of 
centrosomes were severely impaired in spermatocytes because of an unusual accumulation of 
actin at this site (Gunsalus et al., 1995). These studies strongly demonstrated that the LIMK and 
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cofilin-mediated actin cytoskeleton dynamics might be a key component of gametogenesis, and 
abnormalities in the LIMK-cofilin system and could contribute to infertility in humans. 
Furthermore, it has been demonstrated that cell cycle progression depends on the regulated 
activity of the LIMK-cofilin system. In HeLa cells, LIMK1 became hyperphosphorylated during 
prometaphase and metaphase (Amano et al., 2002; Sumi et al., 2002). Cofilin phosphorylation 
also peaked during this period. Both LIMK1 and cofilin phosphorylation declined to interphase 
levels, as cells entered the telophase and began cytokinesis. Furthermore, LIMK1 activation 
during mitosis is abrogated by cyclin-dependent kinase (CDK) inhibitors, suggesting that 
activation of CDKs directly or indirectly participates in LIMK1 activation (Sumi et al., 2002).  
 
Figure 5.3 Schematic representation of the pathway regulates the function of LIMK2. See text for details. 
It has been reported recently that LIMKs control cyclin D1 expression in a manner independent 
of cofilin phosphorylation and actin polymerization (Roovers et al., 2003). Induction of cyclin D1 
is the critical step during the G1-S phase transition of cell cycle in mammalian cells, and involves 
cooperative signaling by receptor tyrosine kinases, integrins, and the actin cytoskeleton (Assoian 
and Schwartz, 2001). In fibroblasts, cyclin D1 is induced in mid-G1 phase (~9 hr) after mitogen 
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stimulation of quiescent cells, and requires sustained (~5-6 hr) ERK activity (Welsh et al., 2001). 
Rac and/or Cdc42 can induce an early cyclin D1 expression (~3hr) in an ERK-independent 
manner after mitogen stimulation of quiescent cells. Rho-kinase is required for sustained ERK 
signaling and maintains the mid-G1 phase. Rho kinase prevents early G1 phase induction of 
cyclin D1 in response to Rac/Cdc42 signaling (Welsh et al., 2001). The recent study shows that 
LIMKs act in the nucleus to suppress Rac/Cdc42-mediated cyclin D1 expression (Roovers et al., 
2003). This suggests that the regulation of nucleocytoplasmic shuttling of LIMKs may play a role 
in cell cycle regulation. Various studies also show that cyclin D1 expression was enhanced by the 
several growth stimulatory signaling pathways such as PKC (Blobe et al., 1994; Soh and 
Weinstein, 2003). These studies together with our findings lead us to suggest that PKC 
phosphorylation of LIMK2 serves to keep this protein out of the nucleus thereby relieving LIMK-
mediated suppression of cyclin D1. 
Based on the findings in the present study, I propose that LIMK2 has a dual function in 
endothelial cells. LIMK2 in the cytoplasm regulates the cofilin-mediated actin cytoskeleton 
rearrangement. The other function of the LIMK2 in the nucleus might be to suppress cyclin D1 








The endothelium regulates cellular and nutrient trafficking, maintains blood fluidity, regulates 
vasomotor tone, contributes to the local balance of pro-inflammatory and anti-inflammatory 
mediators, and participates in the generation of new blood vessels. Actin microfilaments, their 
associated adherens junctions and focal adhesions are important regulators of endothelial 
permeability and adhesiveness. After injury of the endothelium, the actin cytoskeleton is essential 
for endothelial cell migration and proliferation leading to wound repair. Disruption and 
dysfunction of the cytoskeleton may result in impairment of endothelial function, subsequently 
tipping the balance towards vascular disease. Thus, an understanding of the cellular and 
molecular biology of the endothelial cytoskeleton is important for our understanding of the 
pathogenesis of vascular disease such as atherosclerosis and pathological angiogenesis. 
Small Rho-like GTPases such as Rho, Rac, and Cdc42 play a major role in regulating actin 
dynamics in stimulated endothelial cells. They often act by stimulation of specific kinases. Rho-
kinase, activated by Rho, is essential for thrombin-induced endothelial stress fiber formation and 
cell contraction. This enzyme directly phosphorylates and inhibits myosin phosphatase leading to 
an increase of myosin light chain phosphorylation. Phosphorylated myosin interacts with actin 
filaments, and develops actin-activated ATPase-activity. Transfection studies have shown that 
Rho-kinase also phosphorylates LIMKs and enhances their kinase activity. LIMKs consisting of 
LIMK1 and LIMK2 specifically phosphorylate cofilin at Ser-3 and inactivate this actin-
depolymerizing protein. The precise mechanism by which Rho-kinase regulates thrombin-
induced stress fiber formation in endothelial cells is unknown. 
In this study, it is found that endothelial cells express both LIMK1 and LIMK2, and a smaller 
isoform of LIMK2. This study for first time demonstrates the stimulation of the Rho-
kinase/LIMK/cofilin pathway upon physiological cell activation. In thrombin-stimulated 
endothelial cells, Rho-kinase activation led to LIMK stimulation and subsequent cofilin 
phosphorylation. Actin stress fiber formation was blocked by dominant negative LIMK2 in 
thrombin-stimulated endothelial cells. These results demonstrate that in thrombin-stimulated 
endothelial cells, the other signal cascade downstream of Rho-kinase, i.e. the LIMK/cofilin 
pathway is also essential for stress fiber formation.  
LIMKs have two repeats of the LIM domain at the N-terminus, followed by a PDZ domain and 
an unusual protein kinase domain at the carboxy terminus. A proline/serine-rich (P/S) region 
separates the PDZ domain from the kinase domain. In this study, it has been shown that the 
kinase domain of LIMK2 has a unique basic amino acid-rich motif, and that LIMK2 in resting 
endothelial cells shuttles between the nucleus and cytoplasm. This has been shown indirectly by 
inhibition of the nuclear export of LIMK2 with LMB and demonstrated directly by FRAP and 
FLIP analysis of the PDZ-kinase domain of LIMK2. The LIM domains of LIMK2, but not of 
LIMK1 inhibited its nuclear import thereby keeping LIMK2 mainly in the cytoplasm. Primary 
sequence analysis predicted three NLS sequences in the kinase domain of LIMK2, and two NES 
 
Summary 112 
sequences at C-terminal of PDZ domain. The NLS sequences of LIMK2 were very different of 
that of LIMK1. Interestingly the PDZ-kinase domain of LIMK2, but not of LIMK1 was enriched 
in the nucleus, and the kinase domain of LIMK2, but not of LIMK1 was found in the nucleolus.  
Mutational analysis of the basic amino acid-rich motif (amino acids 480-503) indicated that the 
bipartite NLS-2 (amino acids 480-503) containing the monopartite NLS-1 (amino acids 500-503) 
at one end and the unique RK (amino acids 496-497) in the middle is the functional NLS and 
NoLS. This motif regulated the nuclear and nucleolar localization of LIMK2. 
Primary sequence analysis indicated that LIMK2 has two highly disordered regions: one is 
present between the PDZ and the kinase domain, and the other is present in the kinase domain.  
Two PKC phosphorylation sites (Ser283, Thr494) were predicted in these regions. These sites 
were absent in the same homologous regions of LIMK1. Activation of PKC in PMA-stimulated 
endothelial cells stimulated the phosphorylation of LIMK2 at Ser283 and the translocation of 
LIMK2 and the PDZ-kinase construct of LIMK2 from the nucleus to the cytoplasm. Of the 
various PKC isoforms, PKC-α and PKC-β were found to be mainly responsible for Ser283 
phosphorylation and the regulation of translocation of LIMK2. Mutational analysis indicated that 
LIMK2 phosphorylation at Ser283 is functional, and revealed that phosphorylation at Thr494 
might also play a role in the regulation of nucleocytoplasmic shuttling of LIMK2 by PKC.  
Based on the findings of this dissertation and the data in the literature, a model of the regulation 
of nucleocytoplasmic shuttling of LIMK2 by PKC is proposed. LIMK2 in resting endothelial 
cells adopts a close conformation: the LIM domains interact with the kinase domain thereby 
masking the NLS and keeping the protein mainly in the cytoplasm. PDZ-kinase is more localized 
in the nucleus than LIMK2, due to lack of inhibition of the NLS by the LIM domains. Activation 
of PKCs induces phosphorylation of LIMK2 in a first step at Ser283, and probably in a second 
step at Thr494, causing the binding of adapter proteins such as 14-3-3., This protein complex 
exhibiting a locked conformation and  masking the NLS might not bind to importin-α, and the 
nuclear import of this protein is inhibited. 
What may be the function of LIMK2 in the nucleus? It has been reported very recently that 
nuclear LIMKs suppress cyclin D1 expression in a manner independent of cofilin 
phosphorylation and actin polymerization. Induction of cyclin D1 expression is a critical step 
during the G1-S phase transition of cell cycle in mammalian cells, and controlled by several 
growth stimulatory signaling pathways such as PKC. It is therefore suggested that the PKC-
mediated inhibition of nucleocytoplasmic shuttling of LIMK2 may stimulates the expression of 
cyclin D1 and cell cycle progression.  
Based on the findings presented in this study, I propose that LIMK2 has a dual function in 
endothelial cells. LIMK2 in the cytoplasm regulates the cofilin-mediated actin dynamics and 
stress fiber formation downstream of Rho-kinase in physiologically activated endothelial cells. 
Nucleocytoplasmic shuttling of LIMK2 in resting endothelial cells and its direct regulation by 
PKC suggests that LIMK2 might also have a function in the nucleus such as the suppression of 




Das Endothel ist am Stoffaustausch zwischen Blut und umliegenden Geweben beteiligt, unterhält 
die Fließfähigkeit des Blutes, beeinflusst den vaskulären Tonus, trägt zum Gleichgewicht 
zwischen pro- und anti-inflammatorischen Mediatoren bei und ist von Bedeutung für die 
Angiogenese. Aktin-Mikrofilamente, die mit interzellulären adherent junctions und über focal 
adhesions mit der subendothelialen Matrix verbunden sind, spielen eine wichtige Rolle bei der 
Steuerung der endothelialen Adhäsionsfähigkeit und Barrierefunktion. Das Aktin-Zytoskelett ist 
vor allem nach Verletzung des Endothels essentiell für Migration und Proliferation der Zellen, 
was zur Wundheilung führt. Veränderungen des Zytoskeletts können somit zur Beeinträchtigung 
der Endothelfunktion führen, wodurch vaskuläre Erkrankungen ausgelöst werden könnten. 
Aufgrund dessen ist das Aufdecken der zellulären und molekularbiologischen Zusammenhänge 
des Endothelzytoskeletts bedeutend für das Verständnis der pathogenen Vorgänge bei 
Gefäßerkrankungen wie z. B. der Atherosklerose und pathologischer Angiogenese. 
Eine wichtige Rolle in der Regulation der Aktindynamik stimulierter Endothelzellen spielen die 
kleinen Rho-ähnlichen GTPasen wie Rho, Rac und Cdc42. Diese wirken häufig über die 
Stimulation spezifischer Kinasen. Rho-Kinase, aktiviert durch Rho, ist bedeutend für die 
Thrombin - induzierte Bildung von Stressfasern und die Zellkontraktion. Dieses Enzym phos-
phoryliert und inhibiert  direkt die Myosinphosphatase, was  unmittelbar zum Anstieg der 
Phosphorylierung der leichten Kette des Myosin führt. Phosphoryliertes Myosin interagiert mit 
Aktinfilamenten und entwickelt eine Aktin-aktivierte ATPase Aktivität. In Transfektionsstudien 
wurde gezeigt, daß Rho-Kinase einen zweiten Signalweg stimuliert, und zwar phosphoryliert die 
Rho-Kinase auch LIM-Kinasen (LIMK) und erhöht deren Aktivität. LIM-Kinasen, bestehend aus 
LIMK1 und LIMK2, phosphorylieren Cofilin an Position Ser3 und inaktivieren dieses Aktin-
depolymerisierende Protein. Der genaue Mechanismus, wie die Rho-Kinase die Thrombin - 
induzierte Stressfaserbildung reguliert, ist unbekannt. 
In dieser Arbeit wird gezeigt, daß Endothelzellen sowohl LIMK1 als auch LIMK2 und eine 
kleinere Isoform von LIMK2 exprimieren. Zum ersten Mal wird die Stimulation des Rho-Kinase/ 
LIMK/ Cofilin-Signalwegs in physiologisch stimulierten Zellen beschrieben. In Thrombin - 
stimulierten Endothelzellen führte die Aktivierung der Rho-Kinase zu LIM-Kinasen Stimulierung 
und anschließender Cofilinphosphorylierung. Die Bildung von Aktinstressfasern wurde durch 
Transfektion der Endothelzellen mit dominant negativer LIMK2 blockiert. Diese Ergebnisse 
zeigen, daß in Thrombin - stimulierten Endothelzellen die andere Signalkaskade abwärts der 
Rho-Kinase,  und zwar der  LIMK / Cofilin-Signalweg, auch essentiell für die Ausbildung von 
Aktinstressfasern ist. 
LIM-Kinasen haben zwei Wiederholungen der LIM-Domäne am N-Terminus, gefolgt von einer 
PDZ- Domäne und einer ungewöhnlichen Proteinkinase-Domäne am C-Terminus. Eine Prolin/ 
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Serin (P/S)-reiche Region teilt die PDZ-Domäne von der Kinase-Domäne. In dieser Arbeit wurde 
gezeigt, dass die Kinase-Domäne von LIMK2 ein einzigartiges Motiv reich an basischen 
Aminosäuren enthält, und dass LIMK2 in ruhenden Endothelzellen zwischen Zellkern und 
Zytoplasma hin und her wandert. Das konnte indirekt durch Inhibition des Kernexports von 
LIMK2 mit LMB und direkt durch FRAP- und FLIP-Analysen der PDZ-Kinase-Domäne (PDZK) 
dargestellt werden. Die LIM-Domänen von LIMK2, nicht jedoch von LIMK1, verhinderten den 
Kernimport, so daß die LIM-Domänen wahrscheinlich für die vorwiegende Lokalisation der 
LIMK2 im Zytoplasma verantwortlich sind. Primäre Sequenzanalysen sagten drei NLS (nuclear 
localization signal) Sequenzen in der Kinase- Domäne von LIMK2 und zwei NES (nuclear 
export signal) Sequenzen C-terminal der PDZ-Domäne voraus. Die NLS-Sequenzen der LIMK2 
waren sehr verschieden von denen der LIMK1. Interessanterweise war die PDZ-Domäne von 
LIMK2, aber nicht die von LIMK1, im Zellkern angereichert, und die Kinase-Domäne von 
LIMK2, aber nicht von LIMK1, wurde im Nukleolus gefunden.  
Mutationsanalysen des an basischen Aminosäuren reichen  Motivs von LIMK2 (AS 480-503) 
zeigten, dass das zweiteilige NLS-2 (AS 480-503), welches zusätzlich den einteiligen NLS-1 an 
einem Ende und die einmalige RK-Sequenz (AS 496-497) in der Mitte enthält, das wichtige NLS 
und NoLS (nucleolus localization signal) ist. Dieses Motiv regulierte die nukleäre und nukleoläre 
Lokalisation. 
Weitere Sequenzanalysen zeigten zwei stark ungeordnete Regionen in LIMK2: eine zwischen der 
PDZ-Region und der Kinase-Domäne, die andere innerhalb der Kinase-Domäne. In diesen 
Regionen wurden zwei Phosphorylierungspositionen (Ser283 und Thr494) für Proteinkinase C 
(PKC) vorausgesagt. Diese Positionen waren nicht in LIMK1 vorhanden. Eine Aktivierung der 
PKC in Phorbol-12-myristat-13-acetat-stimulierten Endothelzellen stimulierte die 
Phosphorylierung von LIMK2 an Ser283 und die Translokation der LIMK2 und des PDZ-Kinase 
Konstrukts von LIMK2 vom Nukleus ins Zytoplasma. Unter den verschiedenen PKC Isoformen 
wurden PKC-α  und PKC-β als die hauptverantwortlichen Formen für die Ser283 
Phosphorylierung und die Translokation identifiziert. Mutationsanalysen zeigten, dass die 
Phosphorylierung an Ser283 essentiell und die Phosphorylierung an Thr494 wichtig für die 
Regulation des Kern-Zytoplasma-shuttle durch PKC sind. 
Basierend auf den Ergebnissen dieser Arbeit und den Daten aus der Literatur wird ein Modell der 
PKC-abhängigen Regulation des nukleozytoplasmatischen shuttling von LIMK2 vorgestellt 
(siehe Abb.5.2.). LIMK2 nimmt in ruhenden Endothelzellen eine geschlossene Konformation an: 
Die LIM-Domänen interagieren mit der Kinase-Domäne, wobei die NLS maskiert wird und das 
Protein im Zytoplasma verbleibt. PDZK ist eher im Zellkern lokalisiert infolge des Fehlens der 
NLS-Inhibition durch die LIM-Domänen. Die Aktivierung von PKC induziert in einem ersten 
Schritt eine Phosphorylierung von LIMK2 an Ser283, und eventuell in einem weiteren Schritt an 
Thr494, die eine Bindung von Adapterproteinen, wie z. Bsp. 14-3-3, verursacht. Dieser 
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Proteinkomplex mit maskierter NLS liegt dann in einer locked conformation vor und würde nicht 
an Importin- α binden. Somit wäre der nukleäre  Import dieses Proteins komplett inhibiert. 
Was aber ist die Funktion von LIMK2 im Zellkern? In einer kürzlich veröffentlichten Publikation 
wurde gezeigt, daß nukleäre LIM-Kinasen eine Cyclin D1 Expression unter-binden, unabhängig 
von ihrer Wirkung auf Cofilinphosphorylierung und Aktinpolymerisation. Die Induktion der 
Cyclin D1 Expression ist ein wichtiger Schritt während des Übergangs der G1- zur S-Phase im 
Zellzyklus von Säugerzellen. Es wird deshalb vermutet, daß die PKC- vermittelte Inhibition des 
Imports von LIMK2 in den Zellkern die Cyclin D1 Suppression durch LIMK2 aufhebt und 
dadurch die Expression von Cyclin D1 stimuliert. 
Basierend auf den Ergebnissen dieser Studie schlage ich eine duale Funktion der LIMK2 in 
Endothelzellen vor. LIMK2 reguliert im Zytoplasma die Cofilin - vermittelte Aktindynamik und 
Stressfaserbildung in physiologisch aktivierten Endothelzellen abwärts der Rho-Kinase. Das 
nukleozytoplasmatische shuttling der LIMK2 in Endothelzellen und dessen Regulation durch 
PKC suggeriert dass LIMK2 auch eine Funktion im Zellkern hat, wie z. Bsp. die Suppression der 
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